Polycystic Ovary Syndrome

Complex MONDO:0008487 Pathograph 19 Show in embeddings browser Endocrine Disease Reproductive Disease

Polycystic ovary syndrome is a common endocrine and reproductive disorder of women of reproductive age, defined by the combination of hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. Its pathophysiology centers on hypothalamic-pituitary dysregulation with increased LH-driven ovarian androgen production and on insulin resistance that amplifies androgen excess, although lean and obese subtypes differ in the relative contribution of intrinsic versus adiposity-amplified insulin signaling defects. Clinical features include irregular menstruation, hirsutism, acne, and infertility, with downstream metabolic consequences and chronic low-grade inflammation.

Ask OpenScientist

Ask a research question about Polycystic Ovary Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🏷

Classifications

Harrison's Part

◆

Subtypes

Lean / nonobese PCOS

PCOS occurring without obesity. This stratum is useful for separating intrinsic, obesity-independent insulin signaling defects and neuroendocrine/ovarian androgen mechanisms from adiposity-amplified metabolic dysfunction. Lean PCOS is still heterogeneous; some lean affected groups may have normal insulin sensitivity.

Show evidence (2 references)

PMID:1397698 SUPPORT Human Clinical

"These defects in insulin action appear to represent intrinsic abnormalities that are independent of obesity, metabolic derangements, body fat topography, and sex hormone levels."

Euglycemic clamp and adipocyte data support an obesity-independent intrinsic insulin-action defect relevant to nonobese PCOS.

PMID:23065822 SUPPORT Other

"There is general agreement that obese women with PCOS are insulin resistant, but some groups of lean affected women may have normal insulin sensitivity."

The review supports subtype heterogeneity within lean PCOS, so lean status should not be modeled as synonymous with insulin resistance.

Obese / adiposity-amplified PCOS

PCOS with overweight, obesity, or abdominal/visceral adiposity. This stratum emphasizes adiposity-driven insulin resistance, hyperinsulinemia, lower SHBG, and inflammatory amplification of androgen excess and anovulation.

Show evidence (2 references)

PMID:12080440 SUPPORT Other

"Obesity, particularly the abdominal phenotype, may be partly responsible for insulin resistance and associated hyperinsulinemia in women with PCOS."

Review evidence supports abdominal obesity as an amplifier of insulin resistance and hyperinsulinemia in PCOS.

PMID:12080440 SUPPORT Other

"Irrespective of the pathogenetic mechanism involved, obese PCOS women have more severe hyperandrogenism and related clinical features (such as hirsutism, menstrual abnormalities and anovulation) than normal-weight PCOS women."

The subtype description is supported by evidence that obesity worsens androgenic and reproductive PCOS features.

Comorbidities

Obesity <-> Polycystic Ovary Syndrome

◈

Mechanistic Hypotheses

Androgen-First Feedback Model

androgen_first_feedback_model ALTERNATIVE Lean PCOS Obese PCOS

Evidence balance 7 support

Intrinsic ovarian/adrenal androgen excess, potentially reinforced by heightened LH action and theca-cell steroidogenic machinery, is the initiating lesion. Androgen excess then promotes insulin resistance and hyperinsulinemia, disrupts hypothalamic steroid feedback, and contributes to visceral adiposity, closing an androgen-insulin-adiposity feedback loop.

OpenScientist deep-research verdict (see kb/hypotheses/Polycystic_Ovary_Syndrome/androgen_first_feedback_model): PARTIALLY SUPPORTED. The androgen-sensitive ovarian and neuroendocrine components are supported — global and neuron-specific androgen-receptor knockout in the DHT mouse model shows that androgen-receptor signalling is required for the PCOS-like phenotype and that its critical locus is extraovarian (PMID:28320971) — but temporal primacy of androgen excess is not demonstrated in humans, so `status:` stays ALTERNATIVE rather than being promoted. Three qualifications from the assessment (assessments/openscientist-assessment-by-codex.yaml) are carried here. (1) The report's central argument that androgen reduction leaves insulin resistance unchanged was rejected on source check: it reads a 12-month placebo-controlled flutamide trial that reported *improved* insulin sensitivity as null, so no claim of a purely indirect androgen-to-insulin route is curated here; see the discussion gap_pcos_androgen_to_insulin_resistance_directness. (2) Long-term testosterone exposure in transmasculine adults is a non-PCOS setting and cannot adjudicate PCOS-specific causality. (3) The model is strongest for the "reproductive" cluster of PCOS (21-23% of NIH-defined European-ancestry cases, enriched for rare DENND1A variants), but that cluster is a cross-sectional phenotype grouping, not a demonstrated androgen-first subtype, and its subtype GWAS was small and unreplicated (PMID:32574161).

Pathograph links

Hyperandrogenism -> Intrinsic Post-Receptor Insulin Signaling Defect INDIRECT KNOWN INTERMEDIATES Androgen excess can worsen insulin resistance and hyperinsulinemia, creating a self-perpetuating endocrine-metabolic loop. Intermediates: androgen receptor effects in skeletal muscle and adipose tissue; compensatory or androgen-augmented hyperinsulinemia

Hyperandrogenism -> Adiposity-Amplified Insulin Resistance INDIRECT KNOWN INTERMEDIATES Hyperandrogenism favors visceral adiposity and adverse adipose signaling, which can amplify insulin resistance in obese PCOS. Intermediates: visceral fat deposition; adipokine and free-fatty-acid changes

Hyperandrogenism -> Hypothalamic-Pituitary Dysregulation INDIRECT KNOWN INTERMEDIATES Ongoing androgen excess helps sustain abnormal hypothalamic sensitivity to estradiol/progesterone negative feedback, maintaining rapid LH/GnRH pulse secretion. Intermediates: impaired ovarian steroid negative feedback

Hyperandrogenism -> Ovulatory Dysfunction INDIRECT KNOWN INTERMEDIATES Elevated androgen exposure disrupts follicle maturation and contributes to anovulation. Intermediates: follicular arrest; impaired dominant follicle selection

Adiposity-Amplified Insulin Resistance -> Chronic Low-Grade Inflammation INDIRECT KNOWN INTERMEDIATES Visceral adiposity and insulin resistance contribute to the inflammatory state shared by PCOS, obesity, type 2 diabetes, and cardiovascular disease. Intermediates: adipokine dysregulation; inflammatory cytokine production

Deep research

OpenScientist citations 33 citations 2026-06-06T23:47:40.676815

Show evidence (7 references)

PMID:38152131 SUPPORT Other

"Compelling evidence suggests that hyperandrogenism is not just a primary feature of PCOS. Instead, it may be a causative factor for this condition."

This review explicitly frames androgen excess as a possible causal driver, supporting the androgen-first hypothesis group.

PMID:35356614 SUPPORT Other

"However, the overexposure of androgen has direct and specific influence on the development of insulin resistance."

Supports the androgen-to-insulin-resistance arm of the proposed feedback model.

PMID:28320971 SUPPORT Model Organism

"Global loss of the AR reveals that AR signaling is required for all DHT-induced features of PCOS."

Global androgen-receptor knockout in the DHT-induced mouse model shows the whole PCOS-like phenotype depends on androgen-receptor signalling, the strongest available causal test of the androgen arm of this hypothesis. Graded MODEL_ORGANISM: it is a mouse result and does not by itself establish androgen primacy in human PCOS.

+ 4 more references

Insulin/Hyperinsulinemia-First Model

insulin_hyperinsulinemia_first_model ALTERNATIVE Lean PCOS Obese PCOS

Evidence balance 5 support

Primary insulin resistance or primary hyperinsulinemia initiates the endocrine-metabolic loop. High insulin acts as a co-gonadotropin in the ovary and lowers hepatic SHBG, increasing bioactive androgen exposure; the resulting hyperandrogenism can then worsen insulin resistance and adiposity.

OpenScientist deep-research verdict (see kb/hypotheses/Polycystic_Ovary_Syndrome/insulin_hyperinsulinemia_first_model): PARTIALLY SUPPORTED — a co-driving parallel pathway rather than a universal primary cause, so `status:` stays ALTERNATIVE. What survives source check: suppressing insulin secretion with diazoxide lowers androgens and raises SHBG even in lean PCOS women with normal metabolic insulin sensitivity (PMID:17559844); insulin drives adipose androgen generation through AKR1C3 (PMID:26312838); and Mendelian randomization infers a causal effect of higher insulin resistance on PCOS risk (PMID:26416764). What does not: the report's claim that PCOS GWAS do not implicate insulin genes and that no insulin-specific Mendelian-randomization work exists is contradicted by that same 2015 analysis and by the INSR locus already curated in `genetic:`; its claimed insulin-independent 28-52% testosterone contrast across two NK3-antagonist trials misreports those endpoints (52% was the LH area-under-curve reduction in the AZD4901 trial); and average null gonadotropin effects in a heterogeneous metformin meta-analysis do not prove parallel causal pathways. Note also that metformin lowers LH-stimulated testosterone within days, before any insulin-sensitising effect (PMID:25304843), so therapeutic response to an insulin sensitiser is not on its own evidence for the insulin-first ordering.

Pathograph links

Intrinsic Post-Receptor Insulin Signaling Defect -> Hyperandrogenism INDIRECT KNOWN INTERMEDIATES Hyperinsulinemia arising from impaired insulin signaling can act as a co-gonadotropin and increase bioactive androgen exposure. Intermediates: compensatory hyperinsulinemia; ovarian insulin receptor signaling; hepatic SHBG suppression

Intrinsic Post-Receptor Insulin Signaling Defect -> Ovulatory Dysfunction INDIRECT KNOWN INTERMEDIATES Hyperinsulinemia and androgen amplification contribute to follicular arrest and anovulation. Intermediates: increased bioactive androgens; altered pituitary hormone balance

Adiposity-Amplified Insulin Resistance -> Hyperandrogenism INDIRECT KNOWN INTERMEDIATES Obesity-related hyperinsulinemia increases ovarian androgen synthesis and lowers SHBG, raising bioactive androgen exposure. Intermediates: obesity-related hyperinsulinemia; ovarian insulin co-gonadotropin activity; decreased hepatic SHBG synthesis

Deep research

OpenScientist citations 30 citations 2026-06-04T00:54:15.281185

Show evidence (5 references)

PMID:40013621 SUPPORT Other

"Hyperinsulinemia (i.e., elevated insulin without hypoglycemia) is a common metabolic feature of PCOS that worsens its reproductive symptoms by exacerbating pituitary hormone imbalances and increasing levels of bioactive androgens."

Supports hyperinsulinemia as an upstream amplifier of pituitary imbalance and bioactive androgen excess.

PMID:23065822 SUPPORT Other

"Insulin functions as a co-gonadotropin through its cognate receptor to modulate ovarian steroidogenesis."

Supports the ovarian steroidogenesis route by which hyperinsulinemia can increase androgen production.

PMID:17559844 SUPPORT Human Clinical

"In women with typical PCOS and normal insulin levels and metabolic insulin sensitivity, reducing insulin secretion significantly decreased androgen and increased SHBG levels."

Prospective insulin-lowering intervention: eight days of diazoxide lowered androgens and raised SHBG in lean PCOS women whose metabolic insulin sensitivity was normal, so an insulin contribution to hyperandrogenemia does not require measurable insulin resistance. Nine participants and no concurrent randomized control group, so this shows a contribution, not temporal primacy.

+ 2 more references

Neuroendocrine LH-Pulse Model

neuroendocrine_lh_first_model ALTERNATIVE Lean PCOS Obese PCOS

Evidence balance 8 support

Impaired hypothalamic-pituitary sensitivity to ovarian steroid negative feedback maintains rapid LH/GnRH pulse secretion. Elevated LH signaling then drives theca-cell androgen biosynthesis, while androgen excess further impairs steroid feedback and can secondarily worsen insulin resistance.

OpenScientist deep-research verdict (see kb/hypotheses/Polycystic_Ovary_Syndrome/neuroendocrine_lh_first_model): PARTIALLY SUPPORTED — established as a validated component mechanism within a multi-hit PCOS model rather than a standalone causal driver. The upstream arm (impaired progesterone feedback at arcuate KNDy/GABAergic neurons maintaining rapid GnRH/LH pulsatility) is pharmacologically validated by three independent NK3-receptor-antagonist trials (AZD4901, fezolinetant, MLE4901), corroborated by GWAS at the FSHB locus, and reproduced across mouse, sheep, and primate prenatal-androgen models. Key qualifications: (1) LH excess alone is insufficient for ovarian hyperandrogenism — an intrinsic ovarian steroidogenic defect is required (PMID:11756367); (2) correcting the neuronal androgen-receptor axis alone does not rescue the reproductive phenotype in prenatally androgenized mice, so multi-organ programming is needed (PMID:41206009); (3) the neuroendocrine arm best explains anovulation in non-hyperandrogenic PCOS, whereas insulin resistance drives the hyperandrogenic phenotype; and (4) obesity masks pituitary LH output despite persistent hypothalamic GnRH pulse-frequency elevation.

Pathograph links

Hypothalamic-Pituitary Dysregulation -> Hyperandrogenism INDIRECT KNOWN INTERMEDIATES Rapid LH/GnRH pulse secretion increases LH action on ovarian theca cells, promoting androgen biosynthesis. Intermediates: increased LH action at theca-cell LHCGR; CYP17A1-mediated androgen biosynthesis

Deep research

OpenScientist citations 29 citations 2026-07-06T11:24:43.441514

Show evidence (8 references)

PMID:11095431 SUPPORT Human Clinical

"The majority of patients have elevated LH levels in plasma and a persistent rapid frequency of LH (GnRH) pulse secretion, the mechanisms of which are unclear."

Supports the upstream neuroendocrine abnormality represented by this hypothesis group.

PMID:11095431 SUPPORT Human Clinical

"These results suggest that although the elevated LH pulse frequency in PCOS may in part reflect impaired sensitivity to E2 and P, continuing actions of hyperandrogenemia are important for sustaining the abnormal hypothalamic sensitivity to feedback inhibition by ovarian steroids."

Supports the feedback component connecting androgen excess and persistent hypothalamic-pituitary dysregulation.

PMID:27459523 SUPPORT Human Clinical

"The NK3 receptor antagonist AZD4901 specifically reduced LH pulse frequency and subsequently serum LH and T concentrations, thus presenting NK3 receptor antagonism as a potential approach to treating the central neuroendocrine pathophysiology of PCOS."

Phase 2 placebo-controlled RCT pharmacologically validates the KNDy neuron -> GnRH/LH-pulse arm: blocking NK3 signaling lowers LH pulse frequency and downstream androgens in PCOS women.

+ 5 more references

Population-Stratified Mechanistic Heterogeneity

population_stratified_mechanistic_heterogeneity EMERGING

Evidence balance 2 support

PCOS pathophysiology exhibits significant population-specific molecular phenotypes. East Asian populations show a predominant enrichment of metabolic dysregulation-associated pathways (insulin receptor signaling, GLUT4 translocation, metabolic syndrome), whereas European populations exhibit a stronger inflammatory and immune-related signature (NF-kB signaling, innate immunity, and interleukin/cytokine and inflammasome pathways). These population-specific mechanistic differences may drive differential therapeutic responsiveness and clinical phenotypes across ancestry groups.

Show evidence (2 references)

PMID:42365073 SUPPORT Computational

"our analyses reveal a predominant enrichment of metabolic dysregulation-associated pathways in East Asian PCOS, whereas European PCOS exhibits a stronger inflammatory and immune-related signature"

Population-aware gene prioritization framework combining regulatory genomics, QTLs, and protein networks reveals distinct pathway enrichment patterns: East Asian PCOS driven by metabolic dysfunction, European PCOS by inflammation/immunity, with implications for subtype-specific therapeutics.

PMID:42365073 SUPPORT Computational

"These population-specific molecular phenotypes were further supported by transcriptomic data from PCOS patient samples"

Patient transcriptome data validate population-stratified pathway enrichment, confirming mechanistic divergence between East Asian and European PCOS cohorts rather than technical artifacts.

Discussions and Knowledge Gaps

In which PCOS patient strata is androgen excess, insulin resistance or hyperinsulinemia, adiposity, or hypothalamic-pituitary dysregulation the initiating event rather than an amplifier of an already established endocrine-metabolic cycle?

KNOWLEDGE GAP OPEN gap_pcos_causal_hierarchy_by_adiposity

Attached to

pathophysiology#Hyperandrogenism pathophysiology#Intrinsic Post-Receptor Insulin Signaling Defect pathophysiology#Adiposity-Amplified Insulin Resistance pathophysiology#Hypothalamic-Pituitary Dysregulation

Current evidence supports bidirectional reinforcement among androgen excess, hyperinsulinemia/insulin resistance, and adiposity, but it does not establish a single causal sequence that applies across lean and obese PCOS. The entry therefore models three competing or superimposed hypothesis groups and annotates causal edges by subgroup.

Show evidence (4 references)

PMID:38637590 SUPPORT Other

"Treatment remains ad hoc owing to limited understanding of underlying mechanisms, highlighting the need for research delineating the aetiology and pathophysiology of the syndrome."

The Disease Primer frames unresolved PCOS mechanisms as a research need, supporting the explicit knowledge-gap discussion.

PMID:40013621 SUPPORT Other

"Considering the heterogeneous nature of PCOS, it is improbable that its metabolic characteristics always follow the same progression."

Supports subtype-specific causal hierarchy rather than a single universal insulin-resistance sequence.

PMID:41180187 SUPPORT Human Clinical

"Cluster C (43.3%) showed lower BP, BMI, HOMA-IR, triglycerides, testosterone, and FAI and higher LH: FSH, DHEAS, androstenedione, 17-hydroxyprogesterone, SHBG, and HDL."

The largest cluster in a 975-patient NIH-defined cohort combines low insulin resistance with a high LH:FSH ratio, so no single insulin-first or adiposity-first ordering can hold across the syndrome. The measurements are contemporaneous and cross-sectional, so this establishes stratum heterogeneity, not which mechanism initiates in that stratum — which is exactly the gap stated here.

+ 1 more reference

Granulosa cell apoptosis is a primary driver of follicular arrest and impaired oocyte maturation in PCOS, but the upstream triggers of that apoptosis remain unclear. Is a PCSK9 -> lipid metabolism abnormality -> AMPK/GSK-3beta -> apoptosis cascade a primary, translatable mechanism in human PCOS, and how does it relate to the parallel ferroptosis-autophagy and ER/oxidative-stress death programs already described in granulosa cells?

KNOWLEDGE GAP OPEN gap_pcos_granulosa_apoptosis_pcsk9

Attached to

pathophysiology#Granulosa Cell Apoptosis via PCSK9-Lipid Dysregulation pathophysiology#Ovulatory Dysfunction pathophysiology#Chronic Low-Grade Inflammation

Granulosa cell death is recognized as one of the primary factors impairing follicular growth, development, and oocyte maturation in PCOS, yet its upstream pathological triggers have been poorly defined. Teng et al. (2026) propose a specific cascade in which elevated proprotein convertase subtilisin/kexin type-9 (PCSK9) drives lipid metabolism abnormalities that activate AMP-activated protein kinase (AMPK) and glycogen synthase kinase 3beta (GSK-3beta) within follicles, triggering granulosa cell apoptosis and impairing ovarian function. Several questions remain unresolved. First, the cascade was established in PCOS model mice and primary follicles, so whether elevated PCSK9 is a primary driver in human PCOS rather than a species- or model-specific finding is unknown. Second, the proximal mechanism by which PCSK9-driven lipid abnormalities impair granulosa cell survival (intracellular lipid-droplet accumulation versus altered membrane lipid composition versus lipotoxic oxidative stress) is undefined. Third, it is unclear whether AMPK/GSK-3beta is the dominant death pathway or whether it operates in parallel with the previously modeled ferroptosis-autophagy crosstalk and ER/oxidative-stress programs that also drive granulosa cell loss. Resolving the relative contribution and translatability of these death pathways would clarify whether PCSK9 inhibition is a viable PCOS-directed therapeutic target.

Proposed experiments

PCSK9-lipid-AMPK/GSK-3beta apoptosis cascade in human granulosa cells with model comparison

mechanistic intervention study with human-tissue and animal-model arms

exp_pcos_pcsk9_granulosa_apoptosis_human_vs_model

Compare PCSK9 expression, follicular-fluid and intracellular lipid profiles, AMPK/GSK-3beta activation status, and apoptosis markers in granulosa cells from PCOS patients versus controls, alongside PCSK9 gain- and loss-of-function in primary granulosa cells and PCOS model mice. Use pharmacologic PCSK9 inhibition and AMPK/GSK-3beta blockade to test whether interrupting the cascade rescues granulosa cell survival and follicular development, and assay ferroptosis/autophagy and ER-stress markers in parallel to determine pathway dominance versus redundancy.

Readouts

Granulosa cell apoptosis after PCSK9 modulation

pathophysiology#Granulosa Cell Apoptosis via PCSK9-Lipid Dysregulation

Quantify granulosa cell apoptosis (caspase-3 activity, TUNEL, annexin V) in response to PCSK9 overexpression, PCSK9 inhibition, and AMPK/GSK-3beta blockade in human and mouse granulosa cells.

TUNEL apoptosis assay caspase-3 activity assay

Direction: POSITIVE

Lipid handling and AMPK/GSK-3beta signaling

pathophysiology#Granulosa Cell Apoptosis via PCSK9-Lipid Dysregulation

Measure intracellular lipid-droplet content, membrane lipid composition, and phosphorylation of AMPK and GSK-3beta to map the proximal lipotoxic-to-apoptotic signaling link.

intracellular lipid quantification phospho-protein immunoblotting

Direction: POSITIVE

Follicular development and ovulatory rescue

pathophysiology#Ovulatory Dysfunction

Assess antral follicle counts, dominant follicle selection, ovulation rate, and oocyte maturation after cascade interruption in PCOS model mice to test functional reversibility.

ovarian histomorphometry oocyte maturation scoring

Direction: NEGATIVE

Decision criterion

The PCSK9-lipid-AMPK/GSK-3beta cascade is supported as a primary, translatable apoptosis driver if elevated PCSK9 and AMPK/GSK-3beta activation are reproducibly associated with increased granulosa cell apoptosis in human PCOS tissue, PCSK9 or AMPK/GSK-3beta inhibition reduces apoptosis and restores follicular development in models, and the effect is at least partially independent of the ferroptosis-autophagy and ER-stress death programs.

Would support

pathophysiology#Granulosa Cell Apoptosis via PCSK9-Lipid Dysregulation pathophysiology#Ovulatory Dysfunction

Show evidence (2 references)

PMID:42093080 SUPPORT Model Organism

"The mechanism underlying granulosa cell apoptosis in polycystic ovary syndrome remains unclear."

Directly states the unresolved mechanism that this knowledge-gap discussion captures.

PMID:42093080 SUPPORT Model Organism

"Results demonstrated that elevated PCSK9 levels induce lipid metabolism abnormalities in PCOS mice, subsequently activating AMP-activated protein kinase and glycogen synthase kinase 3β within follicles."

Establishes the proposed PCSK9 -> lipid abnormality -> AMPK/GSK-3beta cascade in PCOS model mice that the gap and proposed experiments interrogate for human translatability.

Given the distinct population-stratified molecular phenotypes of PCOS (metabolic-dominant in East Asian populations, inflammatory-dominant in European populations), are currently approved therapies (metformin, oral contraceptives, spironolactone) equally effective across ancestry groups? Should therapeutic prioritization differ by population-specific mechanism, with metabolic pathway inhibitors favored in East Asian PCOS and immunomodulatory or anti-inflammatory agents in European PCOS?

KNOWLEDGE GAP OPEN gap_pcos_population_specific_therapeutics

Attached to

pathophysiology#Intrinsic Post-Receptor Insulin Signaling Defect pathophysiology#Adiposity-Amplified Insulin Resistance pathophysiology#Chronic Low-Grade Inflammation

Population-stratified mechanistic analyses reveal that East Asian PCOS is enriched for metabolic dysregulation pathways while European PCOS exhibits stronger inflammatory and immune signatures. The heterogeneous molecular architecture suggests that therapeutic responses may vary by ancestry, yet current PCOS treatment guidelines do not account for mechanistic diversity. Whether therapies targeting the predominant mechanism in each population (e.g., metabolic pathway inhibitors for East Asian PCOS, anti-inflammatory agents for European PCOS) would improve clinical outcomes relative to universal treatment remains untested.

Show evidence (1 reference)

PMID:42365073 SUPPORT Computational

"integration of genetic evidence with a network-based approach enabled the identification of druggable targets lacking direct genetic cues"

Network-based gene prioritization strategy identifies population-specific druggable targets and therapeutic candidates that would not emerge from genetic associations alone, laying a foundation for ancestry-informed precision therapeutics.

The PCSK9 -> lipid metabolism abnormality -> AMPK/GSK-3beta -> granulosa cell apoptosis cascade was established in PCOS model mice and primary mouse follicles. Is elevated PCSK9 a primary driver of granulosa cell apoptosis in human PCOS, or is its causal, apoptosis-initiating role a species- or model-specific finding that does not translate to human follicular biology?

HUMAN MODEL MISMATCH OPEN gap_pcos_pcsk9_granulosa_mouse_model_mismatch

Attached to

pathophysiology#Granulosa Cell Apoptosis via PCSK9-Lipid Dysregulation pathophysiology#Ovulatory Dysfunction

Granulosa cell apoptosis is recognized as a primary factor impairing follicular growth, oocyte maturation, and fertility in PCOS, but its upstream triggers remain unclear. Teng et al. (2026) provide mechanistic evidence in PCOS model mice that elevated proprotein convertase subtilisin/ kexin type-9 (PCSK9) induces lipid metabolism abnormalities that activate AMP-activated protein kinase (AMPK) and glycogen synthase kinase 3beta (GSK-3beta) within follicles, triggering granulosa cell apoptosis. This is not a generic knowledge gap in which evidence is absent; rather, positive mechanistic evidence exists in a mouse model and the open question is its translational validity to human disease. The mismatch is mechanistically meaningful because PCSK9, hepatic and ovarian lipid handling, and androgen-driven lipotoxicity differ substantially between rodents and humans, so a cascade that is causal and apoptosis-initiating in mouse follicles could be absent, secondary, or merely correlative in human PCOS ovaries. Resolving whether elevated PCSK9 is a primary human driver is a prerequisite for treating PCSK9 inhibition as a PCOS-directed therapeutic target rather than a mouse-specific observation.

Proposed experiments

PCSK9 and granulosa cell apoptosis in human PCOS follicles

human granulosa cell apoptosis and follicular-fluid PCSK9 profiling study

exp_pcos_pcsk9_human_granulosa_apoptosis

Measure PCSK9 levels in follicular fluid and granulosa cells from PCOS patients versus matched controls undergoing assisted reproduction, and correlate with intrafollicular lipid profiles, AMPK and GSK-3beta phosphorylation status, and granulosa cell apoptosis markers. Elevated PCSK9 reproducibly tracking with AMPK/GSK-3beta activation and increased apoptosis in human PCOS tissue would support translational validity of the mouse-derived cascade; absence of this association would indicate a model-specific finding.

Model systems

Human PCOS patient-derived granulosa cells

Granulosa cells and matched follicular fluid recovered at oocyte retrieval from PCOS patients and ovulatory controls, preserving human ovarian lipid-handling and apoptosis biology.

PRIMARY CELL CULTURE

PCSK9 gain- and loss-of-function in human granulosa cell apoptosis assay

human granulosa cell apoptosis assay

exp_pcos_pcsk9_human_granulosa_perturbation

In primary human granulosa cells, test whether PCSK9 overexpression induces, and PCSK9 inhibition or AMPK/GSK-3beta blockade rescues, lipid accumulation and apoptosis. Demonstrating that PCSK9 manipulation causally raises and lowers human granulosa cell apoptosis through the AMPK/GSK-3beta axis would establish the cascade as a primary, translatable human mechanism rather than a mouse-restricted one.

Model systems

Primary human granulosa cell culture

Cultured primary granulosa cells from human ovarian follicles used for PCSK9 gain- and loss-of-function manipulation and apoptosis readouts.

PRIMARY CELL CULTURE

Seeded from PMID:42093080 — Lipid metabolism abnormalities induced by elevated PCSK9 in polycystic ovary syndrome mice lead to ovarian granulosa cell apoptosis via AMPK and GSK-3β. Complements the same-source KNOWLEDGE_GAP discussion gap_pcos_granulosa_apoptosis_pcsk9; this entry adds the HUMAN_MODEL_MISMATCH translational framing and proposed human experiments.

Does androgen excess in PCOS impair insulin action directly at insulin target tissues, or only indirectly — by promoting visceral and android fat deposition, and through androgen-receptor signalling in neurons? The entry asserts both an androgen-to-intrinsic-insulin-defect edge and an androgen-to-adiposity-amplified-insulin-resistance edge; is the first of those a distinct mechanism, or the second one seen at a different scale?

KNOWLEDGE GAP OPEN gap_pcos_androgen_to_insulin_resistance_directness

Attached to

pathophysiology#Hyperandrogenism pathophysiology#Intrinsic Post-Receptor Insulin Signaling Defect pathophysiology#Adiposity-Amplified Insulin Resistance

Both androgen-to-insulin edges on the Hyperandrogenism node are already typed INDIRECT_KNOWN_INTERMEDIATES, but their intermediates differ (androgen receptor action in muscle and adipose tissue versus visceral fat deposition and adipokine change) and nothing in the entry distinguishes them experimentally. The mouse data locate the critical androgen-receptor target for the metabolic phenotype outside the ovary, in neurons, which is a mediated rather than a direct tissue-level route; but the mediation itself — hypothalamic androgen receptor to gonadotropin output to metabolic regulation — has not been tested by any experiment cited here. The nearest human evidence of prolonged androgen exposure comes from testosterone-treated transmasculine adults, where body composition and lipids deteriorate while fasting glucose and insulin do not measurably change; that is a different population with a different developmental history and an exogenously controlled gonadal axis, so it constrains a simple pharmacological androgen-to-insulin-resistance claim without settling the question in PCOS. Resolving this matters for whether antiandrogen therapy should be expected to improve metabolic endpoints at all, or only those that follow fat redistribution.

Show evidence (2 references)

PMID:28320971 SUPPORT Model Organism

"Neuron-specific AR signaling was required for the development of dysfunctional ovulation, classic polycystic ovaries, reduced large antral follicle health, and several metabolic traits including obesity and dyslipidemia."

Shows the metabolic arm of the DHT mouse phenotype depends on androgen-receptor signalling in neurons rather than in the ovary, which is what makes a purely direct peripheral androgen-to-insulin route doubtful and the mediating steps the open question.

PMID:42171672 SUPPORT INDIRECT Human Clinical

"Fasting glucose, insulin, and blood pressure did not change meaningfully. The lipid profile worsened: LDL, total cholesterol and triglycerides increased, and HDL decreased throughout the study period. Weight, body mass index, waist circumference, and waist-to-hip ratio increased."

Ten years of testosterone in 57 transmasculine adults shifted body composition toward android fat and worsened lipids while leaving fasting glucose and insulin unchanged — the dissociation this gap is about. Graded INDIRECT: a single-centre observational cohort outside PCOS, with no PCOS counterfactual and a pharmacologically controlled gonadal axis, so it cannot adjudicate causality within the syndrome.

Are the elevated 11-oxygenated androgens of PCOS a driver of the hyperandrogenic phenotype, or a marker of adrenal and adipose androgen handling that tracks it? And is their production insulin-dependent in common PCOS, as insulin-receptor signalling makes it in syndromes of severe insulin resistance?

KNOWLEDGE GAP OPEN gap_pcos_11_oxygenated_androgen_causality

Attached to

biochemical#11-Oxygenated Androgens pathophysiology#Hyperandrogenism pathophysiology#Adiposity-Amplified Insulin Resistance

11-oxygenated C19 steroids discriminate PCOS from controls better than total testosterone does, which is why they are curated as a biochemical marker here. Diagnostic discrimination is not mechanism, however, and the entry deliberately does not give them a pathophysiology node. Two lines of work make an insulin-dependent route plausible without establishing it for common PCOS: in women with syndromes of severe insulin resistance, 11-oxygenated androgens are raised in lipodystrophy but not in insulin receptoropathy, implying that intact insulin-receptor signalling is required for the adrenal excess; and in an adipocyte model, insulin-induced AKR1C3 converts 11-oxygenated precursors to potent androgens. The first is 18 women with rare monogenic disease, the second is a cell model, and neither measures the route in ordinary PCOS. The question is also directional: if 11-oxygenated androgens are largely adrenal and insulin-driven, they sit downstream of hyperinsulinemia rather than upstream of it, which would make the classical ovarian and the 11-oxygenated arms separate contributors rather than one androgen pool.

Show evidence (2 references)

PMID:35696182 SUPPORT INDIRECT Human Clinical

"11-Oxygenated androgens are elevated in lipodystrophy but not receptoropathy. In SIR, insulin receptor signaling is necessary for adrenal hyperandrogenemia but not ovarian hyperandrogenemia; excess classic androgens are derived from the ovaries."

The natural-experiment contrast that motivates the insulin-dependence half of this gap, and the reason it is a gap rather than a curated mechanism: the cohort is 18 women with rare severe-insulin-resistance syndromes, not common PCOS, so the inference to PCOS is an extrapolation.

PMID:35560164 SUPPORT In Vitro

"We conclude that the 11-oxygenated androgens formed in adipocytes may contribute to the hyperandrogenic profile of PCOS women and that AKR1C3 is a potential therapeutic target to mitigate the AE of PCOS."

Supplies the candidate peripheral mechanism — insulin-induced AKR1C3 activating 11-oxygenated precursors in adipocytes — while stating it at the level this gap records: the authors write that these androgens "may contribute", from recombinant-enzyme kinetics and a differentiated adipocyte line rather than from PCOS tissue.

⚙

Pathophysiology

Hyperandrogenism

Excess androgen production from ovarian theca cells and adrenal glands leads to hirsutism, acne, and alopecia. Elevated LH stimulates theca cell androgen production.

Androgen-First Feedback Model Neuroendocrine LH-Pulse Model

Androgen Biosynthesis GO:0006702

Downstream

Intrinsic Post-Receptor Insulin Signaling Defect Androgen excess can worsen insulin resistance and hyperinsulinemia, creating a self-perpetuating endocrine-metabolic loop.

Adiposity-Amplified Insulin Resistance Hyperandrogenism favors visceral adiposity and adverse adipose signaling, which can amplify insulin resistance in obese PCOS.

Hypothalamic-Pituitary Dysregulation Ongoing androgen excess helps sustain abnormal hypothalamic sensitivity to estradiol/progesterone negative feedback, maintaining rapid LH/GnRH pulse secretion.

Ovulatory Dysfunction Elevated androgen exposure disrupts follicle maturation and contributes to anovulation.

Show evidence (4 references)

PMID:38152131 SUPPORT Other

"Compelling evidence suggests that hyperandrogenism is not just a primary feature of PCOS. Instead, it may be a causative factor for this condition."

This review establishes hyperandrogenism as potentially causative rather than merely symptomatic in PCOS pathophysiology.

PMID:24014605 SUPPORT Human Clinical

"LHCGR and 17α-hydroxylase/17-20-lyase (CYP17A1) protein levels are increased in polycystic ovaries (PCOs)."

Direct evidence of increased androgen biosynthetic machinery (CYP17A1) in PCOS ovaries, supporting intrinsic theca cell abnormality.

PMID:24014605 SUPPORT Human Clinical

"A significant increase in the intensity of immunostaining for CYP17A1 was identified in antral follicles in sections of PCO compared with ovaries from normal women (P = 0.04)."

Quantitative demonstration of elevated CYP17A1 protein in polycystic ovaries compared to controls.

+ 1 more reference

Hypothalamic-Pituitary Dysregulation

Impaired hypothalamic-pituitary sensitivity to estradiol and progesterone negative feedback maintains rapid LH/GnRH pulse secretion. Elevated LH then stimulates theca-cell androgen biosynthesis, while hyperandrogenism can sustain the abnormal feedback state.

Neuroendocrine LH-Pulse Model

Increased Luteinizing Hormone Secretion GO:0032275 ↑ INCREASED

Downstream

Hyperandrogenism Rapid LH/GnRH pulse secretion increases LH action on ovarian theca cells, promoting androgen biosynthesis.

Show evidence (2 references)

PMID:11095431 SUPPORT Human Clinical

"The majority of patients have elevated LH levels in plasma and a persistent rapid frequency of LH (GnRH) pulse secretion, the mechanisms of which are unclear."

Human endocrine profiling supports elevated LH and rapid LH/GnRH pulse secretion as a PCOS pathophysiology node.

PMID:11095431 SUPPORT Human Clinical

Antiandrogen intervention restoring feedback sensitivity supports a bidirectional link between hyperandrogenism and hypothalamic-pituitary dysregulation.

Intrinsic Post-Receptor Insulin Signaling Defect

PCOS-associated insulin resistance can reflect an intrinsic post-binding or post-receptor defect in insulin signaling that is independent of obesity. Defective insulin receptor or IRS-associated signaling decreases metabolic glucose disposal while ovarian steroidogenic actions of insulin may remain active, allowing insulin and LH to amplify androgen production.

Insulin/Hyperinsulinemia-First Model

Insulin Signaling GO:0008286 ↓ DECREASED

Downstream

Hyperandrogenism Hyperinsulinemia arising from impaired insulin signaling can act as a co-gonadotropin and increase bioactive androgen exposure.

Ovulatory Dysfunction Hyperinsulinemia and androgen amplification contribute to follicular arrest and anovulation.

Show evidence (6 references)

PMID:1397698 SUPPORT Human Clinical

"Because insulin binding was not changed, we conclude that the major lesion causing insulin resistance in PCO is a striking decrease in insulin sensitivity secondary to a defect in the insulin receptor and/or postreceptor signal transduction."

Human clamp and adipocyte data support a post-binding/post-receptor insulin signaling defect as an intrinsic PCOS mechanism.

PMID:11440917 SUPPORT Human Clinical

"We conclude that there is a physiologically relevant defect in insulin receptor signaling in PCOS that is independent of obesity and type 2 diabetes mellitus."

Skeletal muscle signaling data support an obesity-independent insulin receptor signaling defect in PCOS.

PMID:23065822 SUPPORT Other

"There is a post-binding defect in receptor signaling likely due to increased receptor and insulin receptor substrate-1 serine phosphorylation that selectively affects metabolic but not mitogenic pathways in classic insulin target tissues and in the ovary."

Review evidence supports selective metabolic insulin resistance with preserved non-metabolic insulin signaling branches.

+ 3 more references

Adiposity-Amplified Insulin Resistance

Abdominal or visceral adiposity amplifies insulin resistance and hyperinsulinemia in susceptible PCOS patients. This pathway separates obesity-related hepatic/adipose insulin resistance from intrinsic lean-PCOS insulin signaling defects and explains why obesity worsens androgenic and reproductive features without being required for PCOS.

Androgen-First Feedback Model Insulin/Hyperinsulinemia-First Model

Insulin Signaling GO:0008286 ↓ DECREASED

Downstream

Hyperandrogenism Obesity-related hyperinsulinemia increases ovarian androgen synthesis and lowers SHBG, raising bioactive androgen exposure.

Chronic Low-Grade Inflammation Visceral adiposity and insulin resistance contribute to the inflammatory state shared by PCOS, obesity, type 2 diabetes, and cardiovascular disease.

Show evidence (3 references)

PMID:12080440 SUPPORT Other

"Obesity, particularly the abdominal phenotype, may be partly responsible for insulin resistance and associated hyperinsulinemia in women with PCOS."

Supports a distinct adiposity-amplified insulin resistance node for obese PCOS.

PMID:12080440 SUPPORT Other

"Therefore, obesity-related hyperinsulinemia may play a key role in favouring hyperandrogenism in these women."

Supports the adiposity-to-hyperinsulinemia-to-hyperandrogenism causal route.

PMID:37213054 SUPPORT Other

"This disease causes menstrual, metabolic, and biochemical abnormalities such as hyperandrogenism, oligo-anovulatory menstrual cycles, polycystic ovary, hyperleptinemia, insulin resistance (IR), and cardiometabolic disorders, often associated with overweight or obesity and visceral adiposity."

Recent review evidence supports separating visceral-adiposity-associated PCOS metabolic dysfunction from nonobese mechanisms.

Ovulatory Dysfunction

Disrupted folliculogenesis with arrest at small antral stage leads to anovulation. Multiple small follicles accumulate (polycystic morphology) without dominant follicle selection.

Ovulation GO:0030728

Show evidence (3 references)

PMID:14671196 SUPPORT Human Clinical

"Because PCOS is associated with a 2- to 3-fold increase in growing FN, we investigated whether an increased AMH serum level correlates to other hormonal and/or U/S features of PCOS."

Documents the 2-3 fold increase in small growing follicle number characteristic of PCOS polycystic morphology.

PMID:14671196 SUPPORT Human Clinical

"Mean serum AMH level was markedly increased in the PCOS group (47.1 +/- 22.9 vs. 20.8 +/- 11.6 pmol/liter in controls; P < 0.0001), an increase in the same order of magnitude as the one of the FN in the 2- to 5-mm range at U/S (12.8 +/- 8.3 vs. 4.8 +/- 1.9; P < 0.0001, respectively)."

Shows parallel elevation of AMH levels and small antral follicle count in PCOS, implicating AMH in follicular arrest.

PMID:14671196 SUPPORT Human Clinical

"We hypothesize that an increased AMH tone within the cohort could be involved in the follicular arrest of PCOS, by interacting negatively with FSH at the time of selection."

Proposes mechanism by which elevated AMH interferes with FSH action to prevent dominant follicle selection in PCOS.

Oxidative and Endoplasmic Reticulum Stress

Synergistic oxidative stress (OS) and endoplasmic reticulum stress (ERS) form an intracellular stress hub that initiates autophagy-ferroptosis crosstalk in ovarian granulosa cells, driving follicular atresia and ovulatory dysfunction.

granulosa cell CL:0000501

Oxidative Stress Response GO:0006979 ↑ INCREASED Endoplasmic Reticulum Stress Response GO:0034976 ↑ INCREASED

Downstream

Granulosa Cell Ferroptosis-Autophagy Crosstalk Oxidative and ER stress serve as the initiating hub that triggers downstream autophagy-ferroptosis crosstalk in granulosa cells.

Show evidence (1 reference)

PMID:42178591 SUPPORT Other

"the intracellular stress hub formed by the synergistic action of oxidative stress (OS) and endoplasmic reticulum stress (ERS) serves as the initiating factor"

Establishes OS and ERS synergy as the initiating hub driving granulosa cell dysfunction and autophagy-ferroptosis crosstalk in PCOS.

Gut Microbiome Dysregulation and Gut-Ovarian Axis Inflammation

Dysbiosis-driven gut microbiome dysfunction amplifies low-grade chronic inflammation via the gut-ovarian axis, exacerbating granulosa cell dysfunction and follicular atresia through long-range immune and metabolic signaling.

Inflammatory Response GO:0006954 ↑ INCREASED

Downstream

Chronic Low-Grade Inflammation Gut microbiome dysregulation amplifies systemic low-grade chronic inflammation via the gut-ovarian axis.

Show evidence (1 reference)

PMID:42178591 SUPPORT Other

"the gut-ovarian axis's long-range amplification effect, mediated by gut microbiome (GM) dysregulation and low-grade chronic inflammation (LGI), collectively disrupting cellular homeostasis"

Establishes the gut-ovarian axis as a long-range amplification mechanism linking microbiome dysregulation to granulosa cell dysfunction via chronic inflammation.

Chronic Low-Grade Inflammation

Elevated inflammatory markers (CRP, IL-6) contribute to insulin resistance and cardiovascular risk in PCOS.

Inflammatory Response GO:0006954

Show evidence (2 references)

PMID:39036884 SUPPORT Human Clinical

"Polycystic ovarian syndrome (PCOS) is related to pro-apoptotic and pro-inflammatory conditions generated by Endoplasmic reticulum (ER) stress."

Establishes the link between ER stress, inflammation, and apoptotic pathways in PCOS pathophysiology.

PMID:39036884 SUPPORT Human Clinical

"The levels of TNF-α (p = 0.009), IL-18 (p = 0.003), IL-6 (p = 0.013) and active caspase-3 (p = 0.012) were also statistically significant lower in the therapy group."

Shows that TNF-alpha, IL-18 and IL-6 are pharmacologically reducible in women with PCOS, indicating an active inflammatory state that is a treatment target. It compares treated vs placebo PCOS arms, so it does NOT by itself demonstrate that these cytokines are elevated in PCOS relative to healthy controls; a PCOS-versus-control comparison is still needed for the "elevated inflammatory markers" claim.

Granulosa Cell Ferroptosis-Autophagy Crosstalk

Granulosa cell dysfunction in PCOS arises from pathological crosstalk between autophagy and ferroptosis rather than from a single mode of cell death. Selective autophagy mechanisms (ferritinophagy and mitophagy) amplify ferroptosis through iron overload and energy collapse, driving follicular atresia and ovulatory dysfunction.

Granulosa cell CL:0000501

Ferroptosis GO:0097707 ↑ INCREASED Autophagy GO:0006914 ↑ INCREASED

Downstream

Ovulatory Dysfunction Granulosa-cell ferroptosis and autophagy-amplified cell death promote follicular atresia and impair dominant-follicle selection.

Show evidence (2 references)

PMID:42178591 SUPPORT Other

"The dysfunction of GCs in PCOS is not an isolated event involving a single mode of cell death, but rather a pathological crosstalk arising from the disruption of the dynamic equilibrium between autophagy and ferroptosis."

The review identifies ferroptosis-autophagy crosstalk as a central feature of granulosa-cell dysfunction in PCOS.

PMID:42178591 SUPPORT Other

"selective autophagy (e.g., ferritinophagy and mitophagy) acts as a key amplifier of ferroptosis by exacerbating iron overload and energy collapse."

Supports selective autophagy as an amplifier of ferroptosis through iron overload and energetic failure.

Circadian Disruption and Epigenetic Reprogramming in Granulosa Cells

Circadian rhythm disruption and epigenetic reprogramming entrench the granulosa cell autophagy-ferroptosis imbalance at the temporal and molecular memory levels, amplifying follicular atresia.

Granulosa cell CL:0000501

Circadian Rhythm GO:0007623 ⚠ ABNORMAL Epigenetic Regulation of Gene Expression GO:0040029 ⚠ ABNORMAL

Downstream

Granulosa Cell Ferroptosis-Autophagy Crosstalk Circadian and epigenetic reprogramming entrench the autophagy-ferroptosis imbalance rather than initiating it.

Show evidence (1 reference)

PMID:42178591 SUPPORT Other

"circadian rhythm disruption and epigenetic reprogramming, respectively, cement this imbalance at the temporal and molecular memory levels."

Highlights circadian rhythm disruption and epigenetic reprogramming as the mechanisms that entrench the ferroptosis-autophagy imbalance in PCOS.

Granulosa Cell Apoptosis via PCSK9-Lipid Dysregulation

Elevated PCSK9 (proprotein convertase subtilisin/kexin type-9) in ovarian follicles triggers lipid metabolism abnormalities that activate AMP-activated protein kinase (AMPK) and glycogen synthase kinase 3β (GSK-3β), leading to granulosa cell apoptosis. This PCSK9-lipid-AMPK/GSK-3β cascade represents a distinct apoptotic pathway in granulosa cell death, independent of the ferroptosis-autophagy crosstalk mechanism, and may contribute to follicular atresia and ovulatory dysfunction in PCOS.

Granulosa cell CL:0000501

Phosphorylation (AMPK and GSK-3β Activation) GO:0016310 ↑ INCREASED Apoptosis GO:0006915 ↑ INCREASED Lipid Metabolism Abnormalities GO:0006629 ⚠ ABNORMAL

Downstream

Ovulatory Dysfunction PCSK9-driven granulosa cell apoptosis leads to loss of granulosa cell support for follicular maturation, resulting in follicular arrest and anovulation.

Show evidence (2 references)

PMID:42093080 SUPPORT Model Organism

"elevated PCSK9 levels induce lipid metabolism abnormalities in PCOS mice, subsequently activating AMP-activated protein kinase and glycogen synthase kinase 3β within follicles. This activation triggers granulosa cell apoptosis"

Direct mechanistic evidence in PCOS model mice establishing the PCSK9 → lipid abnormality → AMPK/GSK-3β → apoptosis cascade as a driver of granulosa cell death.

PMID:42093080 SUPPORT Model Organism

"Granulosa cell apoptosis in the ovaries is one of the primary factors affecting follicular growth and development as well as oocyte maturation in PCOS, yet its pathological mechanisms remain unclear."

Establishes granulosa cell apoptosis as a primary mechanism impairing follicular development and oocyte maturation in PCOS, motivating mechanistic investigation of upstream drivers like PCSK9.

Population-Specific Metabolic vs. Inflammatory Dysregulation

PCOS manifests with distinct molecular pathophysiology across populations. East Asian PCOS exhibits predominant enrichment of metabolic dysregulation pathways with emphasis on insulin/IGF signaling and gonadotropin receptor pathways. European PCOS shows a stronger inflammatory and immune-related signature, featuring enrichment of the TLR4-NF-κB-NLRP3 signaling axis. This population-specific molecular heterogeneity suggests distinct pathophysiological drivers and therapeutic opportunities across ancestries.

INS hgnc:6081 INSR hgnc:6091 IGF1R hgnc:5465 FSHR hgnc:3969 LHCGR hgnc:6585 NFKB1 hgnc:7794 IRF1 hgnc:6116

Insulin Receptor Signaling GO:0008286 Inflammatory Response GO:0006954

Show evidence (3 references)

PMID:42365073 SUPPORT Computational

"Notably, our analyses reveal a predominant enrichment of metabolic dysregulation-associated pathways in East Asian PCOS, whereas European PCOS exhibits a stronger inflammatory and immune-related signature."

Population-stratified gene prioritization reveals distinct metabolic versus inflammatory molecular signatures across East Asian and European populations, supported by transcriptomic validation in PCOS patient samples.

PMID:42365073 SUPPORT Computational

"genes like INS, INSR and IGF1R implicating insulin signaling and FSHR, LHCGR involving gonadotropin related signaling were exclusively present in the EAS population"

East Asian PCOS prioritizes insulin/IGF and gonadotropin signaling genes, reflecting the metabolic and hormonal dysfunction-dominant phenotype in this population.

PMID:42365073 SUPPORT Computational

"immune-related genes were differentially prioritized in the EUR population (Supplementary Data 2, II) with, NF-B1, APP, IRF1 and few others"

European PCOS shows preferential prioritization of immune-centric genes, reflecting the stronger inflammatory and immune-related signature of this population.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Genitourinary 2

Irregular Menstruation VERY_FREQUENT HP:0000858

Show evidence (1 reference)

PMID:14671196 SUPPORT Human Clinical

"We hypothesize that an increased AMH tone within the cohort could be involved in the follicular arrest of PCOS, by interacting negatively with FSH at the time of selection."

Supports the follicular-arrest mechanism that underlies anovulation. The snippet is an explicitly hypothetical statement and does not mention menstrual irregularity or its frequency.

Infertility FREQUENT HP:0000789

Show evidence (1 reference)

PMID:14671196 SUPPORT Human Clinical

"Because PCOS is associated with a 2- to 3-fold increase in growing FN, we investigated whether an increased AMH serum level correlates to other hormonal and/or U/S features of PCOS."

Documents the increased growing-follicle number that underlies polycystic ovarian morphology. It does not mention infertility or fertility outcomes; a dedicated fertility-outcome citation is still needed.

Immune 1

Acne FREQUENT HP:0001061

Integument 2

Hirsutism VERY_FREQUENT HP:0001007

Show evidence (1 reference)

PMID:38152131 SUPPORT Other

"Compelling evidence suggests that hyperandrogenism is not just a primary feature of PCOS. Instead, it may be a causative factor for this condition."

Supports hyperandrogenism as a central and possibly causal PCOS mechanism, the accepted driver of hirsutism. The snippet itself does not mention hirsutism and does not support the VERY_FREQUENT band; a hirsutism-specific prevalence citation is still needed.

Alopecia OCCASIONAL HP:0001596

Androgenic pattern

Growth 1

Obesity FREQUENT HP:0001513

🧬

Genetic Associations

DENND1A (Risk Factor)

Gene: DENND1A hgnc:29324

Show evidence (2 references)

PMID:31184707 SUPPORT In Vitro

"The comparison of miR-130b-3p in normal and PCOS theca cells demonstrated decreased miR-130b-3p expression in PCOS theca cells, which was correlated with increased DENND1A.V2, cytochrome P450 17α-hydroxylase (CYP17A1) mRNA and androgen biosynthesis."

Connects the DENND1A risk locus to the intrinsic theca-cell steroidogenic phenotype curated under Hyperandrogenism: loss of miR-130b-3p repression raises DENND1A.V2 and CYP17A1 together with androgen output in theca cells isolated from women with PCOS. In vitro in isolated theca cells, and the DENND1A.V2 link is correlative within that system.

PMID:32574161 SUPPORT Human Clinical

"carriers of previously reported rare variants in DENND1A, a gene that regulates androgen biosynthesis, were significantly more likely to have the reproductive subtype of PCOS"

Rare DENND1A variant carriers segregate with the reproductive (higher LH and SHBG, lower BMI and insulin) rather than the metabolic phenotype cluster, so this locus is not uniformly distributed across PCOS. European ancestry, NIH criteria, and a family-based classification cohort of 73.

THADA (Risk Factor)

Gene: THADA hgnc:19217

LHCGR (Risk Factor)

Gene: LHCGR hgnc:6585 gene page

Show evidence (1 reference)

PMID:42365073 SUPPORT Computational

"genes like INS, INSR and IGF1R implicating insulin signaling and FSHR, LHCGR involving gonadotropin related signaling were exclusively present in the EAS population"

Gonadotropin-signaling gene exclusively prioritized in the East Asian PCOS gene-prioritization list.

FSHR (Risk Factor)

Gene: FSHR hgnc:3969 gene page

Show evidence (1 reference)

PMID:42365073 SUPPORT Computational

"genes like INS, INSR and IGF1R implicating insulin signaling and FSHR, LHCGR involving gonadotropin related signaling were exclusively present in the EAS population"

Gonadotropin-signaling gene exclusively prioritized in the East Asian PCOS gene-prioritization list.

INS (Risk Factor)

Gene: INS hgnc:6081 gene page

Show evidence (1 reference)

PMID:42365073 SUPPORT Computational

"genes like INS, INSR and IGF1R implicating insulin signaling and FSHR, LHCGR involving gonadotropin related signaling were exclusively present in the EAS population"

Insulin-signaling gene exclusively prioritized in the East Asian PCOS gene-prioritization list.

INSR (Risk Factor)

Gene: INSR hgnc:6091 gene page

Show evidence (1 reference)

PMID:42365073 SUPPORT Computational

"genes like INS, INSR and IGF1R implicating insulin signaling and FSHR, LHCGR involving gonadotropin related signaling were exclusively present in the EAS population"

Insulin-receptor gene exclusively prioritized in the East Asian PCOS gene-prioritization list.

IGF1R (Risk Factor)

Gene: IGF1R hgnc:5465 gene page

Show evidence (1 reference)

PMID:42365073 SUPPORT Computational

"genes like INS, INSR and IGF1R implicating insulin signaling and FSHR, LHCGR involving gonadotropin related signaling were exclusively present in the EAS population"

IGF-signaling gene prioritized in the East Asian PCOS gene-prioritization list.

ERBB3 (Risk Factor)

Gene: ERBB3 hgnc:3431 gene page

EGFR (Risk Factor)

Gene: EGFR hgnc:3236 gene page

YAP1 (Risk Factor)

Gene: YAP1 hgnc:16262 gene page

PDGFRA (Risk Factor)

Gene: PDGFRA hgnc:8803 gene page

APP (Risk Factor)

Gene: APP hgnc:620 gene page

Show evidence (1 reference)

PMID:42365073 SUPPORT Computational

"immune-related genes were differentially prioritized in the EUR population (Supplementary Data 2, II) with, NF-B1, APP, IRF1 and few others"

Immune/inflammatory gene preferentially prioritized in the European PCOS gene-prioritization list.

NFKB1 (Risk Factor)

Gene: NFKB1 hgnc:7794 gene page

Show evidence (1 reference)

PMID:42365073 SUPPORT Computational

"immune-related genes were differentially prioritized in the EUR population (Supplementary Data 2, II) with, NF-B1, APP, IRF1 and few others"

NF-kB (NF-B1) immune-pathway gene preferentially prioritized in the European PCOS gene-prioritization list.

IRF1 (Risk Factor)

Gene: IRF1 hgnc:6116 gene page

Show evidence (1 reference)

PMID:42365073 SUPPORT Computational

"immune-related genes were differentially prioritized in the EUR population (Supplementary Data 2, II) with, NF-B1, APP, IRF1 and few others"

Interferon regulatory factor 1 immune-related gene preferentially prioritized in the European PCOS gene-prioritization list.

AR (Risk Factor)

Gene: AR hgnc:644 gene page

Show evidence (1 reference)

PMID:42531755 SUPPORT Human Clinical

"Polymorphisms in genes such as the androgen receptor (AR), cytochrome P450 17A1 (CYP17), and follicle-stimulating hormone receptor (FSHR) have been associated with altered steroidogenesis and ovarian dysfunction, thereby influencing disease severity."

Recent review establishes AR polymorphisms as contributors to altered steroidogenesis and ovarian dysfunction in PCOS pathophysiology.

CYP17A1 (Risk Factor)

Gene: CYP17A1 hgnc:2593 gene page

Show evidence (1 reference)

PMID:42531755 SUPPORT Human Clinical

Recent review identifies CYP17 polymorphisms as key contributors to altered steroidogenesis and ovarian androgen dysregulation in PCOS.

💊

Medical Actions

Combined Oral Contraceptives

Action: combined oral contraceptive therapy Ontology label: Pharmacotherapy NCIT:C15986

Agent: oral contraceptive NCIT:C389

Platform: Small molecule

First-line for menstrual irregularity and hyperandrogenism.

Metformin

Action: Pharmacotherapy NCIT:C15986

Agent: metformin CHEBI:6801

Platform: Small molecule

Improves insulin sensitivity and may restore ovulation.

Show evidence (1 reference)

PMID:25304843 SUPPORT Human Clinical

"In women with PCOS, Metformin induces a prompt decrease in LH-stimulated T secretion after only several days of use. This action precedes the medication's effects on insulin sensitivity or weight loss."

Randomized, double-blinded, placebo-controlled crossover in 19 women with PCOS: two days of metformin already lowered LH-stimulated testosterone, which is the shortest-latency human evidence that metformin acts on ovarian steroidogenesis directly and not only through insulin sensitisation. Small and short, and the free-androgen-index effect was only borderline.

Spironolactone

Action: Pharmacotherapy NCIT:C15986

Agent: spironolactone CHEBI:9241

Platform: Small molecule

Anti-androgen for hirsutism and acne.

Letrozole

Action: aromatase inhibitor therapy Ontology label: Aromatase Inhibition Therapy NCIT:C15525

Agent: letrozole CHEBI:6413

Platform: Small molecule

First-line ovulation induction for fertility.

Clomiphene Citrate

Action: Pharmacotherapy NCIT:C15986

Agent: clomiphene CHEBI:3752

Platform: Small molecule

Alternative ovulation induction agent.

Lifestyle Modification

Action: lifestyle therapy Ontology label: Lifestyle Therapy NCIT:C15900

Platform: Behavioral / lifestyle

Weight loss improves all PCOS features.

ERBB Family Signaling Inhibitors

Action: Pharmacotherapy NCIT:C15986

Platform: Small molecule

ERBB3 and ERBB2 signaling are central nodes in both East Asian and European PCOS genetic networks. ERBB-family receptor tyrosine kinase inhibition is a computationally identified candidate population-agnostic target for disrupting tyrosine kinase signaling implicated in follicular dysfunction and inflammatory amplification. This is an in silico target prediction from gene prioritization and has not been clinically tested in PCOS; no specific inhibitor is nominated by the source.

Show evidence (1 reference)

PMID:42365073 SUPPORT Computational

"EGFR, ERBB3, and YAP1 present in the network of both the population , are involved in signaling by receptor tyrosine kinases and Hippo which are known for their role in PCOS"

Gene prioritization in both East Asian and European populations identifies ERBB family members as highly ranked druggable targets with direct therapeutic potential.

Growth Factor Receptor Inhibitors (FGFR, EGFR, PDGFRA)

Action: Pharmacotherapy NCIT:C15986

Platform: Small molecule

FGFR, EGFR, and PDGFRA signaling pathways are preferentially enriched in East Asian PCOS and are implicated in follicular growth and ovulation. Inhibition of these growth factor receptors is a computationally identified population-specific candidate target for metabolic-dominant PCOS phenotypes. This is an in silico target prediction from gene prioritization and has not been clinically tested in PCOS; no specific inhibitor is nominated by the source.

Show evidence (1 reference)

PMID:42365073 SUPPORT Computational

"signaling pathways involving EGFR, PDGFRA and FGFR which are exclusively enriched due to peripheral genes (Figure 2A (iv)) are within the top priority pathways in EAS population."

Exclusive prioritization of FGFR/EGFR/PDGFRA pathways in East Asian PCOS identifies these as population-specific therapeutic targets for metabolic-dysregulation-dominant disease.

NF-kB and Inflammasome Pathway Inhibitors

Action: Pharmacotherapy NCIT:C15986

Platform: Small molecule

European PCOS exhibits preferential enrichment of TLR4-NF-kB-NLRP3 signaling and inflammasome activation. NF-kB and NLRP3 inflammasome inhibition are computationally identified population-specific candidate targets for inflammatory-dominant PCOS phenotypes, addressing chronic low-grade inflammation driven by immune pathway dysregulation. This is an in silico target prediction from gene prioritization and has not been clinically tested in PCOS; no specific inhibitor is nominated by the source.

Show evidence (1 reference)

PMID:42365073 SUPPORT Computational

"the prioritization of the TLR4 -NF-κB-NLRP3 signaling axis in EUR population"

Gene prioritization in European PCOS reveals preferential dysregulation of TLR4-NF-kB-NLRP3 inflammatory axis, identifying NF-kB and inflammasome inhibition as population-specific therapeutic strategies for immune-dominant disease.

Mesenchymal Stem Cell and Exosome-Based Regenerative Therapy

Action: Mesenchymal stem cell and exosome therapy Ontology label: Cellular Therapy NCIT:C70601

Platform: Cell therapy

Investigational, preclinical regenerative and cell-based disease-modifying strategy for PCOS. Mesenchymal stem cells (MSCs) and their secreted derivatives (including exosomes), together with gene-edited induced pluripotent stem cell (iPSC) platforms, are being explored to move beyond symptom-focused management toward mechanism-directed intervention. In preclinical models these approaches modulate ovarian inflammation, restore ovarian structure, and improve metabolic parameters, while iPSC-based models support patient-specific investigation of steroidogenic and metabolic abnormalities. Not clinically validated in PCOS; translational barriers include targeted delivery, off-target effects, and phenotypic heterogeneity.

Show evidence (1 reference)

PMID:42412303 SUPPORT Model Organism

"Preclinical studies demonstrate that MSCs and their derivatives modulate inflammation, restore ovarian structure, and improve metabolic parameters"

Narrative review summarizing preclinical (predominantly animal-model) mesenchymal stem cell and exosome regenerative studies in PCOS. Investigational and not yet clinically validated in humans.

Glucagon-like Peptide-1 Receptor Agonists

Action: Pharmacotherapy NCIT:C15986

Agent: GLP-1 receptor agonist NCIT:C98085

Platform: Peptide

GLP-1 receptor agonists are emerging as potential therapeutic agents in PCOS, targeting insulin resistance and metabolic dysregulation. Beyond their glucose-lowering effects, GLP-1RAs may improve androgen metabolism and ovulatory function through weight loss and insulin sensitization, offering a multi-pathway intervention approach in metabolic-dominant PCOS phenotypes.

Show evidence (1 reference)

PMID:42531755 SUPPORT Other

"novel therapeutic strategies have emerged, including glucagon-like peptide-1 receptor agonists (GLP-1RAs), microRNA-based therapies, and interleukin-22 (IL-22)-mediated interventions, which show potential in targeting IR and metabolic dysfunction in PCOS."

Recent comprehensive review identifies GLP-1RAs as an emerging therapeutic strategy with demonstrated potential in addressing insulin resistance and metabolic dysfunction in PCOS. The cited sentence is the narrative review's own summary of an emerging therapeutic landscape rather than a result from a primary clinical study, so it is graded OTHER.

microRNA-Based Therapies

Action: Pharmacotherapy NCIT:C15986

Platform: Other

MicroRNA-based therapies represent an emerging precision medicine approach targeting dysregulated miRNA expression in PCOS. MicroRNA modulation may address pathways affecting ovarian function, insulin signaling, and inflammation, offering a mechanistic intervention approach distinct from conventional hormone and metabolic therapies.

Show evidence (1 reference)

PMID:42531755 SUPPORT Other

Recent review establishes microRNA-based therapies as an emerging approach for PCOS with demonstrated potential in targeting insulin resistance and metabolic dysfunction. The cited sentence is the narrative review's own summary of an emerging therapeutic landscape rather than a result from a primary clinical study, so it is graded OTHER, consistent with this treatment's preclinical-stage notes.

Interleukin-22-Mediated Interventions

Action: Pharmacotherapy NCIT:C15986

Platform: Other

IL-22-mediated interventions represent an emerging immunomodulatory approach to PCOS, targeting the IL-22 cytokine pathway to enhance metabolic and reproductive function. IL-22 signaling supports epithelial barrier integrity and metabolic homeostasis, with potential applications in addressing both metabolic dysfunction and chronic low-grade inflammation in PCOS.

Show evidence (1 reference)

PMID:42531755 SUPPORT Other

Recent review identifies IL-22-mediated interventions as an emerging therapeutic strategy with potential in PCOS pathophysiology. The cited sentence is the narrative review's own summary of an emerging therapeutic landscape rather than a result from a primary clinical study, so it is graded OTHER, consistent with this treatment's preclinical-stage notes.

Microbiota Modulation Therapy

Action: microbiota modulation therapy Ontology label: Lifestyle Therapy NCIT:C15900

Platform: Behavioral / lifestyle

Microbiota modulation through probiotics, prebiotics, and fecal microbiota transplantation (FMT) represents an emerging strategy for restoring metabolic homeostasis in PCOS. Dysbiosis-driven metabolic endotoxemia and altered short-chain fatty acid production contribute to PCOS pathophysiology, and microbiota restoration may improve insulin sensitivity, hormone metabolism, and reproductive function through multiple mechanisms.

Show evidence (1 reference)

PMID:42531755 SUPPORT Other

"modulation of gut microbiota through probiotics, prebiotics, and fecal microbiota transplantation (FMT) represents an emerging strategy for restoring metabolic homeostasis."

Recent review establishes microbiota modulation as an emerging therapeutic approach with potential for restoring metabolic homeostasis in PCOS. The quoted sentence is the review's forward-looking framing of a strategy that "represents an emerging" one, not a reported clinical result, so it is graded OTHER to match the three sibling emerging-therapy entries in this section and the entry's own notes.

🌍

Environmental Factors

Sedentary Lifestyle

Worsens metabolic features.

Show evidence (1 reference)

PMID:39861440 SUPPORT Human Clinical

"Physical activity, like aerobic and resistance exercise, enhances insulin sensitivity, helps weight loss, and improves metabolic and reproductive outcomes in women with PCOS."

Systematic review establishing that physical activity improves insulin sensitivity and metabolic outcomes in this disease. PARTIAL because it states the benefit of activity rather than measuring harm from sedentariness; the exposure claim here is the inverse of what the source reports.

Prenatal Androgen Exposure

May program the PCOS phenotype. The hedge is deliberate: the evidence is strong and reproducible across several species in animal models, and indirect in humans, because fetal sampling during gestation is not ethically available.

Show evidence (3 references)

PMID:31499494 SUPPORT Model Organism

"In utero androgen excess reliably induces polycystic ovary syndrome (PCOS)-like reproductive and metabolic traits in female monkeys, sheep, rats, and mice."

The strongest form of this claim, and it is an animal one: prenatal androgen excess reproducibly induces the phenotype across four species. Graded MODEL_ORGANISM so it is not read as a human finding.

PMID:31499494 SUPPORT Human Clinical

"Evidence consistent with in utero origins for PCOS in humans has thus been slow to amass, but the balance now leans toward developmental fetal origins."

The human counterpart, and the reason this entry's note hedges. PARTIAL because it reports a balance of indirect evidence rather than a measured exposure effect, the same review being explicit that fetal sampling constraints are why.

PMID:34529765 SUPPORT Model Organism

"We tested the pAMH model in kisspeptin-specific androgen receptor knockout (KARKO) mice and found that virtually all pAMH-induced phenotypes assayed are eliminated in KARKO offspring compared to littermate controls."

Places the androgen receptor in kisspeptin neurons downstream of the other candidate prenatal hit: the reproductive phenotype produced by prenatal AMH exposure disappears when that receptor is deleted, so the AMH and androgen developmental routes converge on androgen-receptor signalling rather than acting in parallel. Mouse only. It does not show that AMH and testosterone are both required prenatal hits in humans, and no human fetal-exposure measurement supports the two-hit sequence.

Endocrine-Disrupting Chemicals

Exposure to endocrine-disrupting chemicals (EDCs) may exacerbate metabolic disturbances and increase PCOS risk through interference with estrogen, androgen, and thyroid signaling pathways.

Show evidence (1 reference)

PMID:42531755 SUPPORT Human Clinical

"environmental influences, including exposure to endocrine-disrupting chemicals (EDCs) and air pollution, may exacerbate metabolic disturbances and increase the risk of developing PCOS."

Recent comprehensive review establishes EDC exposure as an environmental risk factor that may exacerbate metabolic dysfunction and PCOS severity.

Air Pollution Exposure

Air pollution exposure may contribute to systemic inflammation and metabolic disturbances in PCOS pathophysiology through oxidative stress mechanisms.

Show evidence (1 reference)

PMID:42531755 SUPPORT Human Clinical

"environmental influences, including exposure to endocrine-disrupting chemicals (EDCs) and air pollution, may exacerbate metabolic disturbances and increase the risk of developing PCOS."

Recent review identifies air pollution as an environmental contributor to metabolic dysfunction and increased PCOS risk.

🔬

Biochemical Markers

Testosterone (Elevated)

Context: Total and free testosterone

Show evidence (1 reference)

PMID:14671196 SUPPORT Human Clinical

"AMH was also positively related to the serum testosterone and androstenedione levels, in PCOS exclusively (P < 0.0005 and <0.002, respectively)."

Documents positive correlation between AMH and testosterone levels in PCOS patients.

11-Oxygenated Androgens (Elevated)

Context: Adrenal-derived C19 steroids (11-ketotestosterone, 11-ketoandrostenedione, 11beta-hydroxytestosterone, 11beta-hydroxyandrostenedione), measured by mass spectrometry. Not part of any diagnostic criterion; curated because they discriminate PCOS from controls better than total testosterone does, and because their production is insulin-sensitive.

Show evidence (2 references)

PMID:39815717 SUPPORT Human Clinical

"Total testosterone, androstenedione, and four 11-oxyandrogens were significantly elevated in women with PCOS compared to age matched controls, controlling for age and BMI"

Case-control comparison of 114 women with PCOS against 78 controls establishes the elevation itself, adjusted for age and BMI.

PMID:39815717 SUPPORT Human Clinical

"When considered together, the four 11-oxyandrogens were more predictive of PCOS compared to testosterone and androstenedione."

Supports curating these separately from the Testosterone marker rather than folding them into it: they carry discriminative information the classical androgens do not. Discrimination is not causation — whether they drive the phenotype is the open question recorded in gap_pcos_11_oxygenated_androgen_causality.

LH (Elevated)

Context: Often elevated LH:FSH ratio

Show evidence (1 reference)

PMID:24014605 SUPPORT Human Clinical

"A higher proportion of theca cells from anovulatory PCO expressed LHCGR protein when compared with control ovaries (P = 0.01)."

Increased LH receptor expression in PCOS theca cells supports elevated LH action in driving androgen production.

SHBG (Decreased)

Context: Increases free androgen index

Show evidence (1 reference)

PMID:40013621 SUPPORT Other

Supports hyperinsulinemia raising bioactive androgen levels. Hepatic SHBG suppression is the accepted intermediate but is not stated in this snippet, so this reference does not directly evidence the decreased-SHBG finding.

Fasting Insulin (Elevated)

Context: Insulin resistance

Show evidence (1 reference)

PMID:40013621 SUPPORT Other

"However, it is challenging to define the sequential relationship between insulin sensitivity and insulin secretion, as they are tightly interlinked, and evidence suggests that hyperinsulinemia can alternatively precede insulin resistance."

Hyperinsulinemia is a core feature in PCOS that may precede or result from insulin resistance.

Anti-Mullerian Hormone (Elevated)

Context: Reflects increased antral follicle count

Show evidence (1 reference)

PMID:14671196 SUPPORT Human Clinical

Demonstrates markedly elevated AMH levels in PCOS patients paralleling increased small antral follicle count.

📊

Related Datasets

Single-cell analysis of follicular fluid reveals dysregulation of ovulatory immune function in Polycystic Ovary Syndrome patients undergoing ovarian stimulation geo:GSE313660

Polycystic ovary syndrome is the most common endocrine condition in women and anovulatory cause of female infertility. While a pro-inflammatory cytokines and leukocyte bias in systemic circulation is well-documented in PCOS, it is not known how this inflammation extends to or affects the ovary. Additionally, the relationship between ovulation and inflammation in PCOS is not well-defined. We hypothesize that the ovarian follicular immune environment in PCOS is uniquely dysregulated, and that resolving anovulation through ovulation induction is not sufficient to alleviate this dysregulation.

human SINGLE CELL RNA SEQ n=16

PMID:41766605

Identified by GEO DataSets index search for Polycystic Ovary Syndrome (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.

THBS1 Induces Dysfunction of Ovarian Granulosa Cells in Patients with Polycystic Ovary Syndrome by Activating the TGF-β/Smad Pathway geo:GSE330821

To investigate the role of thrombospondin-1 (THBS1) in polycystic ovary syndrome (PCOS) pathogenesis and its mechanism in regulating granulosa cell (GC) function.

human BULK RNA SEQ n=6

PMID:42351701

CNOT6L regulates energy metabolism in the ovarian granulosa cells associated with polycystic ovary syndrome. geo:GSE294074

As somatic cells surround the oocyte, the endocrine functions exerted by ovarian granulosa cells (GCs) are crucial factors in maintaining follicle development, as oocyte development relies on the provision of energy substrates and cytokines by ovarian granulosa cells. The mRNA deadenylase level of granulosa cells precisely regulates the transcription processes of key molecules involved in oocyte maturation. In this study, we detect the expression level of the deadenylase CNOT6L in PCOS patients' granulosa cells and mouse models' ovaries. We found that the CNOT6L significantly upregulated in the ovarian granulosa cells of both PCOS patients and mouse models.

human BULK RNA SEQ n=6

PMID:40458121

Transgenerational transmission of reproductive and metabolic dysfunction in the male progeny of polycystic ovary syndrome ega:EGAS00001007079

The transgenerational maternal effects of PCOS in female progeny have been revealed. As there are evidence that a male equivalent of PCOS may exist, we asked whether sons born to mother with PCOS (PCOS-sons) transmit reproductive and metabolic phenotypes to their male progeny. Here, in a Swedish nationwide register-based cohort and a clinical case-control study from Chile we found that PCOS-sons are more often obese and dyslipidemic. Their serum miRNAs are found to potentially regulate PCOS-risk genes. Our prenatal androgenized PCOS-like mouse model with or without diet-induced obesity confirmed that reproductive and metabolic dysfunctions in F1 male offspring are passed down to F3.

human

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Polycystic Ovary Syndrome"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

Single-Cell Profiling of the Human Endometrium in Polycystic Ovary Syndrome: Uncovering Disease Signatures and Treatment Responses ega:EGAS50000000735

We generated the first single-nuclei map of human endometrial biopsies from women with and without PCOS to identify cell-type-specific disease signatures, compositional variations, and transcriptomic reversibility after a 16-week intervention with metformin or lifestyle. Single nuclei were extracted from 27 frozen endometrial biopsies for snRNA-seq using the 10X Genomics protocol.

human

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Polycystic Ovary Syndrome"); description-level mentions were not accepted. EGA study_type: Transcriptome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

Metabolomic Profiling of Follicular Fluid from Patients with Polycystic Ovary Syndrome and Hyper Response to In Vitro Fertilization Treatment metabolomics_workbench:ST000618

Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Polycystic Ovary Syndrome"). Retrieved 2026-08-02.

Mechanisms for Insulin Resistance in Polycystic Ovary Syndrome with metformin therapy: aminoadipic acid, lysine concentrations, and enrichment (part I) metabolomics_workbench:ST000947

{ }

Source YAML

click to show

name: Polycystic Ovary Syndrome
creation_date: '2025-12-18T17:01:35Z'
description: >-
  Polycystic ovary syndrome is a common endocrine and reproductive disorder of
  women of reproductive age, defined by the combination of hyperandrogenism,
  ovulatory dysfunction, and polycystic ovarian morphology. Its pathophysiology
  centers on hypothalamic-pituitary dysregulation with increased LH-driven
  ovarian androgen production and on insulin resistance that amplifies androgen
  excess, although lean and obese subtypes differ in the relative contribution
  of intrinsic versus adiposity-amplified insulin signaling defects. Clinical
  features include irregular menstruation, hirsutism, acne, and infertility,
  with downstream metabolic consequences and chronic low-grade inflammation.
category: Complex
parents:
- Endocrine Disease
- Reproductive Disease
review_notes: >-
  The `environmental:` entry "Obesity" was removed and migrated to
  kb/comorbidities/com_Obesity__Polycystic_Ovary_Syndrome.yaml (dismech#8296, dismech#8551). It is a disease in
  its own right rather than something external to the organism acting on
  it, so ECTO and XCO have no term that could bind it. All of its evidence
  was carried across. This clears one row from the dismech#8296
  evidence-free backlog for a structural reason rather than by citing it.
disease_term:
  preferred_term: polycystic ovary syndrome
  term:
    id: MONDO:0008487
    label: polycystic ovary syndrome
has_subtypes:
- name: Lean PCOS
  display_name: Lean / nonobese PCOS
  classification: adiposity_stratum
  description: >
    PCOS occurring without obesity. This stratum is useful for separating
    intrinsic, obesity-independent insulin signaling defects and
    neuroendocrine/ovarian androgen mechanisms from adiposity-amplified
    metabolic dysfunction. Lean PCOS is still heterogeneous; some lean affected
    groups may have normal insulin sensitivity.
  evidence:
  - reference: PMID:1397698
    reference_title: Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These defects in insulin action appear to represent intrinsic abnormalities that are independent of obesity, metabolic derangements, body fat topography, and sex hormone levels."
    explanation: >
      Euglycemic clamp and adipocyte data support an obesity-independent
      intrinsic insulin-action defect relevant to nonobese PCOS.
  - reference: PMID:23065822
    reference_title: "Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "There is general agreement that obese women with PCOS are insulin resistant, but some groups of lean affected women may have normal insulin sensitivity."
    explanation: >
      The review supports subtype heterogeneity within lean PCOS, so lean status
      should not be modeled as synonymous with insulin resistance.
- name: Obese PCOS
  display_name: Obese / adiposity-amplified PCOS
  classification: adiposity_stratum
  description: >
    PCOS with overweight, obesity, or abdominal/visceral adiposity. This stratum
    emphasizes adiposity-driven insulin resistance, hyperinsulinemia, lower SHBG,
    and inflammatory amplification of androgen excess and anovulation.
  evidence:
  - reference: PMID:12080440
    reference_title: Obesity and the polycystic ovary syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Obesity, particularly the abdominal phenotype, may be partly responsible for insulin resistance and associated hyperinsulinemia in women with PCOS."
    explanation: >
      Review evidence supports abdominal obesity as an amplifier of insulin
      resistance and hyperinsulinemia in PCOS.
  - reference: PMID:12080440
    reference_title: Obesity and the polycystic ovary syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Irrespective of the pathogenetic mechanism involved, obese PCOS women have more severe hyperandrogenism and related clinical features (such as hirsutism, menstrual abnormalities and anovulation) than normal-weight PCOS women."
    explanation: >
      The subtype description is supported by evidence that obesity worsens
      androgenic and reproductive PCOS features.
mechanistic_hypotheses:
- hypothesis_group_id: androgen_first_feedback_model
  hypothesis_label: Androgen-First Feedback Model
  status: ALTERNATIVE
  applies_to_subtypes:
  - Lean PCOS
  - Obese PCOS
  description: >
    Intrinsic ovarian/adrenal androgen excess, potentially reinforced by
    heightened LH action and theca-cell steroidogenic machinery, is the initiating
    lesion. Androgen excess then promotes insulin resistance and hyperinsulinemia,
    disrupts hypothalamic steroid feedback, and contributes to visceral adiposity,
    closing an androgen-insulin-adiposity feedback loop.
  notes: >
    OpenScientist deep-research verdict (see
    kb/hypotheses/Polycystic_Ovary_Syndrome/androgen_first_feedback_model):
    PARTIALLY SUPPORTED. The androgen-sensitive ovarian and neuroendocrine
    components are supported — global and neuron-specific androgen-receptor
    knockout in the DHT mouse model shows that androgen-receptor signalling is
    required for the PCOS-like phenotype and that its critical locus is
    extraovarian (PMID:28320971) — but temporal primacy of androgen excess is
    not demonstrated in humans, so `status:` stays ALTERNATIVE rather than being
    promoted. Three qualifications from the assessment
    (assessments/openscientist-assessment-by-codex.yaml) are carried here.
    (1) The report's central argument that androgen reduction leaves insulin
    resistance unchanged was rejected on source check: it reads a 12-month
    placebo-controlled flutamide trial that reported *improved* insulin
    sensitivity as null, so no claim of a purely indirect androgen-to-insulin
    route is curated here; see the discussion
    gap_pcos_androgen_to_insulin_resistance_directness. (2) Long-term
    testosterone exposure in transmasculine adults is a non-PCOS setting and
    cannot adjudicate PCOS-specific causality. (3) The model is strongest for
    the "reproductive" cluster of PCOS (21-23% of NIH-defined European-ancestry
    cases, enriched for rare DENND1A variants), but that cluster is a
    cross-sectional phenotype grouping, not a demonstrated androgen-first
    subtype, and its subtype GWAS was small and unreplicated (PMID:32574161).
  evidence:
  - reference: PMID:38152131
    reference_title: "Androgen excess: a hallmark of polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Compelling evidence suggests that hyperandrogenism is not just a primary feature of PCOS. Instead, it may be a causative factor for this condition."
    explanation: >
      This review explicitly frames androgen excess as a possible causal driver,
      supporting the androgen-first hypothesis group.
  - reference: PMID:35356614
    reference_title: "Association of Insulin Resistance and Elevated Androgen Levels with Polycystic Ovarian Syndrome (PCOS): A Review of Literature."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "However, the overexposure of androgen has direct and specific influence on the development of insulin resistance."
    explanation: >
      Supports the androgen-to-insulin-resistance arm of the proposed feedback
      model.
  - reference: PMID:28320971
    reference_title: Neuroendocrine androgen action is a key extraovarian mediator in the development of polycystic ovary syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Global loss of the AR reveals that AR signaling is required for all DHT-induced features of PCOS."
    explanation: >
      Global androgen-receptor knockout in the DHT-induced mouse model shows the
      whole PCOS-like phenotype depends on androgen-receptor signalling, the
      strongest available causal test of the androgen arm of this hypothesis.
      Graded MODEL_ORGANISM: it is a mouse result and does not by itself
      establish androgen primacy in human PCOS.
  - reference: PMID:28320971
    reference_title: Neuroendocrine androgen action is a key extraovarian mediator in the development of polycystic ovary syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Neuron-specific AR signaling was required for the development of dysfunctional ovulation, classic polycystic ovaries, reduced large antral follicle health, and several metabolic traits including obesity and dyslipidemia."
    explanation: >
      Locates the critical androgen-receptor target extraovarially, in neurons:
      the same cell-specific knockouts that prevent the reproductive phenotype
      also prevent obesity and dyslipidemia, which is why this entry routes the
      androgen arm through hypothalamic-pituitary dysregulation rather than
      asserting a direct ovarian-only mechanism.
  - reference: PMID:17710731
    reference_title: Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "We hypothesize that excess peripubertal androgens may reduce the sensitivity of the GnRH pulse generator to sex steroid inhibition in susceptible individuals, resulting in increased GnRH pulse frequency and subsequent abnormalities in gonadotropin secretion, ovarian androgen production, and ovulatory function."
    explanation: >
      States the androgen-first developmental sequence this hypothesis group
      encodes — peripubertal androgen excess desensitising the GnRH pulse
      generator. Cited as the review's own hypothesis, not as a demonstration:
      the authors frame it explicitly as a hypothesis, which is why this group
      remains ALTERNATIVE.
  - reference: PMID:32574161
    reference_title: "Distinct subtypes of polycystic ovary syndrome with novel genetic associations: An unsupervised, phenotypic clustering analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "carriers of previously reported rare variants in DENND1A, a gene that regulates androgen biosynthesis, were significantly more likely to have the reproductive subtype of PCOS"
    explanation: >
      Ties an intrinsic androgen-biosynthesis genotype to a reproductive
      (higher-LH, lower-BMI/insulin) phenotype cluster, the stratum in which the
      androgen-first ordering is most plausible.
  - reference: PMID:32574161
    reference_title: "Distinct subtypes of polycystic ovary syndrome with novel genetic associations: An unsupervised, phenotypic clustering analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Limitations of our study were that only PCOS cases of European ancestry diagnosed by National Institutes of Health (NIH) criteria were included, the sample sizes for the subtype GWAS were small, and the GWAS findings were not replicated."
    explanation: >
      The authors' own limitations statement, curated so the subtype restriction
      above is not read as a settled population prevalence or a validated
      androgen-first subtype.
- hypothesis_group_id: insulin_hyperinsulinemia_first_model
  hypothesis_label: Insulin/Hyperinsulinemia-First Model
  status: ALTERNATIVE
  applies_to_subtypes:
  - Lean PCOS
  - Obese PCOS
  description: >
    Primary insulin resistance or primary hyperinsulinemia initiates the
    endocrine-metabolic loop. High insulin acts as a co-gonadotropin in the ovary
    and lowers hepatic SHBG, increasing bioactive androgen exposure; the resulting
    hyperandrogenism can then worsen insulin resistance and adiposity.
  notes: >
    OpenScientist deep-research verdict (see
    kb/hypotheses/Polycystic_Ovary_Syndrome/insulin_hyperinsulinemia_first_model):
    PARTIALLY SUPPORTED — a co-driving parallel pathway rather than a universal
    primary cause, so `status:` stays ALTERNATIVE. What survives source check:
    suppressing insulin secretion with diazoxide lowers androgens and raises
    SHBG even in lean PCOS women with normal metabolic insulin sensitivity
    (PMID:17559844); insulin drives adipose androgen generation through AKR1C3
    (PMID:26312838); and Mendelian randomization infers a causal effect of
    higher insulin resistance on PCOS risk (PMID:26416764). What does not: the
    report's claim that PCOS GWAS do not implicate insulin genes and that no
    insulin-specific Mendelian-randomization work exists is contradicted by that
    same 2015 analysis and by the INSR locus already curated in `genetic:`; its
    claimed insulin-independent 28-52% testosterone contrast across two
    NK3-antagonist trials misreports those endpoints (52% was the LH
    area-under-curve reduction in the AZD4901 trial); and average null
    gonadotropin effects in a heterogeneous metformin meta-analysis do not prove
    parallel causal pathways. Note also that metformin lowers LH-stimulated
    testosterone within days, before any insulin-sensitising effect
    (PMID:25304843), so therapeutic response to an insulin sensitiser is not on
    its own evidence for the insulin-first ordering.
  evidence:
  - reference: PMID:40013621
    reference_title: "Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Hyperinsulinemia (i.e., elevated insulin without hypoglycemia) is a common metabolic feature of PCOS that worsens its reproductive symptoms by exacerbating pituitary hormone imbalances and increasing levels of bioactive androgens."
    explanation: >
      Supports hyperinsulinemia as an upstream amplifier of pituitary imbalance
      and bioactive androgen excess.
  - reference: PMID:23065822
    reference_title: "Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Insulin functions as a co-gonadotropin through its cognate receptor to modulate ovarian steroidogenesis."
    explanation: >
      Supports the ovarian steroidogenesis route by which hyperinsulinemia can
      increase androgen production.
  - reference: PMID:17559844
    reference_title: Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In women with typical PCOS and normal insulin levels and metabolic insulin sensitivity, reducing insulin secretion significantly decreased androgen and increased SHBG levels."
    explanation: >
      Prospective insulin-lowering intervention: eight days of diazoxide lowered
      androgens and raised SHBG in lean PCOS women whose metabolic insulin
      sensitivity was normal, so an insulin contribution to hyperandrogenemia
      does not require measurable insulin resistance. Nine participants and no
      concurrent randomized control group, so this shows a contribution, not
      temporal primacy.
  - reference: PMID:26312838
    reference_title: "Effect of insulin on AKR1C3 expression in female adipose tissue: in-vivo and in-vitro study of adipose androgen generation in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Insulin significantly increased AKR1C3 expression in differentiated subcutaneous adipocytes (p=0·04). Incubation with insulin significantly increased testosterone generation from androstenedione in cultured subcutaneous cell media compared with controls (p<0·001)."
    explanation: >
      Identifies an extra-ovarian route from insulin to androgen: insulin
      induces AKR1C3 in subcutaneous adipocytes, which converts androstenedione
      to testosterone. Graded IN_VITRO because these two measurements are the
      cultured-adipocyte arm of the study.
  - reference: PMID:26416764
    reference_title: Causal mechanisms and balancing selection inferred from genetic associations with polycystic ovary syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mendelian randomization analyses indicate causal roles in PCOS aetiology for higher BMI (P=2.5 × 10(-9)), higher insulin resistance (P=6 × 10(-4)) and lower serum sex hormone binding globulin concentrations (P=5 × 10(-4))."
    explanation: >
      Genetic instrumental-variable analysis in a European-ancestry GWAS infers
      a causal direction from insulin resistance (and BMI, and low SHBG) to
      PCOS, which is the strongest hypothesis-independent support for this
      group. The BMI effect is larger, so this supports insulin resistance as a
      causal contributor rather than as the sole initiating lesion.
- hypothesis_group_id: neuroendocrine_lh_first_model
  hypothesis_label: Neuroendocrine LH-Pulse Model
  status: ALTERNATIVE
  applies_to_subtypes:
  - Lean PCOS
  - Obese PCOS
  description: >
    Impaired hypothalamic-pituitary sensitivity to ovarian steroid negative
    feedback maintains rapid LH/GnRH pulse secretion. Elevated LH signaling then
    drives theca-cell androgen biosynthesis, while androgen excess further
    impairs steroid feedback and can secondarily worsen insulin resistance.
  notes: >
    OpenScientist deep-research verdict (see
    kb/hypotheses/Polycystic_Ovary_Syndrome/neuroendocrine_lh_first_model):
    PARTIALLY SUPPORTED — established as a validated component mechanism within a
    multi-hit PCOS model rather than a standalone causal driver. The upstream arm
    (impaired progesterone feedback at arcuate KNDy/GABAergic neurons maintaining
    rapid GnRH/LH pulsatility) is pharmacologically validated by three independent
    NK3-receptor-antagonist trials (AZD4901, fezolinetant, MLE4901), corroborated
    by GWAS at the FSHB locus, and reproduced across mouse, sheep, and primate
    prenatal-androgen models. Key qualifications: (1) LH excess alone is
    insufficient for ovarian hyperandrogenism — an intrinsic ovarian steroidogenic
    defect is required (PMID:11756367); (2) correcting the neuronal androgen-receptor
    axis alone does not rescue the reproductive phenotype in prenatally androgenized
    mice, so multi-organ programming is needed (PMID:41206009); (3) the neuroendocrine
    arm best explains anovulation in non-hyperandrogenic PCOS, whereas insulin
    resistance drives the hyperandrogenic phenotype; and (4) obesity masks pituitary
    LH output despite persistent hypothalamic GnRH pulse-frequency elevation.
  evidence:
  - reference: PMID:11095431
    reference_title: "Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The majority of patients have elevated LH levels in plasma and a persistent rapid frequency of LH (GnRH) pulse secretion, the mechanisms of which are unclear."
    explanation: >
      Supports the upstream neuroendocrine abnormality represented by this
      hypothesis group.
  - reference: PMID:11095431
    reference_title: "Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These results suggest that although the elevated LH pulse frequency in PCOS may in part reflect impaired sensitivity to E2 and P, continuing actions of hyperandrogenemia are important for sustaining the abnormal hypothalamic sensitivity to feedback inhibition by ovarian steroids."
    explanation: >
      Supports the feedback component connecting androgen excess and persistent
      hypothalamic-pituitary dysregulation.
  - reference: PMID:27459523
    reference_title: "Neurokinin B Receptor Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The NK3 receptor antagonist AZD4901 specifically reduced LH pulse frequency and subsequently serum LH and T concentrations, thus presenting NK3 receptor antagonism as a potential approach to treating the central neuroendocrine pathophysiology of PCOS."
    explanation: >
      Phase 2 placebo-controlled RCT pharmacologically validates the KNDy
      neuron -> GnRH/LH-pulse arm: blocking NK3 signaling lowers LH pulse
      frequency and downstream androgens in PCOS women.
  - reference: PMID:34000049
    reference_title: "Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fezolinetant had a sustained effect to suppress hyperandrogenism and reduce the LH-to-FSH ratio in women with PCOS."
    explanation: >
      Independent phase 2a RCT of a second NK3-receptor antagonist replicates the
      neuroendocrine effect (reduced LH-to-FSH ratio and suppressed
      hyperandrogenism), reinforcing the KNDy/GnRH-pulse mechanism.
  - reference: PMID:26284813
    reference_title: "Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The same chr 11p14.1 SNP, rs11031006, in the region of the follicle-stimulating hormone B polypeptide (FSHB) gene strongly associates with PCOS diagnosis and luteinizing hormone levels. These findings implicate neuroendocrine changes in disease pathogenesis."
    explanation: >
      Unbiased European-ancestry GWAS links a gonadotropin-secretion (FSHB) locus
      to both PCOS diagnosis and LH levels, providing hypothesis-independent
      genetic support for a neuroendocrine contribution.
  - reference: PMID:41968288
    reference_title: "Arcuate nucleus-specific progesterone receptor knockdown in female mice is sufficient to induce PCOS-like hyperactivity in the reproductive axis."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These data show that reduced PR signalling in the ARC of adult female mice is sufficient to drive hyperactivity within the HPG axis and mimic some but not all reproductive features of PCOS."
    explanation: >
      Targeted arcuate progesterone-receptor knockdown demonstrates that loss of
      progesterone negative feedback within arcuate GABAergic neurons is
      sufficient to raise LH pulse frequency, confirming a key node in the
      neuroendocrine causal chain.
  - reference: PMID:11756367
    reference_title: "The role of LH and FSH in ovarian androgen secretion and ovarian follicular development: clinical studies in a patient with isolated FSH deficiency and multicystic ovaries."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There were no clinical or laboratory consequences of LH excess in this FSH-deficient woman. These findings support the hypothesis that excessive LH stimulation alone does not cause ovarian hyperandrogenism."
    explanation: >
      Qualifies the model: a woman with FSH-beta-deficiency-driven LH excess and
      PCOS-like LH pulse characteristics had normal androgens, showing that the
      neuroendocrine LH arm requires an intrinsic ovarian steroidogenic defect to
      produce hyperandrogenism.
  - reference: PMID:16434454
    reference_title: "Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "LH pulse frequency and quantity of GnRH are increased in PCOS, but there is no influence of BMI on either marker of hypothalamic function. The pituitary response to a weight-based dose of GnRH is inversely related to BMI in PCOS."
    explanation: >
      Substantiates qualification (4) in this entry's notes, which was previously
      uncited: GnRH pulse frequency and drive are raised in PCOS irrespective of
      BMI, and it is the pituitary response that falls with rising BMI. So a
      normal serum LH in an obese patient does not exclude the hypothalamic
      abnormality this hypothesis group posits, and LH concentration is a poor
      proxy for it. Frequent-sampling and GnRH/antagonist testing in 24 women.
- hypothesis_group_id: population_stratified_mechanistic_heterogeneity
  hypothesis_label: Population-Stratified Mechanistic Heterogeneity
  status: EMERGING
  description: >
    PCOS pathophysiology exhibits significant population-specific molecular
    phenotypes. East Asian populations show a predominant enrichment of metabolic
    dysregulation-associated pathways (insulin receptor signaling, GLUT4
    translocation, metabolic syndrome), whereas European populations exhibit a
    stronger inflammatory and immune-related signature (NF-kB signaling, innate
    immunity, and interleukin/cytokine and inflammasome pathways). These
    population-specific mechanistic differences may drive differential therapeutic
    responsiveness and clinical phenotypes across ancestry groups.
  evidence:
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "our analyses reveal a predominant enrichment of metabolic dysregulation-associated pathways in East Asian PCOS, whereas European PCOS exhibits a stronger inflammatory and immune-related signature"
    explanation: >
      Population-aware gene prioritization framework combining regulatory genomics,
      QTLs, and protein networks reveals distinct pathway enrichment patterns:
      East Asian PCOS driven by metabolic dysfunction, European PCOS by
      inflammation/immunity, with implications for subtype-specific therapeutics.
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "These population-specific molecular phenotypes were further supported by transcriptomic data from PCOS patient samples"
    explanation: >
      Patient transcriptome data validate population-stratified pathway enrichment,
      confirming mechanistic divergence between East Asian and European PCOS
      cohorts rather than technical artifacts.
discussions:
- discussion_id: gap_pcos_causal_hierarchy_by_adiposity
  prompt: >
    In which PCOS patient strata is androgen excess, insulin resistance or
    hyperinsulinemia, adiposity, or hypothalamic-pituitary dysregulation the
    initiating event rather than an amplifier of an already established
    endocrine-metabolic cycle?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Hyperandrogenism
  - pathophysiology#Intrinsic Post-Receptor Insulin Signaling Defect
  - pathophysiology#Adiposity-Amplified Insulin Resistance
  - pathophysiology#Hypothalamic-Pituitary Dysregulation
  rationale: >
    Current evidence supports bidirectional reinforcement among androgen excess,
    hyperinsulinemia/insulin resistance, and adiposity, but it does not establish
    a single causal sequence that applies across lean and obese PCOS. The entry
    therefore models three competing or superimposed hypothesis groups and
    annotates causal edges by subgroup.
  evidence:
  - reference: PMID:38637590
    reference_title: Polycystic ovary syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Treatment remains ad hoc owing to limited understanding of underlying mechanisms, highlighting the need for research delineating the aetiology and pathophysiology of the syndrome."
    explanation: >
      The Disease Primer frames unresolved PCOS mechanisms as a research need,
      supporting the explicit knowledge-gap discussion.
  - reference: PMID:40013621
    reference_title: "Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Considering the heterogeneous nature of PCOS, it is improbable that its metabolic characteristics always follow the same progression."
    explanation: >
      Supports subtype-specific causal hierarchy rather than a single universal
      insulin-resistance sequence.
  - reference: PMID:41180187
    reference_title: Characterization of distinct polycystic ovary syndrome subtypes by cluster and principal component analyses.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cluster C (43.3%) showed lower BP, BMI, HOMA-IR, triglycerides, testosterone, and FAI and higher LH: FSH, DHEAS, androstenedione, 17-hydroxyprogesterone, SHBG, and HDL."
    explanation: >
      The largest cluster in a 975-patient NIH-defined cohort combines low
      insulin resistance with a high LH:FSH ratio, so no single insulin-first or
      adiposity-first ordering can hold across the syndrome. The measurements are
      contemporaneous and cross-sectional, so this establishes stratum
      heterogeneity, not which mechanism initiates in that stratum — which is
      exactly the gap stated here.
  - reference: PMID:42026183
    reference_title: Genomic analyses implicate hormonal and metabolic dysregulation in polycystic ovary syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hormonal regulation in the etiology of this condition, through metabolic and reproductive features, was emphasized. The proteomic analysis highlighted metabolic biology known to be related to PCOS."
    explanation: >
      The largest PCOS genetic study to date (n = 544,513, 29 loci) implicates
      reproductive/hormonal and metabolic biology together rather than resolving
      to one, which is hypothesis-independent evidence that the causal-hierarchy
      question posed here is not settled by genetics.
- discussion_id: gap_pcos_granulosa_apoptosis_pcsk9
  prompt: >-
    Granulosa cell apoptosis is a primary driver of follicular arrest and
    impaired oocyte maturation in PCOS, but the upstream triggers of that
    apoptosis remain unclear. Is a PCSK9 -> lipid metabolism abnormality ->
    AMPK/GSK-3beta -> apoptosis cascade a primary, translatable mechanism in
    human PCOS, and how does it relate to the parallel ferroptosis-autophagy
    and ER/oxidative-stress death programs already described in granulosa cells?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Granulosa Cell Apoptosis via PCSK9-Lipid Dysregulation
  - pathophysiology#Ovulatory Dysfunction
  - pathophysiology#Chronic Low-Grade Inflammation
  rationale: >-
    Granulosa cell death is recognized as one of the primary factors impairing
    follicular growth, development, and oocyte maturation in PCOS, yet its
    upstream pathological triggers have been poorly defined. Teng et al. (2026)
    propose a specific cascade in which elevated proprotein convertase
    subtilisin/kexin type-9 (PCSK9) drives lipid metabolism abnormalities that
    activate AMP-activated protein kinase (AMPK) and glycogen synthase kinase
    3beta (GSK-3beta) within follicles, triggering granulosa cell apoptosis and
    impairing ovarian function. Several questions remain unresolved. First, the
    cascade was established in PCOS model mice and primary follicles, so whether
    elevated PCSK9 is a primary driver in human PCOS rather than a species- or
    model-specific finding is unknown. Second, the proximal mechanism by which
    PCSK9-driven lipid abnormalities impair granulosa cell survival
    (intracellular lipid-droplet accumulation versus altered membrane lipid
    composition versus lipotoxic oxidative stress) is undefined. Third, it is
    unclear whether AMPK/GSK-3beta is the dominant death pathway or whether it
    operates in parallel with the previously modeled ferroptosis-autophagy
    crosstalk and ER/oxidative-stress programs that also drive granulosa cell
    loss. Resolving the relative contribution and translatability of these
    death pathways would clarify whether PCSK9 inhibition is a viable
    PCOS-directed therapeutic target.
  proposed_experiments:
  - experiment_id: exp_pcos_pcsk9_granulosa_apoptosis_human_vs_model
    name: PCSK9-lipid-AMPK/GSK-3beta apoptosis cascade in human granulosa cells with model comparison
    description: >-
      Compare PCSK9 expression, follicular-fluid and intracellular lipid
      profiles, AMPK/GSK-3beta activation status, and apoptosis markers in
      granulosa cells from PCOS patients versus controls, alongside PCSK9
      gain- and loss-of-function in primary granulosa cells and PCOS model
      mice. Use pharmacologic PCSK9 inhibition and AMPK/GSK-3beta blockade to
      test whether interrupting the cascade rescues granulosa cell survival and
      follicular development, and assay ferroptosis/autophagy and ER-stress
      markers in parallel to determine pathway dominance versus redundancy.
    experiment_type:
      preferred_term: mechanistic intervention study with human-tissue and animal-model arms
    readouts:
    - name: Granulosa cell apoptosis after PCSK9 modulation
      target: pathophysiology#Granulosa Cell Apoptosis via PCSK9-Lipid Dysregulation
      description: >-
        Quantify granulosa cell apoptosis (caspase-3 activity, TUNEL, annexin V)
        in response to PCSK9 overexpression, PCSK9 inhibition, and AMPK/GSK-3beta
        blockade in human and mouse granulosa cells.
      assays:
      - preferred_term: TUNEL apoptosis assay
      - preferred_term: caspase-3 activity assay
      direction: POSITIVE
    - name: Lipid handling and AMPK/GSK-3beta signaling
      target: pathophysiology#Granulosa Cell Apoptosis via PCSK9-Lipid Dysregulation
      description: >-
        Measure intracellular lipid-droplet content, membrane lipid composition,
        and phosphorylation of AMPK and GSK-3beta to map the proximal
        lipotoxic-to-apoptotic signaling link.
      assays:
      - preferred_term: intracellular lipid quantification
      - preferred_term: phospho-protein immunoblotting
      direction: POSITIVE
    - name: Follicular development and ovulatory rescue
      target: pathophysiology#Ovulatory Dysfunction
      description: >-
        Assess antral follicle counts, dominant follicle selection, ovulation
        rate, and oocyte maturation after cascade interruption in PCOS model
        mice to test functional reversibility.
      assays:
      - preferred_term: ovarian histomorphometry
      - preferred_term: oocyte maturation scoring
      direction: NEGATIVE
    decision_criterion: >-
      The PCSK9-lipid-AMPK/GSK-3beta cascade is supported as a primary,
      translatable apoptosis driver if elevated PCSK9 and AMPK/GSK-3beta
      activation are reproducibly associated with increased granulosa cell
      apoptosis in human PCOS tissue, PCSK9 or AMPK/GSK-3beta inhibition
      reduces apoptosis and restores follicular development in models, and the
      effect is at least partially independent of the ferroptosis-autophagy and
      ER-stress death programs.
    would_support:
    - pathophysiology#Granulosa Cell Apoptosis via PCSK9-Lipid Dysregulation
    - pathophysiology#Ovulatory Dysfunction
  evidence:
  - reference: PMID:42093080
    reference_title: "Lipid metabolism abnormalities induced by elevated PCSK9 in polycystic ovary syndrome mice lead to ovarian granulosa cell apoptosis via AMPK and GSK-3β."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The mechanism underlying granulosa cell apoptosis in polycystic ovary syndrome remains unclear."
    explanation: >-
      Directly states the unresolved mechanism that this knowledge-gap
      discussion captures.
  - reference: PMID:42093080
    reference_title: "Lipid metabolism abnormalities induced by elevated PCSK9 in polycystic ovary syndrome mice lead to ovarian granulosa cell apoptosis via AMPK and GSK-3β."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Results demonstrated that elevated PCSK9 levels induce lipid metabolism abnormalities in PCOS mice, subsequently activating AMP-activated protein kinase and glycogen synthase kinase 3β within follicles."
    explanation: >-
      Establishes the proposed PCSK9 -> lipid abnormality -> AMPK/GSK-3beta
      cascade in PCOS model mice that the gap and proposed experiments
      interrogate for human translatability.
- discussion_id: gap_pcos_population_specific_therapeutics
  prompt: >-
    Given the distinct population-stratified molecular phenotypes of PCOS
    (metabolic-dominant in East Asian populations, inflammatory-dominant in
    European populations), are currently approved therapies (metformin, oral
    contraceptives, spironolactone) equally effective across ancestry groups?
    Should therapeutic prioritization differ by population-specific mechanism,
    with metabolic pathway inhibitors favored in East Asian PCOS and
    immunomodulatory or anti-inflammatory agents in European PCOS?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Intrinsic Post-Receptor Insulin Signaling Defect
  - pathophysiology#Adiposity-Amplified Insulin Resistance
  - pathophysiology#Chronic Low-Grade Inflammation
  rationale: >-
    Population-stratified mechanistic analyses reveal that East Asian PCOS is
    enriched for metabolic dysregulation pathways while European PCOS exhibits
    stronger inflammatory and immune signatures. The heterogeneous molecular
    architecture suggests that therapeutic responses may vary by ancestry,
    yet current PCOS treatment guidelines do not account for mechanistic
    diversity. Whether therapies targeting the predominant mechanism in each
    population (e.g., metabolic pathway inhibitors for East Asian PCOS,
    anti-inflammatory agents for European PCOS) would improve clinical outcomes
    relative to universal treatment remains untested.
  evidence:
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "integration of genetic evidence with a network-based approach enabled the identification of druggable targets lacking direct genetic cues"
    explanation: >
      Network-based gene prioritization strategy identifies population-specific
      druggable targets and therapeutic candidates that would not emerge from
      genetic associations alone, laying a foundation for ancestry-informed
      precision therapeutics.
- discussion_id: gap_pcos_pcsk9_granulosa_mouse_model_mismatch
  prompt: >-
    The PCSK9 -> lipid metabolism abnormality -> AMPK/GSK-3beta -> granulosa
    cell apoptosis cascade was established in PCOS model mice and primary mouse
    follicles. Is elevated PCSK9 a primary driver of granulosa cell apoptosis
    in human PCOS, or is its causal, apoptosis-initiating role a species- or
    model-specific finding that does not translate to human follicular biology?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Granulosa Cell Apoptosis via PCSK9-Lipid Dysregulation
  - pathophysiology#Ovulatory Dysfunction
  rationale: >-
    Granulosa cell apoptosis is recognized as a primary factor impairing
    follicular growth, oocyte maturation, and fertility in PCOS, but its
    upstream triggers remain unclear. Teng et al. (2026) provide mechanistic
    evidence in PCOS model mice that elevated proprotein convertase subtilisin/
    kexin type-9 (PCSK9) induces lipid metabolism abnormalities that activate
    AMP-activated protein kinase (AMPK) and glycogen synthase kinase 3beta
    (GSK-3beta) within follicles, triggering granulosa cell apoptosis. This is
    not a generic knowledge gap in which evidence is absent; rather, positive
    mechanistic evidence exists in a mouse model and the open question is its
    translational validity to human disease. The mismatch is mechanistically
    meaningful because PCSK9, hepatic and ovarian lipid handling, and
    androgen-driven lipotoxicity differ substantially between rodents and
    humans, so a cascade that is causal and apoptosis-initiating in mouse
    follicles could be absent, secondary, or merely correlative in human PCOS
    ovaries. Resolving whether elevated PCSK9 is a primary human driver is a
    prerequisite for treating PCSK9 inhibition as a PCOS-directed therapeutic
    target rather than a mouse-specific observation.
  proposed_experiments:
  - experiment_id: exp_pcos_pcsk9_human_granulosa_apoptosis
    name: PCSK9 and granulosa cell apoptosis in human PCOS follicles
    description: >-
      Measure PCSK9 levels in follicular fluid and granulosa cells from PCOS
      patients versus matched controls undergoing assisted reproduction, and
      correlate with intrafollicular lipid profiles, AMPK and GSK-3beta
      phosphorylation status, and granulosa cell apoptosis markers. Elevated
      PCSK9 reproducibly tracking with AMPK/GSK-3beta activation and increased
      apoptosis in human PCOS tissue would support translational validity of
      the mouse-derived cascade; absence of this association would indicate a
      model-specific finding.
    experiment_type:
      preferred_term: human granulosa cell apoptosis and follicular-fluid PCSK9 profiling study
    model_systems:
    - name: Human PCOS patient-derived granulosa cells
      description: >-
        Granulosa cells and matched follicular fluid recovered at oocyte
        retrieval from PCOS patients and ovulatory controls, preserving human
        ovarian lipid-handling and apoptosis biology.
      experimental_model_type: PRIMARY_CELL_CULTURE
  - experiment_id: exp_pcos_pcsk9_human_granulosa_perturbation
    name: PCSK9 gain- and loss-of-function in human granulosa cell apoptosis assay
    description: >-
      In primary human granulosa cells, test whether PCSK9 overexpression
      induces, and PCSK9 inhibition or AMPK/GSK-3beta blockade rescues,
      lipid accumulation and apoptosis. Demonstrating that PCSK9 manipulation
      causally raises and lowers human granulosa cell apoptosis through the
      AMPK/GSK-3beta axis would establish the cascade as a primary, translatable
      human mechanism rather than a mouse-restricted one.
    experiment_type:
      preferred_term: human granulosa cell apoptosis assay
    model_systems:
    - name: Primary human granulosa cell culture
      description: >-
        Cultured primary granulosa cells from human ovarian follicles used for
        PCSK9 gain- and loss-of-function manipulation and apoptosis readouts.
      experimental_model_type: PRIMARY_CELL_CULTURE
  notes: "Seeded from PMID:42093080 — Lipid metabolism abnormalities induced by elevated PCSK9 in polycystic ovary syndrome mice lead to ovarian granulosa cell apoptosis via AMPK and GSK-3β. Complements the same-source KNOWLEDGE_GAP discussion gap_pcos_granulosa_apoptosis_pcsk9; this entry adds the HUMAN_MODEL_MISMATCH translational framing and proposed human experiments."
- discussion_id: gap_pcos_androgen_to_insulin_resistance_directness
  prompt: >-
    Does androgen excess in PCOS impair insulin action directly at insulin
    target tissues, or only indirectly — by promoting visceral and android fat
    deposition, and through androgen-receptor signalling in neurons? The entry
    asserts both an androgen-to-intrinsic-insulin-defect edge and an
    androgen-to-adiposity-amplified-insulin-resistance edge; is the first of
    those a distinct mechanism, or the second one seen at a different scale?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Hyperandrogenism
  - pathophysiology#Intrinsic Post-Receptor Insulin Signaling Defect
  - pathophysiology#Adiposity-Amplified Insulin Resistance
  rationale: >-
    Both androgen-to-insulin edges on the Hyperandrogenism node are already
    typed INDIRECT_KNOWN_INTERMEDIATES, but their intermediates differ (androgen
    receptor action in muscle and adipose tissue versus visceral fat deposition
    and adipokine change) and nothing in the entry distinguishes them
    experimentally. The mouse data locate the critical androgen-receptor target
    for the metabolic phenotype outside the ovary, in neurons, which is a
    mediated rather than a direct tissue-level route; but the mediation itself
    — hypothalamic androgen receptor to gonadotropin output to metabolic
    regulation — has not been tested by any experiment cited here. The nearest
    human evidence of prolonged androgen exposure comes from
    testosterone-treated transmasculine adults, where body composition and
    lipids deteriorate while fasting glucose and insulin do not measurably
    change; that is a different population with a different developmental
    history and an exogenously controlled gonadal axis, so it constrains a
    simple pharmacological androgen-to-insulin-resistance claim without
    settling the question in PCOS. Resolving this matters for whether
    antiandrogen therapy should be expected to improve metabolic endpoints at
    all, or only those that follow fat redistribution.
  evidence:
  - reference: PMID:28320971
    reference_title: Neuroendocrine androgen action is a key extraovarian mediator in the development of polycystic ovary syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Neuron-specific AR signaling was required for the development of dysfunctional ovulation, classic polycystic ovaries, reduced large antral follicle health, and several metabolic traits including obesity and dyslipidemia."
    explanation: >-
      Shows the metabolic arm of the DHT mouse phenotype depends on
      androgen-receptor signalling in neurons rather than in the ovary, which is
      what makes a purely direct peripheral androgen-to-insulin route doubtful
      and the mediating steps the open question.
  - reference: PMID:42171672
    reference_title: Changes in cardiometabolic risk factors in transmasculine individuals over 10 years of Gender-Affirming Hormone Therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: INDIRECT
    snippet: "Fasting glucose, insulin, and blood pressure did not change meaningfully. The lipid profile worsened: LDL, total cholesterol and triglycerides increased, and HDL decreased throughout the study period. Weight, body mass index, waist circumference, and waist-to-hip ratio increased."
    explanation: >-
      Ten years of testosterone in 57 transmasculine adults shifted body
      composition toward android fat and worsened lipids while leaving fasting
      glucose and insulin unchanged — the dissociation this gap is about. Graded
      INDIRECT: a single-centre observational cohort outside PCOS, with no PCOS
      counterfactual and a pharmacologically controlled gonadal axis, so it
      cannot adjudicate causality within the syndrome.
- discussion_id: gap_pcos_11_oxygenated_androgen_causality
  prompt: >-
    Are the elevated 11-oxygenated androgens of PCOS a driver of the
    hyperandrogenic phenotype, or a marker of adrenal and adipose androgen
    handling that tracks it? And is their production insulin-dependent in
    common PCOS, as insulin-receptor signalling makes it in syndromes of severe
    insulin resistance?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - biochemical#11-Oxygenated Androgens
  - pathophysiology#Hyperandrogenism
  - pathophysiology#Adiposity-Amplified Insulin Resistance
  rationale: >-
    11-oxygenated C19 steroids discriminate PCOS from controls better than total
    testosterone does, which is why they are curated as a biochemical marker
    here. Diagnostic discrimination is not mechanism, however, and the entry
    deliberately does not give them a pathophysiology node. Two lines of work
    make an insulin-dependent route plausible without establishing it for common
    PCOS: in women with syndromes of severe insulin resistance, 11-oxygenated
    androgens are raised in lipodystrophy but not in insulin receptoropathy,
    implying that intact insulin-receptor signalling is required for the adrenal
    excess; and in an adipocyte model, insulin-induced AKR1C3 converts
    11-oxygenated precursors to potent androgens. The first is 18 women with
    rare monogenic disease, the second is a cell model, and neither measures the
    route in ordinary PCOS. The question is also directional: if 11-oxygenated
    androgens are largely adrenal and insulin-driven, they sit downstream of
    hyperinsulinemia rather than upstream of it, which would make the classical
    ovarian and the 11-oxygenated arms separate contributors rather than one
    androgen pool.
  evidence:
  - reference: PMID:35696182
    reference_title: Excess 11-Oxygenated Androgens in Women With Severe Insulin Resistance Are Mediated by Adrenal Insulin Receptor Signaling.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: INDIRECT
    snippet: "11-Oxygenated androgens are elevated in lipodystrophy but not receptoropathy. In SIR, insulin receptor signaling is necessary for adrenal hyperandrogenemia but not ovarian hyperandrogenemia; excess classic androgens are derived from the ovaries."
    explanation: >-
      The natural-experiment contrast that motivates the insulin-dependence half
      of this gap, and the reason it is a gap rather than a curated mechanism:
      the cohort is 18 women with rare severe-insulin-resistance syndromes, not
      common PCOS, so the inference to PCOS is an extrapolation.
  - reference: PMID:35560164
    reference_title: Conversion of Classical and 11-Oxygenated Androgens by Insulin-Induced AKR1C3 in a Model of Human PCOS Adipocytes.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We conclude that the 11-oxygenated androgens formed in adipocytes may contribute to the hyperandrogenic profile of PCOS women and that AKR1C3 is a potential therapeutic target to mitigate the AE of PCOS."
    explanation: >-
      Supplies the candidate peripheral mechanism — insulin-induced AKR1C3
      activating 11-oxygenated precursors in adipocytes — while stating it at
      the level this gap records: the authors write that these androgens "may
      contribute", from recombinant-enzyme kinetics and a differentiated
      adipocyte line rather than from PCOS tissue.
pathophysiology:
- name: Hyperandrogenism
  description: >
    Excess androgen production from ovarian theca cells and adrenal glands
    leads to hirsutism, acne, and alopecia. Elevated LH stimulates theca
    cell androgen production.
  biological_processes:
  - preferred_term: Androgen Biosynthesis
    term:
      id: GO:0006702
      label: androgen biosynthetic process
  evidence:
  - reference: PMID:38152131
    reference_title: "Androgen excess: a hallmark of polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Compelling evidence suggests that hyperandrogenism is not just a primary feature of PCOS. Instead, it may be a causative factor for this condition."
    explanation: This review establishes hyperandrogenism as potentially causative rather than merely symptomatic in PCOS pathophysiology.
  - reference: PMID:24014605
    reference_title: "Increased protein expression of LHCG receptor and 17α-hydroxylase/17-20-lyase in human polycystic ovaries."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "LHCGR and 17α-hydroxylase/17-20-lyase (CYP17A1) protein levels are increased in polycystic ovaries (PCOs)."
    explanation: Direct evidence of increased androgen biosynthetic machinery (CYP17A1) in PCOS ovaries, supporting intrinsic theca cell abnormality.
  - reference: PMID:24014605
    reference_title: "Increased protein expression of LHCG receptor and 17α-hydroxylase/17-20-lyase in human polycystic ovaries."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A significant increase in the intensity of immunostaining for CYP17A1 was identified in antral follicles in sections of PCO compared with ovaries from normal women (P = 0.04)."
    explanation: Quantitative demonstration of elevated CYP17A1 protein in polycystic ovaries compared to controls.
  - reference: PMID:24014605
    reference_title: "Increased protein expression of LHCG receptor and 17α-hydroxylase/17-20-lyase in human polycystic ovaries."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A higher proportion of theca cells from anovulatory PCO expressed LHCGR protein when compared with control ovaries (P = 0.01)."
    explanation: Increased LH receptor expression in theca cells explains heightened LH-driven androgen production in PCOS.
  downstream:
  - target: Intrinsic Post-Receptor Insulin Signaling Defect
    description: >
      Androgen excess can worsen insulin resistance and hyperinsulinemia,
      creating a self-perpetuating endocrine-metabolic loop.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - androgen receptor effects in skeletal muscle and adipose tissue
    - compensatory or androgen-augmented hyperinsulinemia
    hypothesis_groups:
    - androgen_first_feedback_model
  - target: Adiposity-Amplified Insulin Resistance
    description: >
      Hyperandrogenism favors visceral adiposity and adverse adipose signaling,
      which can amplify insulin resistance in obese PCOS.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - visceral fat deposition
    - adipokine and free-fatty-acid changes
    hypothesis_groups:
    - androgen_first_feedback_model
  - target: Hypothalamic-Pituitary Dysregulation
    description: >
      Ongoing androgen excess helps sustain abnormal hypothalamic sensitivity to
      estradiol/progesterone negative feedback, maintaining rapid LH/GnRH pulse
      secretion.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired ovarian steroid negative feedback
    hypothesis_groups:
    - androgen_first_feedback_model
    - neuroendocrine_lh_first_model
  - target: Ovulatory Dysfunction
    description: >
      Elevated androgen exposure disrupts follicle maturation and contributes to
      anovulation.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - follicular arrest
    - impaired dominant follicle selection
    hypothesis_groups:
    - androgen_first_feedback_model
    - neuroendocrine_lh_first_model
- name: Hypothalamic-Pituitary Dysregulation
  description: >
    Impaired hypothalamic-pituitary sensitivity to estradiol and progesterone
    negative feedback maintains rapid LH/GnRH pulse secretion. Elevated LH then
    stimulates theca-cell androgen biosynthesis, while hyperandrogenism can
    sustain the abnormal feedback state.
  biological_processes:
  - preferred_term: Increased Luteinizing Hormone Secretion
    term:
      id: GO:0032275
      label: luteinizing hormone secretion
    modifier: INCREASED
  evidence:
  - reference: PMID:11095431
    reference_title: "Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The majority of patients have elevated LH levels in plasma and a persistent rapid frequency of LH (GnRH) pulse secretion, the mechanisms of which are unclear."
    explanation: >
      Human endocrine profiling supports elevated LH and rapid LH/GnRH pulse
      secretion as a PCOS pathophysiology node.
  - reference: PMID:11095431
    reference_title: "Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These results suggest that although the elevated LH pulse frequency in PCOS may in part reflect impaired sensitivity to E2 and P, continuing actions of hyperandrogenemia are important for sustaining the abnormal hypothalamic sensitivity to feedback inhibition by ovarian steroids."
    explanation: >
      Antiandrogen intervention restoring feedback sensitivity supports a
      bidirectional link between hyperandrogenism and hypothalamic-pituitary
      dysregulation.
  downstream:
  - target: Hyperandrogenism
    description: >
      Rapid LH/GnRH pulse secretion increases LH action on ovarian theca cells,
      promoting androgen biosynthesis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - increased LH action at theca-cell LHCGR
    - CYP17A1-mediated androgen biosynthesis
    hypothesis_groups:
    - neuroendocrine_lh_first_model
- name: Intrinsic Post-Receptor Insulin Signaling Defect
  subtypes:
  - Lean PCOS
  description: >
    PCOS-associated insulin resistance can reflect an intrinsic post-binding or
    post-receptor defect in insulin signaling that is independent of obesity.
    Defective insulin receptor or IRS-associated signaling decreases metabolic
    glucose disposal while ovarian steroidogenic actions of insulin may remain
    active, allowing insulin and LH to amplify androgen production.
  biological_processes:
  - preferred_term: Insulin Signaling
    term:
      id: GO:0008286
      label: insulin receptor signaling pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:1397698
    reference_title: Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Because insulin binding was not changed, we conclude that the major lesion causing insulin resistance in PCO is a striking decrease in insulin sensitivity secondary to a defect in the insulin receptor and/or postreceptor signal transduction."
    explanation: >
      Human clamp and adipocyte data support a post-binding/post-receptor insulin
      signaling defect as an intrinsic PCOS mechanism.
  - reference: PMID:11440917
    reference_title: Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We conclude that there is a physiologically relevant defect in insulin receptor signaling in PCOS that is independent of obesity and type 2 diabetes mellitus."
    explanation: >
      Skeletal muscle signaling data support an obesity-independent insulin
      receptor signaling defect in PCOS.
  - reference: PMID:23065822
    reference_title: "Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "There is a post-binding defect in receptor signaling likely due to increased receptor and insulin receptor substrate-1 serine phosphorylation that selectively affects metabolic but not mitogenic pathways in classic insulin target tissues and in the ovary."
    explanation: >
      Review evidence supports selective metabolic insulin resistance with
      preserved non-metabolic insulin signaling branches.
  - reference: PMID:40013621
    reference_title: "Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Hyperinsulinemia (i.e., elevated insulin without hypoglycemia) is a common metabolic feature of PCOS that worsens its reproductive symptoms by exacerbating pituitary hormone imbalances and increasing levels of bioactive androgens."
    explanation: Demonstrates the direct mechanistic link between hyperinsulinemia and worsening of reproductive and androgenic features in PCOS.
  - reference: PMID:40013621
    reference_title: "Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "However, it is challenging to define the sequential relationship between insulin sensitivity and insulin secretion, as they are tightly interlinked, and evidence suggests that hyperinsulinemia can alternatively precede insulin resistance."
    explanation: Challenges traditional causality and suggests hyperinsulinemia may be primary rather than compensatory in some PCOS cases.
  - reference: PMID:40013621
    reference_title: "Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Notably, other drivers of hyperinsulinemia (outside of insulin resistance) may be highly relevant in the context of PCOS. For instance, high androgen levels can augment both hyperinsulinemia and insulin resistance, generating a self-perpetuating cycle of reproductive and metabolic dysfunction."
    explanation: Describes the vicious cycle where androgens exacerbate both hyperinsulinemia and insulin resistance in PCOS.
  downstream:
  - target: Hyperandrogenism
    description: >
      Hyperinsulinemia arising from impaired insulin signaling can act as a
      co-gonadotropin and increase bioactive androgen exposure.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - compensatory hyperinsulinemia
    - ovarian insulin receptor signaling
    - hepatic SHBG suppression
    hypothesis_groups:
    - insulin_hyperinsulinemia_first_model
  - target: Ovulatory Dysfunction
    description: >
      Hyperinsulinemia and androgen amplification contribute to follicular arrest
      and anovulation.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - increased bioactive androgens
    - altered pituitary hormone balance
    hypothesis_groups:
    - insulin_hyperinsulinemia_first_model
- name: Adiposity-Amplified Insulin Resistance
  subtypes:
  - Obese PCOS
  description: >
    Abdominal or visceral adiposity amplifies insulin resistance and
    hyperinsulinemia in susceptible PCOS patients. This pathway separates
    obesity-related hepatic/adipose insulin resistance from intrinsic lean-PCOS
    insulin signaling defects and explains why obesity worsens androgenic and
    reproductive features without being required for PCOS.
  biological_processes:
  - preferred_term: Insulin Signaling
    term:
      id: GO:0008286
      label: insulin receptor signaling pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:12080440
    reference_title: Obesity and the polycystic ovary syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Obesity, particularly the abdominal phenotype, may be partly responsible for insulin resistance and associated hyperinsulinemia in women with PCOS."
    explanation: >
      Supports a distinct adiposity-amplified insulin resistance node for obese
      PCOS.
  - reference: PMID:12080440
    reference_title: Obesity and the polycystic ovary syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Therefore, obesity-related hyperinsulinemia may play a key role in favouring hyperandrogenism in these women."
    explanation: >
      Supports the adiposity-to-hyperinsulinemia-to-hyperandrogenism causal
      route.
  - reference: PMID:37213054
    reference_title: "Pathophysiology and Nutritional Approaches in Polycystic Ovary Syndrome (PCOS): A Comprehensive Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This disease causes menstrual, metabolic, and biochemical abnormalities such as hyperandrogenism, oligo-anovulatory menstrual cycles, polycystic ovary, hyperleptinemia, insulin resistance (IR), and cardiometabolic disorders, often associated with overweight or obesity and visceral adiposity."
    explanation: >
      Recent review evidence supports separating visceral-adiposity-associated
      PCOS metabolic dysfunction from nonobese mechanisms.
  downstream:
  - target: Hyperandrogenism
    description: >
      Obesity-related hyperinsulinemia increases ovarian androgen synthesis and
      lowers SHBG, raising bioactive androgen exposure.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - obesity-related hyperinsulinemia
    - ovarian insulin co-gonadotropin activity
    - decreased hepatic SHBG synthesis
    hypothesis_groups:
    - insulin_hyperinsulinemia_first_model
  - target: Chronic Low-Grade Inflammation
    description: >
      Visceral adiposity and insulin resistance contribute to the inflammatory
      state shared by PCOS, obesity, type 2 diabetes, and cardiovascular disease.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - adipokine dysregulation
    - inflammatory cytokine production
    hypothesis_groups:
    - androgen_first_feedback_model
    - insulin_hyperinsulinemia_first_model
- name: Ovulatory Dysfunction
  description: >
    Disrupted folliculogenesis with arrest at small antral stage leads
    to anovulation. Multiple small follicles accumulate (polycystic
    morphology) without dominant follicle selection.
  biological_processes:
  - preferred_term: Ovulation
    term:
      id: GO:0030728
      label: ovulation
  evidence:
  - reference: PMID:14671196
    reference_title: "Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Because PCOS is associated with a 2- to 3-fold increase in growing FN, we investigated whether an increased AMH serum level correlates to other hormonal and/or U/S features of PCOS."
    explanation: Documents the 2-3 fold increase in small growing follicle number characteristic of PCOS polycystic morphology.
  - reference: PMID:14671196
    reference_title: "Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mean serum AMH level was markedly increased in the PCOS group (47.1 +/- 22.9 vs. 20.8 +/- 11.6 pmol/liter in controls; P < 0.0001), an increase in the same order of magnitude as the one of the FN in the 2- to 5-mm range at U/S (12.8 +/- 8.3 vs. 4.8 +/- 1.9; P < 0.0001, respectively)."
    explanation: Shows parallel elevation of AMH levels and small antral follicle count in PCOS, implicating AMH in follicular arrest.
  - reference: PMID:14671196
    reference_title: "Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We hypothesize that an increased AMH tone within the cohort could be involved in the follicular arrest of PCOS, by interacting negatively with FSH at the time of selection."
    explanation: Proposes mechanism by which elevated AMH interferes with FSH action to prevent dominant follicle selection in PCOS.
- name: Oxidative and Endoplasmic Reticulum Stress
  description: >
    Synergistic oxidative stress (OS) and endoplasmic reticulum stress (ERS)
    form an intracellular stress hub that initiates autophagy-ferroptosis
    crosstalk in ovarian granulosa cells, driving follicular atresia and
    ovulatory dysfunction.
  cell_types:
  - preferred_term: granulosa cell
    term:
      id: CL:0000501
      label: granulosa cell
  biological_processes:
  - preferred_term: Oxidative Stress Response
    term:
      id: GO:0006979
      label: response to oxidative stress
    modifier: INCREASED
  - preferred_term: Endoplasmic Reticulum Stress Response
    term:
      id: GO:0034976
      label: response to endoplasmic reticulum stress
    modifier: INCREASED
  evidence:
  - reference: PMID:42178591
    reference_title: "The crosslink between autophagy and ferroptosis in polycystic ovary syndrome: from synergistic pathogenesis to targeted therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the intracellular stress hub formed by the synergistic action of oxidative stress (OS) and endoplasmic reticulum stress (ERS) serves as the initiating factor"
    explanation: Establishes OS and ERS synergy as the initiating hub driving granulosa cell dysfunction and autophagy-ferroptosis crosstalk in PCOS.
  downstream:
  - target: Granulosa Cell Ferroptosis-Autophagy Crosstalk
    description: >
      Oxidative and ER stress serve as the initiating hub that triggers
      downstream autophagy-ferroptosis crosstalk in granulosa cells.
    causal_link_type: DIRECT
- name: Gut Microbiome Dysregulation and Gut-Ovarian Axis Inflammation
  description: >
    Dysbiosis-driven gut microbiome dysfunction amplifies low-grade chronic
    inflammation via the gut-ovarian axis, exacerbating granulosa cell
    dysfunction and follicular atresia through long-range immune and metabolic
    signaling.
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
    modifier: INCREASED
  evidence:
  - reference: PMID:42178591
    reference_title: "The crosslink between autophagy and ferroptosis in polycystic ovary syndrome: from synergistic pathogenesis to targeted therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the gut-ovarian axis's long-range amplification effect, mediated by gut microbiome (GM) dysregulation and low-grade chronic inflammation (LGI), collectively disrupting cellular homeostasis"
    explanation: Establishes the gut-ovarian axis as a long-range amplification mechanism linking microbiome dysregulation to granulosa cell dysfunction via chronic inflammation.
  downstream:
  - target: Chronic Low-Grade Inflammation
    description: >
      Gut microbiome dysregulation amplifies systemic low-grade chronic
      inflammation via the gut-ovarian axis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - increased intestinal permeability leading to LPS translocation
    - gut-derived inflammatory cytokines amplifying ovarian inflammation
- name: Chronic Low-Grade Inflammation
  description: >
    Elevated inflammatory markers (CRP, IL-6) contribute to insulin
    resistance and cardiovascular risk in PCOS.
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:39036884
    reference_title: "Randomized clinical trial of astaxanthin supplement on serum inflammatory markers and ER stress-apoptosis gene expression in PBMCs of women with PCOS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Polycystic ovarian syndrome (PCOS) is related to pro-apoptotic and pro-inflammatory conditions generated by Endoplasmic reticulum (ER) stress."
    explanation: Establishes the link between ER stress, inflammation, and apoptotic pathways in PCOS pathophysiology.
  - reference: PMID:39036884
    reference_title: "Randomized clinical trial of astaxanthin supplement on serum inflammatory markers and ER stress-apoptosis gene expression in PBMCs of women with PCOS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The levels of TNF-α (p = 0.009), IL-18 (p = 0.003), IL-6 (p = 0.013) and active caspase-3 (p = 0.012) were also statistically significant lower in the therapy group."
    explanation: >-
      Shows that TNF-alpha, IL-18 and IL-6 are pharmacologically reducible in
      women with PCOS, indicating an active inflammatory state that is a
      treatment target. It compares treated vs placebo PCOS arms, so it does NOT
      by itself demonstrate that these cytokines are elevated in PCOS relative to
      healthy controls; a PCOS-versus-control comparison is still needed for the
      "elevated inflammatory markers" claim.
- name: Granulosa Cell Ferroptosis-Autophagy Crosstalk
  description: >
    Granulosa cell dysfunction in PCOS arises from pathological crosstalk between
    autophagy and ferroptosis rather than from a single mode of cell death.
    Selective autophagy mechanisms (ferritinophagy and mitophagy) amplify
    ferroptosis through iron overload and energy collapse, driving follicular
    atresia and ovulatory dysfunction.
  notes: >-
    Scoped to the autophagy-ferroptosis crosstalk itself. The upstream
    oxidative/ER-stress hub, the gut-ovarian amplification arm, the
    circadian/epigenetic entrenchment arm, and the PCSK9-lipid apoptotic arm are
    each modeled as their own nodes, and their GO terms and evidence live there.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: Granulosa cell
    term:
      id: CL:0000501
      label: granulosa cell
  biological_processes:
  - preferred_term: Ferroptosis
    term:
      id: GO:0097707
      label: ferroptosis
    modifier: INCREASED
  - preferred_term: Autophagy
    term:
      id: GO:0006914
      label: autophagy
    modifier: INCREASED
  evidence:
  - reference: PMID:42178591
    reference_title: "The crosslink between autophagy and ferroptosis in polycystic ovary syndrome: from synergistic pathogenesis to targeted therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The dysfunction of GCs in PCOS is not an isolated event involving a single mode of cell death, but rather a pathological crosstalk arising from the disruption of the dynamic equilibrium between autophagy and ferroptosis."
    explanation: >-
      The review identifies ferroptosis-autophagy crosstalk as a central feature
      of granulosa-cell dysfunction in PCOS.
  - reference: PMID:42178591
    reference_title: "The crosslink between autophagy and ferroptosis in polycystic ovary syndrome: from synergistic pathogenesis to targeted therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "selective autophagy (e.g., ferritinophagy and mitophagy) acts as a key amplifier of ferroptosis by exacerbating iron overload and energy collapse."
    explanation: >-
      Supports selective autophagy as an amplifier of ferroptosis through iron
      overload and energetic failure.
  downstream:
  - target: Ovulatory Dysfunction
    description: >-
      Granulosa-cell ferroptosis and autophagy-amplified cell death promote
      follicular atresia and impair dominant-follicle selection.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - granulosa cell death via ferroptosis-autophagy crosstalk
    - loss of granulosa cell support for oocyte maturation
- name: Circadian Disruption and Epigenetic Reprogramming in Granulosa Cells
  description: >
    Circadian rhythm disruption and epigenetic reprogramming entrench the
    granulosa cell autophagy-ferroptosis imbalance at the temporal and molecular
    memory levels, amplifying follicular atresia.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: Granulosa cell
    term:
      id: CL:0000501
      label: granulosa cell
  biological_processes:
  - preferred_term: Circadian Rhythm
    term:
      id: GO:0007623
      label: circadian rhythm
    modifier: ABNORMAL
  - preferred_term: Epigenetic Regulation of Gene Expression
    term:
      id: GO:0040029
      label: epigenetic regulation of gene expression
    modifier: ABNORMAL
  evidence:
  - reference: PMID:42178591
    reference_title: "The crosslink between autophagy and ferroptosis in polycystic ovary syndrome: from synergistic pathogenesis to targeted therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "circadian rhythm disruption and epigenetic reprogramming, respectively, cement this imbalance at the temporal and molecular memory levels."
    explanation: >-
      Highlights circadian rhythm disruption and epigenetic reprogramming as the
      mechanisms that entrench the ferroptosis-autophagy imbalance in PCOS.
  downstream:
  - target: Granulosa Cell Ferroptosis-Autophagy Crosstalk
    description: >-
      Circadian and epigenetic reprogramming entrench the autophagy-ferroptosis
      imbalance rather than initiating it.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Granulosa Cell Apoptosis via PCSK9-Lipid Dysregulation
  description: >
    Elevated PCSK9 (proprotein convertase subtilisin/kexin type-9) in ovarian
    follicles triggers lipid metabolism abnormalities that activate
    AMP-activated protein kinase (AMPK) and glycogen synthase kinase 3β
    (GSK-3β), leading to granulosa cell apoptosis. This PCSK9-lipid-AMPK/GSK-3β
    cascade represents a distinct apoptotic pathway in granulosa cell death,
    independent of the ferroptosis-autophagy crosstalk mechanism, and may
    contribute to follicular atresia and ovulatory dysfunction in PCOS.
  cell_types:
  - preferred_term: Granulosa cell
    term:
      id: CL:0000501
      label: granulosa cell
  biological_processes:
  - preferred_term: Phosphorylation (AMPK and GSK-3β Activation)
    term:
      id: GO:0016310
      label: phosphorylation
    modifier: INCREASED
  - preferred_term: Apoptosis
    term:
      id: GO:0006915
      label: apoptotic process
    modifier: INCREASED
  - preferred_term: Lipid Metabolism Abnormalities
    term:
      id: GO:0006629
      label: lipid metabolic process
    modifier: ABNORMAL
  evidence:
  - reference: PMID:42093080
    reference_title: "Lipid metabolism abnormalities induced by elevated PCSK9 in polycystic ovary syndrome mice lead to ovarian granulosa cell apoptosis via AMPK and GSK-3β."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "elevated PCSK9 levels induce lipid metabolism abnormalities in PCOS mice, subsequently activating AMP-activated protein kinase and glycogen synthase kinase 3β within follicles. This activation triggers granulosa cell apoptosis"
    explanation: >
      Direct mechanistic evidence in PCOS model mice establishing the PCSK9 →
      lipid abnormality → AMPK/GSK-3β → apoptosis cascade as a driver of
      granulosa cell death.
  - reference: PMID:42093080
    reference_title: "Lipid metabolism abnormalities induced by elevated PCSK9 in polycystic ovary syndrome mice lead to ovarian granulosa cell apoptosis via AMPK and GSK-3β."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Granulosa cell apoptosis in the ovaries is one of the primary factors affecting follicular growth and development as well as oocyte maturation in PCOS, yet its pathological mechanisms remain unclear."
    explanation: >
      Establishes granulosa cell apoptosis as a primary mechanism impairing
      follicular development and oocyte maturation in PCOS, motivating
      mechanistic investigation of upstream drivers like PCSK9.
  downstream:
  - target: Ovulatory Dysfunction
    description: >
      PCSK9-driven granulosa cell apoptosis leads to loss of granulosa cell
      support for follicular maturation, resulting in follicular arrest and
      anovulation.
    causal_link_type: DIRECT
- name: Population-Specific Metabolic vs. Inflammatory Dysregulation
  description: >
    PCOS manifests with distinct molecular pathophysiology across populations.
    East Asian PCOS exhibits predominant enrichment of metabolic dysregulation
    pathways with emphasis on insulin/IGF signaling and gonadotropin receptor
    pathways. European PCOS shows a stronger inflammatory and immune-related
    signature, featuring enrichment of the TLR4-NF-κB-NLRP3 signaling axis. This
    population-specific molecular heterogeneity suggests distinct pathophysiological
    drivers and therapeutic opportunities across ancestries.
  biological_processes:
  - preferred_term: Insulin Receptor Signaling
    term:
      id: GO:0008286
      label: insulin receptor signaling pathway
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  genes:
  - preferred_term: INS
    term:
      id: hgnc:6081
      label: INS
  - preferred_term: INSR
    term:
      id: hgnc:6091
      label: INSR
  - preferred_term: IGF1R
    term:
      id: hgnc:5465
      label: IGF1R
  - preferred_term: FSHR
    term:
      id: hgnc:3969
      label: FSHR
  - preferred_term: LHCGR
    term:
      id: hgnc:6585
      label: LHCGR
  - preferred_term: NFKB1
    term:
      id: hgnc:7794
      label: NFKB1
  - preferred_term: IRF1
    term:
      id: hgnc:6116
      label: IRF1
  evidence:
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Notably, our analyses reveal a predominant enrichment of metabolic dysregulation-associated pathways in East Asian PCOS, whereas European PCOS exhibits a stronger inflammatory and immune-related signature."
    explanation: >
      Population-stratified gene prioritization reveals distinct metabolic versus
      inflammatory molecular signatures across East Asian and European populations,
      supported by transcriptomic validation in PCOS patient samples.
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "genes like INS, INSR and IGF1R implicating insulin signaling and FSHR, LHCGR involving gonadotropin related signaling were exclusively present in the EAS population"
    explanation: >
      East Asian PCOS prioritizes insulin/IGF and gonadotropin signaling genes,
      reflecting the metabolic and hormonal dysfunction-dominant phenotype in
      this population.
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "immune-related genes were differentially prioritized in the EUR population (Supplementary Data 2, II) with, NF-B1, APP, IRF1 and few others"
    explanation: >
      European PCOS shows preferential prioritization of immune-centric genes,
      reflecting the stronger inflammatory and immune-related signature of
      this population.
phenotypes:
- name: Irregular Menstruation
  category: Reproductive
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Irregular Menstruation
    term:
      id: HP:0000858
      label: Irregular menstruation
  evidence:
  - reference: PMID:14671196
    reference_title: "Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We hypothesize that an increased AMH tone within the cohort could be involved in the follicular arrest of PCOS, by interacting negatively with FSH at the time of selection."
    explanation: >-
      Supports the follicular-arrest mechanism that underlies anovulation. The
      snippet is an explicitly hypothetical statement and does not mention
      menstrual irregularity or its frequency.
- name: Hirsutism
  category: Dermatological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Hirsutism
    term:
      id: HP:0001007
      label: Hirsutism
  evidence:
  - reference: PMID:38152131
    reference_title: "Androgen excess: a hallmark of polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Compelling evidence suggests that hyperandrogenism is not just a primary feature of PCOS. Instead, it may be a causative factor for this condition."
    explanation: >-
      Supports hyperandrogenism as a central and possibly causal PCOS mechanism,
      the accepted driver of hirsutism. The snippet itself does not mention
      hirsutism and does not support the VERY_FREQUENT band; a hirsutism-specific
      prevalence citation is still needed.
- name: Acne
  category: Dermatological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Acne
    term:
      id: HP:0001061
      label: Acne
- name: Obesity
  category: Metabolic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Obesity
    term:
      id: HP:0001513
      label: Obesity
- name: Infertility
  category: Reproductive
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Infertility
    term:
      id: HP:0000789
      label: Infertility
  evidence:
  - reference: PMID:14671196
    reference_title: "Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Because PCOS is associated with a 2- to 3-fold increase in growing FN, we investigated whether an increased AMH serum level correlates to other hormonal and/or U/S features of PCOS."
    explanation: >-
      Documents the increased growing-follicle number that underlies polycystic
      ovarian morphology. It does not mention infertility or fertility outcomes;
      a dedicated fertility-outcome citation is still needed.
- name: Alopecia
  category: Dermatological
  frequency: OCCASIONAL
  notes: Androgenic pattern
  phenotype_term:
    preferred_term: Alopecia
    term:
      id: HP:0001596
      label: Alopecia
biochemical:
- name: Testosterone
  presence: Elevated
  context: Total and free testosterone
  evidence:
  - reference: PMID:14671196
    reference_title: "Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "AMH was also positively related to the serum testosterone and androstenedione levels, in PCOS exclusively (P < 0.0005 and <0.002, respectively)."
    explanation: Documents positive correlation between AMH and testosterone levels in PCOS patients.
- name: 11-Oxygenated Androgens
  presence: Elevated
  context: >-
    Adrenal-derived C19 steroids (11-ketotestosterone, 11-ketoandrostenedione,
    11beta-hydroxytestosterone, 11beta-hydroxyandrostenedione), measured by mass
    spectrometry. Not part of any diagnostic criterion; curated because they
    discriminate PCOS from controls better than total testosterone does, and
    because their production is insulin-sensitive.
  evidence:
  - reference: PMID:39815717
    reference_title: Exploring the Predictive Role of 11-Oxyandrogens in Diagnosing Polycystic Ovary Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Total testosterone, androstenedione, and four 11-oxyandrogens were significantly elevated in women with PCOS compared to age matched controls, controlling for age and BMI"
    explanation: >-
      Case-control comparison of 114 women with PCOS against 78 controls
      establishes the elevation itself, adjusted for age and BMI.
  - reference: PMID:39815717
    reference_title: Exploring the Predictive Role of 11-Oxyandrogens in Diagnosing Polycystic Ovary Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "When considered together, the four 11-oxyandrogens were more predictive of PCOS compared to testosterone and androstenedione."
    explanation: >-
      Supports curating these separately from the Testosterone marker rather than
      folding them into it: they carry discriminative information the classical
      androgens do not. Discrimination is not causation — whether they drive the
      phenotype is the open question recorded in
      gap_pcos_11_oxygenated_androgen_causality.
- name: LH
  presence: Elevated
  context: Often elevated LH:FSH ratio
  evidence:
  - reference: PMID:24014605
    reference_title: "Increased protein expression of LHCG receptor and 17α-hydroxylase/17-20-lyase in human polycystic ovaries."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A higher proportion of theca cells from anovulatory PCO expressed LHCGR protein when compared with control ovaries (P = 0.01)."
    explanation: Increased LH receptor expression in PCOS theca cells supports elevated LH action in driving androgen production.
- name: SHBG
  presence: Decreased
  context: Increases free androgen index
  evidence:
  - reference: PMID:40013621
    reference_title: "Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Hyperinsulinemia (i.e., elevated insulin without hypoglycemia) is a common metabolic feature of PCOS that worsens its reproductive symptoms by exacerbating pituitary hormone imbalances and increasing levels of bioactive androgens."
    explanation: >-
      Supports hyperinsulinemia raising bioactive androgen levels. Hepatic SHBG
      suppression is the accepted intermediate but is not stated in this snippet,
      so this reference does not directly evidence the decreased-SHBG finding.
- name: Fasting Insulin
  presence: Elevated
  context: Insulin resistance
  evidence:
  - reference: PMID:40013621
    reference_title: "Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "However, it is challenging to define the sequential relationship between insulin sensitivity and insulin secretion, as they are tightly interlinked, and evidence suggests that hyperinsulinemia can alternatively precede insulin resistance."
    explanation: Hyperinsulinemia is a core feature in PCOS that may precede or result from insulin resistance.
- name: Anti-Mullerian Hormone
  presence: Elevated
  context: Reflects increased antral follicle count
  evidence:
  - reference: PMID:14671196
    reference_title: "Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mean serum AMH level was markedly increased in the PCOS group (47.1 +/- 22.9 vs. 20.8 +/- 11.6 pmol/liter in controls; P < 0.0001), an increase in the same order of magnitude as the one of the FN in the 2- to 5-mm range at U/S (12.8 +/- 8.3 vs. 4.8 +/- 1.9; P < 0.0001, respectively)."
    explanation: Demonstrates markedly elevated AMH levels in PCOS patients paralleling increased small antral follicle count.
genetic:
- name: DENND1A
  association: Risk Factor
  gene_term:
    preferred_term: DENND1A
    term:
      id: hgnc:29324
      label: DENND1A
  notes: >-
    Commonly prioritized in both East Asian and European populations through
    integrative gene prioritization combining regulatory genomics, long-range
    chromatin interactions, QTLs, and protein networks. The functional route to
    hyperandrogenism runs through the truncated DENND1A variant 2 isoform in
    theca cells rather than through the full-length gene product.
  evidence:
  - reference: PMID:31184707
    reference_title: miRNA Profiling Reveals miRNA-130b-3p Mediates DENND1A Variant 2 Expression and Androgen Biosynthesis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The comparison of miR-130b-3p in normal and PCOS theca cells demonstrated decreased miR-130b-3p expression in PCOS theca cells, which was correlated with increased DENND1A.V2, cytochrome P450 17α-hydroxylase (CYP17A1) mRNA and androgen biosynthesis."
    explanation: >
      Connects the DENND1A risk locus to the intrinsic theca-cell steroidogenic
      phenotype curated under Hyperandrogenism: loss of miR-130b-3p repression
      raises DENND1A.V2 and CYP17A1 together with androgen output in theca cells
      isolated from women with PCOS. In vitro in isolated theca cells, and the
      DENND1A.V2 link is correlative within that system.
  - reference: PMID:32574161
    reference_title: "Distinct subtypes of polycystic ovary syndrome with novel genetic associations: An unsupervised, phenotypic clustering analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "carriers of previously reported rare variants in DENND1A, a gene that regulates androgen biosynthesis, were significantly more likely to have the reproductive subtype of PCOS"
    explanation: >
      Rare DENND1A variant carriers segregate with the reproductive (higher LH
      and SHBG, lower BMI and insulin) rather than the metabolic phenotype
      cluster, so this locus is not uniformly distributed across PCOS. European
      ancestry, NIH criteria, and a family-based classification cohort of 73.
- name: THADA
  association: Risk Factor
  gene_term:
    preferred_term: THADA
    term:
      id: hgnc:19217
      label: THADA
- name: LHCGR
  association: Risk Factor
  gene_term:
    preferred_term: LHCGR
    term:
      id: hgnc:6585
      label: LHCGR
  notes: >-
    Gonadotropin signaling gene; prioritized in East Asian PCOS (rank 13)
    more highly than European populations (rank 53), reflecting enhanced
    LH-driven ovarian androgen production in metabolic-dominant phenotypes.
  evidence:
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "genes like INS, INSR and IGF1R implicating insulin signaling and FSHR, LHCGR involving gonadotropin related signaling were exclusively present in the EAS population"
    explanation: >
      Gonadotropin-signaling gene exclusively prioritized in the East Asian
      PCOS gene-prioritization list.
- name: FSHR
  association: Risk Factor
  gene_term:
    preferred_term: FSHR
    term:
      id: hgnc:3969
      label: FSHR
  notes: >-
    Follicle-stimulating hormone receptor; prioritized in both populations
    (East Asian rank 6, European rank 58), reflects gonadotropin dysregulation
    as a shared PCOS mechanism with population-specific emphasis.
  evidence:
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "genes like INS, INSR and IGF1R implicating insulin signaling and FSHR, LHCGR involving gonadotropin related signaling were exclusively present in the EAS population"
    explanation: >
      Gonadotropin-signaling gene exclusively prioritized in the East Asian
      PCOS gene-prioritization list.
- name: INS
  association: Risk Factor
  gene_term:
    preferred_term: INS
    term:
      id: hgnc:6081
      label: INS
  notes: >-
    Insulin; exclusively prioritized in top 50 genes of East Asian PCOS,
    reflecting enrichment of insulin signaling and metabolic dysregulation
    pathways in East Asian populations.
  evidence:
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "genes like INS, INSR and IGF1R implicating insulin signaling and FSHR, LHCGR involving gonadotropin related signaling were exclusively present in the EAS population"
    explanation: >
      Insulin-signaling gene exclusively prioritized in the East Asian PCOS
      gene-prioritization list.
- name: INSR
  association: Risk Factor
  gene_term:
    preferred_term: INSR
    term:
      id: hgnc:6091
      label: INSR
  notes: >-
    Insulin receptor; exclusively prioritized in top 50 genes of East Asian PCOS,
    supporting insulin resistance as a primary metabolic driver in East Asian
    populations.
  evidence:
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "genes like INS, INSR and IGF1R implicating insulin signaling and FSHR, LHCGR involving gonadotropin related signaling were exclusively present in the EAS population"
    explanation: >
      Insulin-receptor gene exclusively prioritized in the East Asian PCOS
      gene-prioritization list.
- name: IGF1R
  association: Risk Factor
  gene_term:
    preferred_term: IGF1R
    term:
      id: hgnc:5465
      label: IGF1R
  notes: >-
    Insulin-like growth factor 1 receptor; prioritized in East Asian PCOS,
    part of metabolic pathway signature; interacts with ERBB3 and other
    growth factor receptors.
  evidence:
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "genes like INS, INSR and IGF1R implicating insulin signaling and FSHR, LHCGR involving gonadotropin related signaling were exclusively present in the EAS population"
    explanation: >
      IGF-signaling gene prioritized in the East Asian PCOS
      gene-prioritization list.
- name: ERBB3
  association: Risk Factor
  gene_term:
    preferred_term: ERBB3
    term:
      id: hgnc:3431
      label: ERBB3
  notes: >-
    Receptor tyrosine kinase; top prioritized core gene in both populations;
    central hub in metabolic-dominant (East Asian) and inflammatory-dominant
    (European) PCOS networks; interacts with IGF1R, EGFR, and GRB2.
- name: EGFR
  association: Risk Factor
  gene_term:
    preferred_term: EGFR
    term:
      id: hgnc:3236
      label: EGFR
  notes: >-
    Epidermal growth factor receptor; commonly prioritized in both populations;
    exclusively enriched in growth factor (EGFR/PDGFRA/FGFR) pathways in East
    Asian PCOS and connected to NF-κB inflammatory axis in European PCOS.
- name: YAP1
  association: Risk Factor
  gene_term:
    preferred_term: YAP1
    term:
      id: hgnc:16262
      label: YAP1
  notes: >-
    Yes-associated protein 1; prioritized in both populations, involved in
    Hippo signaling dysregulation implicated in PCOS follicular dysfunction.
- name: PDGFRA
  association: Risk Factor
  gene_term:
    preferred_term: PDGFRA
    term:
      id: hgnc:8803
      label: PDGFRA
  notes: >-
    Platelet-derived growth factor receptor alpha; enriched in the East Asian
    PCOS growth-factor signaling cascade (with EGFR and the FGFR receptor
    family) that is critical for follicular growth and ovulation. The paper's
    generic "FGFR" growth-factor enrichment (no single HGNC member specified)
    is captured here rather than as a separate non-specific gene entry.
- name: APP
  association: Risk Factor
  gene_term:
    preferred_term: APP
    term:
      id: hgnc:620
      label: APP
  notes: >-
    Amyloid precursor protein; immune/inflammatory gene preferentially
    prioritized in European PCOS; links oxidative stress and chronic
    inflammation to PCOS pathology.
  evidence:
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "immune-related genes were differentially prioritized in the EUR population (Supplementary Data 2, II) with, NF-B1, APP, IRF1 and few others"
    explanation: >
      Immune/inflammatory gene preferentially prioritized in the European PCOS
      gene-prioritization list.
- name: NFKB1
  association: Risk Factor
  gene_term:
    preferred_term: NFKB1
    term:
      id: hgnc:7794
      label: NFKB1
  notes: >-
    Nuclear factor kappa-B subunit 1; key inflammasome and immune pathway gene
    preferentially prioritized in European PCOS; reflects stronger chronic
    low-grade inflammatory signature.
  evidence:
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "immune-related genes were differentially prioritized in the EUR population (Supplementary Data 2, II) with, NF-B1, APP, IRF1 and few others"
    explanation: >
      NF-kB (NF-B1) immune-pathway gene preferentially prioritized in the
      European PCOS gene-prioritization list.
- name: IRF1
  association: Risk Factor
  gene_term:
    preferred_term: IRF1
    term:
      id: hgnc:6116
      label: IRF1
  notes: >-
    Interferon regulatory factor 1; immune-related gene preferentially
    prioritized in European PCOS; contributes to innate immune pathway
    dysregulation in inflammation-dominant phenotypes.
  evidence:
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "immune-related genes were differentially prioritized in the EUR population (Supplementary Data 2, II) with, NF-B1, APP, IRF1 and few others"
    explanation: >
      Interferon regulatory factor 1 immune-related gene preferentially
      prioritized in the European PCOS gene-prioritization list.
- name: AR
  association: Risk Factor
  gene_term:
    preferred_term: AR
    term:
      id: hgnc:644
      label: AR
  notes: >-
    Androgen receptor; polymorphisms in AR have been associated with altered
    steroidogenesis and ovarian dysfunction in PCOS. AR variants contribute to
    hyperandrogenism and ovarian androgen production.
  evidence:
  - reference: PMID:42531755
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Polymorphisms in genes such as the androgen receptor (AR), cytochrome P450 17A1 (CYP17), and follicle-stimulating hormone receptor (FSHR) have been associated with altered steroidogenesis and ovarian dysfunction, thereby influencing disease severity."
    explanation: >-
      Recent review establishes AR polymorphisms as contributors to altered
      steroidogenesis and ovarian dysfunction in PCOS pathophysiology.
- name: CYP17A1
  association: Risk Factor
  gene_term:
    preferred_term: CYP17A1
    term:
      id: hgnc:2593
      label: CYP17A1
  notes: >-
    Cytochrome P450 17A1 (17-alpha-hydroxylase/17-20-lyase); polymorphisms in
    CYP17 influence androgen biosynthesis capacity in theca cells. Variants
    affect the conversion of pregnenolone and progesterone to their 17-hydroxylated
    intermediates, critical steps in androgen production.
  evidence:
  - reference: PMID:42531755
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Polymorphisms in genes such as the androgen receptor (AR), cytochrome P450 17A1 (CYP17), and follicle-stimulating hormone receptor (FSHR) have been associated with altered steroidogenesis and ovarian dysfunction, thereby influencing disease severity."
    explanation: >-
      Recent review identifies CYP17 polymorphisms as key contributors to altered
      steroidogenesis and ovarian androgen dysregulation in PCOS.
environmental:
- name: Sedentary Lifestyle
  exposure_term:
    preferred_term: sedentary lifestyle
    term:
      id: ECTO:6000004
      label: exposure to sedentary lifestyle
  notes: Worsens metabolic features.
  evidence:
  - reference: PMID:39861440
    reference_title: "The Role of Lifestyle Interventions in PCOS Management: A Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical activity, like aerobic and resistance exercise, enhances insulin sensitivity, helps weight loss, and improves metabolic and reproductive outcomes in women with PCOS."
    explanation: >-
      Systematic review establishing that physical activity improves insulin
      sensitivity and metabolic outcomes in this disease. PARTIAL because it
      states the benefit of activity rather than measuring harm from
      sedentariness; the exposure claim here is the inverse of what the source
      reports.
- name: Prenatal Androgen Exposure
  exposure_term:
    preferred_term: prenatal androgen exposure
    term:
      id: ECTO:9001833
      label: exposure to androgen
  notes: >-
    May program the PCOS phenotype. The hedge is deliberate: the evidence is
    strong and reproducible across several species in animal models, and
    indirect in humans, because fetal sampling during gestation is not
    ethically available.
  evidence:
  - reference: PMID:31499494
    reference_title: "In utero Androgen Excess: A Developmental Commonality Preceding Polycystic Ovary Syndrome?"
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In utero androgen excess reliably induces polycystic ovary syndrome (PCOS)-like reproductive and metabolic traits in female monkeys, sheep, rats, and mice."
    explanation: >-
      The strongest form of this claim, and it is an animal one: prenatal
      androgen excess reproducibly induces the phenotype across four species.
      Graded MODEL_ORGANISM so it is not read as a human finding.
  - reference: PMID:31499494
    reference_title: "In utero Androgen Excess: A Developmental Commonality Preceding Polycystic Ovary Syndrome?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Evidence consistent with in utero origins for PCOS in humans has thus been slow to amass, but the balance now leans toward developmental fetal origins."
    explanation: >-
      The human counterpart, and the reason this entry's note hedges. PARTIAL
      because it reports a balance of indirect evidence rather than a measured
      exposure effect, the same review being explicit that fetal sampling
      constraints are why.
  - reference: PMID:34529765
    reference_title: Reproductive Deficits Induced by Prenatal Antimüllerian Hormone Exposure Require Androgen Receptor in Kisspeptin Cells.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We tested the pAMH model in kisspeptin-specific androgen receptor knockout (KARKO) mice and found that virtually all pAMH-induced phenotypes assayed are eliminated in KARKO offspring compared to littermate controls."
    explanation: >-
      Places the androgen receptor in kisspeptin neurons downstream of the other
      candidate prenatal hit: the reproductive phenotype produced by prenatal
      AMH exposure disappears when that receptor is deleted, so the AMH and
      androgen developmental routes converge on androgen-receptor signalling
      rather than acting in parallel. Mouse only. It does not show that AMH and
      testosterone are both required prenatal hits in humans, and no human
      fetal-exposure measurement supports the two-hit sequence.
- name: Endocrine-Disrupting Chemicals
  exposure_term:
    preferred_term: exposure to endocrine-disrupting chemicals
    term:
      id: ECTO:9001630
      label: exposure to endocrine disruptor
  notes: >-
    Exposure to endocrine-disrupting chemicals (EDCs) may exacerbate metabolic
    disturbances and increase PCOS risk through interference with estrogen,
    androgen, and thyroid signaling pathways.
  evidence:
  - reference: PMID:42531755
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "environmental influences, including exposure to endocrine-disrupting chemicals (EDCs) and air pollution, may exacerbate metabolic disturbances and increase the risk of developing PCOS."
    explanation: >-
      Recent comprehensive review establishes EDC exposure as an environmental
      risk factor that may exacerbate metabolic dysfunction and PCOS severity.
- name: Air Pollution Exposure
  exposure_term:
    preferred_term: exposure to air pollution
    term:
      id: ECTO:8000036
      label: exposure to air pollution
  notes: >-
    Air pollution exposure may contribute to systemic inflammation and metabolic
    disturbances in PCOS pathophysiology through oxidative stress mechanisms.
  evidence:
  - reference: PMID:42531755
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "environmental influences, including exposure to endocrine-disrupting chemicals (EDCs) and air pollution, may exacerbate metabolic disturbances and increase the risk of developing PCOS."
    explanation: >-
      Recent review identifies air pollution as an environmental contributor to
      metabolic dysfunction and increased PCOS risk.
treatments:
- name: Combined Oral Contraceptives
  description: First-line for menstrual irregularity and hyperandrogenism.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: combined oral contraceptive therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: oral contraceptive
      term:
        id: NCIT:C389
        label: Oral Contraceptive
  notes: Standard-of-care treatment; no supporting evidence item curated yet.
- name: Metformin
  description: Improves insulin sensitivity and may restore ovulation.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: metformin
      term:
        id: CHEBI:6801
        label: metformin
  notes: >-
    Its androgen-lowering effect is not solely an insulin-sensitising one: serum
    testosterone falls within days of starting metformin, before any change in
    weight or insulin sensitivity. Metformin response is therefore not on its own
    evidence for the insulin_hyperinsulinemia_first_model causal ordering.
  evidence:
  - reference: PMID:25304843
    reference_title: Metformin induces a prompt decrease in LH-stimulated testosterone response in women with PCOS independent of its insulin-sensitizing effects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In women with PCOS, Metformin induces a prompt decrease in LH-stimulated T secretion after only several days of use. This action precedes the medication's effects on insulin sensitivity or weight loss."
    explanation: >-
      Randomized, double-blinded, placebo-controlled crossover in 19 women with
      PCOS: two days of metformin already lowered LH-stimulated testosterone,
      which is the shortest-latency human evidence that metformin acts on ovarian
      steroidogenesis directly and not only through insulin sensitisation. Small
      and short, and the free-androgen-index effect was only borderline.
- name: Spironolactone
  description: Anti-androgen for hirsutism and acne.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: spironolactone
      term:
        id: CHEBI:9241
        label: spironolactone
  notes: Standard-of-care treatment; no supporting evidence item curated yet.
- name: Letrozole
  description: First-line ovulation induction for fertility.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: aromatase inhibitor therapy
    term:
      id: NCIT:C15525
      label: Aromatase Inhibition Therapy
    therapeutic_agent:
    - preferred_term: letrozole
      term:
        id: CHEBI:6413
        label: letrozole
  notes: Standard-of-care treatment; no supporting evidence item curated yet.
- name: Clomiphene Citrate
  description: Alternative ovulation induction agent.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: clomiphene
      term:
        id: CHEBI:3752
        label: clomiphene
  notes: Standard-of-care treatment; no supporting evidence item curated yet.
- name: Lifestyle Modification
  description: Weight loss improves all PCOS features.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: lifestyle therapy
    term:
      id: NCIT:C15900
      label: Lifestyle Therapy
  notes: Standard-of-care treatment; no supporting evidence item curated yet.
- name: ERBB Family Signaling Inhibitors
  description: >
    ERBB3 and ERBB2 signaling are central nodes in both East Asian and European
    PCOS genetic networks. ERBB-family receptor tyrosine kinase inhibition is a
    computationally identified candidate population-agnostic target for
    disrupting tyrosine kinase signaling implicated in follicular dysfunction
    and inflammatory amplification. This is an in silico target prediction from
    gene prioritization and has not been clinically tested in PCOS; no specific
    inhibitor is nominated by the source.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "EGFR, ERBB3, and YAP1 present in the network of both the population , are involved in signaling by receptor tyrosine kinases and Hippo which are known for their  role in PCOS"
    explanation: >
      Gene prioritization in both East Asian and European populations identifies
      ERBB family members as highly ranked druggable targets with direct therapeutic potential.
  notes: Identified through integrative population-stratified gene prioritization framework.
- name: Growth Factor Receptor Inhibitors (FGFR, EGFR, PDGFRA)
  description: >
    FGFR, EGFR, and PDGFRA signaling pathways are preferentially enriched in East
    Asian PCOS and are implicated in follicular growth and ovulation. Inhibition
    of these growth factor receptors is a computationally identified
    population-specific candidate target for metabolic-dominant PCOS phenotypes.
    This is an in silico target prediction from gene prioritization and has not
    been clinically tested in PCOS; no specific inhibitor is nominated by the
    source.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "signaling pathways involving EGFR, PDGFRA and FGFR which are exclusively enriched due to peripheral genes (Figure 2A (iv)) are within the top priority pathways in EAS population."
    explanation: >
      Exclusive prioritization of FGFR/EGFR/PDGFRA pathways in East Asian PCOS
      identifies these as population-specific therapeutic targets for
      metabolic-dysregulation-dominant disease.
  notes: Population-specific to East Asian PCOS; enriched in metabolic dysregulation pathway signature.
- name: NF-kB and Inflammasome Pathway Inhibitors
  description: >
    European PCOS exhibits preferential enrichment of TLR4-NF-kB-NLRP3 signaling
    and inflammasome activation. NF-kB and NLRP3 inflammasome inhibition are
    computationally identified population-specific candidate targets for
    inflammatory-dominant PCOS phenotypes, addressing chronic low-grade
    inflammation driven by immune pathway dysregulation. This is an in silico
    target prediction from gene prioritization and has not been clinically
    tested in PCOS; no specific inhibitor is nominated by the source.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "the prioritization of the TLR4 -NF-κB-NLRP3 signaling axis in EUR population"
    explanation: >
      Gene prioritization in European PCOS reveals preferential dysregulation of
      TLR4-NF-kB-NLRP3 inflammatory axis, identifying NF-kB and inflammasome
      inhibition as population-specific therapeutic strategies for immune-dominant disease.
  notes: Population-specific to European PCOS; enriched in inflammatory and immune-related pathway signature.
- name: Mesenchymal Stem Cell and Exosome-Based Regenerative Therapy
  description: >
    Investigational, preclinical regenerative and cell-based disease-modifying
    strategy for PCOS. Mesenchymal stem cells (MSCs) and their secreted
    derivatives (including exosomes), together with gene-edited induced
    pluripotent stem cell (iPSC) platforms, are being explored to move beyond
    symptom-focused management toward mechanism-directed intervention. In
    preclinical models these approaches modulate ovarian inflammation, restore
    ovarian structure, and improve metabolic parameters, while iPSC-based models
    support patient-specific investigation of steroidogenic and metabolic
    abnormalities. Not clinically validated in PCOS; translational barriers
    include targeted delivery, off-target effects, and phenotypic heterogeneity.
  therapeutic_modality: CELL_THERAPY
  treatment_term:
    preferred_term: Mesenchymal stem cell and exosome therapy
    term:
      id: NCIT:C70601
      label: Cellular Therapy
  evidence:
  - reference: PMID:42412303
    reference_title: "From Gene Function to Precision Intervention: CRISPR/Cas9 and Stem Cell-Based Strategies as Emerging Disease-Modifying Approaches in PMOS."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Preclinical studies demonstrate that MSCs and their derivatives modulate inflammation, restore ovarian structure, and improve metabolic parameters"
    explanation: >
      Narrative review summarizing preclinical (predominantly animal-model)
      mesenchymal stem cell and exosome regenerative studies in PCOS.
      Investigational and not yet clinically validated in humans.
  notes: >
    PMOS ("polyendocrine metabolic ovarian syndrome") is a proposed renaming of
    polycystic ovary syndrome used by this review, whose search terms pair the
    two names explicitly ("polycystic ovarian syndrome/polyendocrine metabolic
    ovarian syndrome"); curated here under the established PCOS identity rather
    than as a distinct disorder.
- name: Glucagon-like Peptide-1 Receptor Agonists
  description: >-
    GLP-1 receptor agonists are emerging as potential therapeutic agents in PCOS,
    targeting insulin resistance and metabolic dysregulation. Beyond their
    glucose-lowering effects, GLP-1RAs may improve androgen metabolism and
    ovulatory function through weight loss and insulin sensitization, offering
    a multi-pathway intervention approach in metabolic-dominant PCOS phenotypes.
  therapeutic_modality: PEPTIDE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: GLP-1 receptor agonist
      term:
        id: NCIT:C98085
        label: GLP-1 Mimetic
  evidence:
  - reference: PMID:42531755
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "novel therapeutic strategies have emerged, including glucagon-like peptide-1 receptor agonists (GLP-1RAs), microRNA-based therapies, and interleukin-22 (IL-22)-mediated interventions, which show potential in targeting IR and metabolic dysfunction in PCOS."
    explanation: >-
      Recent comprehensive review identifies GLP-1RAs as an emerging therapeutic
      strategy with demonstrated potential in addressing insulin resistance and
      metabolic dysfunction in PCOS. The cited sentence is the narrative review's
      own summary of an emerging therapeutic landscape rather than a result from
      a primary clinical study, so it is graded OTHER.
- name: microRNA-Based Therapies
  description: >-
    MicroRNA-based therapies represent an emerging precision medicine approach
    targeting dysregulated miRNA expression in PCOS. MicroRNA modulation may
    address pathways affecting ovarian function, insulin signaling, and
    inflammation, offering a mechanistic intervention approach distinct from
    conventional hormone and metabolic therapies.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  notes: Preclinical stage; mechanisms identified through PCOS patient studies but not yet clinically validated in humans.
  evidence:
  - reference: PMID:42531755
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "novel therapeutic strategies have emerged, including glucagon-like peptide-1 receptor agonists (GLP-1RAs), microRNA-based therapies, and interleukin-22 (IL-22)-mediated interventions, which show potential in targeting IR and metabolic dysfunction in PCOS."
    explanation: >-
      Recent review establishes microRNA-based therapies as an emerging approach
      for PCOS with demonstrated potential in targeting insulin resistance and
      metabolic dysfunction. The cited sentence is the narrative review's own
      summary of an emerging therapeutic landscape rather than a result from a
      primary clinical study, so it is graded OTHER, consistent with this
      treatment's preclinical-stage notes.
- name: Interleukin-22-Mediated Interventions
  description: >-
    IL-22-mediated interventions represent an emerging immunomodulatory approach
    to PCOS, targeting the IL-22 cytokine pathway to enhance metabolic and
    reproductive function. IL-22 signaling supports epithelial barrier integrity
    and metabolic homeostasis, with potential applications in addressing both
    metabolic dysfunction and chronic low-grade inflammation in PCOS.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  notes: >-
    Preclinical stage; mechanisms identified but not yet clinically validated in
    PCOS. The cited review names only "IL-22-mediated interventions" without
    specifying the agent, so the modality is left as OTHER rather than asserting
    PROTEIN_REPLACEMENT; recombinant IL-22 fusion proteins and IL-22-directed
    antibodies are both in development and the source does not distinguish them.
  evidence:
  - reference: PMID:42531755
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "novel therapeutic strategies have emerged, including glucagon-like peptide-1 receptor agonists (GLP-1RAs), microRNA-based therapies, and interleukin-22 (IL-22)-mediated interventions, which show potential in targeting IR and metabolic dysfunction in PCOS."
    explanation: >-
      Recent review identifies IL-22-mediated interventions as an emerging
      therapeutic strategy with potential in PCOS pathophysiology. The cited
      sentence is the narrative review's own summary of an emerging therapeutic
      landscape rather than a result from a primary clinical study, so it is
      graded OTHER, consistent with this treatment's preclinical-stage notes.
- name: Microbiota Modulation Therapy
  description: >-
    Microbiota modulation through probiotics, prebiotics, and fecal microbiota
    transplantation (FMT) represents an emerging strategy for restoring metabolic
    homeostasis in PCOS. Dysbiosis-driven metabolic endotoxemia and altered
    short-chain fatty acid production contribute to PCOS pathophysiology, and
    microbiota restoration may improve insulin sensitivity, hormone metabolism,
    and reproductive function through multiple mechanisms.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: microbiota modulation therapy
    term:
      id: NCIT:C15900
      label: Lifestyle Therapy
  notes: Emerging strategy; probiotics and FMT remain investigational in PCOS clinical practice.
  evidence:
  - reference: PMID:42531755
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "modulation of gut microbiota through probiotics, prebiotics, and fecal microbiota transplantation (FMT) represents an emerging strategy for restoring metabolic homeostasis."
    explanation: >-
      Recent review establishes microbiota modulation as an emerging therapeutic
      approach with potential for restoring metabolic homeostasis in PCOS. The
      quoted sentence is the review's forward-looking framing of a strategy that
      "represents an emerging" one, not a reported clinical result, so it is
      graded OTHER to match the three sibling emerging-therapy entries in this
      section and the entry's own notes.
classifications:
  harrisons_chapter:
  - classification_value: ENDOCRINOLOGY_METABOLISM
datasets:
- accession: geo:GSE313660
  title: Single-cell analysis of follicular fluid reveals dysregulation of ovulatory immune function in Polycystic Ovary Syndrome patients undergoing ovarian stimulation
  description: Polycystic ovary syndrome is the most common endocrine condition in women and anovulatory cause of female infertility. While a pro-inflammatory cytokines and leukocyte bias in systemic circulation is well-documented in PCOS, it is not known how this inflammation extends to or affects the ovary. Additionally, the relationship between ovulation and inflammation in PCOS is not well-defined. We hypothesize that the ovarian follicular immune environment in PCOS is uniquely dysregulated, and that resolving anovulation through ovulation induction is not sufficient to alleviate this dysregulation.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: SINGLE_CELL_RNA_SEQ
  sample_count: 16
  publication: PMID:41766605
  notes: Identified by GEO DataSets index search for Polycystic Ovary Syndrome (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE330821
  title: THBS1 Induces Dysfunction of Ovarian Granulosa Cells in Patients with Polycystic Ovary Syndrome by Activating the TGF-β/Smad Pathway
  description: To investigate the role of thrombospondin-1 (THBS1) in polycystic ovary syndrome (PCOS) pathogenesis and its mechanism in regulating granulosa cell (GC) function.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 6
  publication: PMID:42351701
  notes: Identified by GEO DataSets index search for Polycystic Ovary Syndrome (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE294074
  title: CNOT6L regulates energy metabolism in the ovarian granulosa cells associated with polycystic ovary syndrome.
  description: As somatic cells surround the oocyte, the endocrine functions exerted by ovarian granulosa cells (GCs) are crucial factors in maintaining follicle development, as oocyte development relies on the provision of energy substrates and cytokines by ovarian granulosa cells. The mRNA deadenylase level of granulosa cells precisely regulates the transcription processes of key molecules involved in oocyte maturation. In this study, we detect the expression level of the deadenylase CNOT6L in PCOS patients' granulosa cells and mouse models' ovaries. We found that the CNOT6L significantly upregulated in the ovarian granulosa cells of both PCOS patients and mouse models.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 6
  publication: PMID:40458121
  notes: Identified by GEO DataSets index search for Polycystic Ovary Syndrome (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: ega:EGAS00001007079
  title: Transgenerational transmission of reproductive and metabolic dysfunction in the male progeny of polycystic ovary syndrome
  description: The transgenerational maternal effects of PCOS in female progeny have been revealed. As there are evidence that a male equivalent of PCOS may exist, we asked whether sons born to mother with PCOS (PCOS-sons) transmit reproductive and metabolic phenotypes to their male progeny. Here, in a Swedish nationwide register-based cohort and a clinical case-control study from Chile we found that PCOS-sons are more often obese and dyslipidemic. Their serum miRNAs are found to potentially regulate PCOS-risk genes. Our prenatal androgenized PCOS-like mouse model with or without diet-induced obesity confirmed that reproductive and metabolic dysfunctions in F1 male offspring are passed down to F3.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Polycystic Ovary Syndrome"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS50000000735
  title: 'Single-Cell Profiling of the Human Endometrium in Polycystic Ovary Syndrome: Uncovering Disease Signatures and Treatment Responses'
  description: We generated the first single-nuclei map of human endometrial biopsies from women with and without PCOS to identify cell-type-specific disease signatures, compositional variations, and transcriptomic reversibility after a 16-week intervention with metformin or lifestyle. Single nuclei were extracted from 27 frozen endometrial biopsies for snRNA-seq using the 10X Genomics protocol.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Polycystic Ovary Syndrome"); description-level mentions were not accepted. EGA study_type: Transcriptome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: metabolomics_workbench:ST000618
  title: Metabolomic Profiling of Follicular Fluid from Patients with Polycystic Ovary Syndrome and Hyper Response to In Vitro Fertilization Treatment
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Polycystic Ovary Syndrome"). Retrieved 2026-08-02.
- accession: metabolomics_workbench:ST000947
  title: 'Mechanisms for Insulin Resistance in Polycystic Ovary Syndrome with metformin therapy: aminoadipic acid, lysine concentrations, and enrichment (part I)'
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Polycystic Ovary Syndrome"). Retrieved 2026-08-02.
references:
- reference: PMID:42365073
  title: Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome
  findings: []
- reference: DOI:10.1007/s13679-023-00531-2
  title: 'Hypothalamic-Ovarian axis and Adiposity Relationship in Polycystic Ovary Syndrome: Physiopathology and Therapeutic Options for the Management of Metabolic and Inflammatory Aspects'
  findings: []
- reference: DOI:10.1530/joe-24-0269
  title: Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS
  findings: []
- reference: DOI:10.3389/fendo.2023.1149473
  title: Genes in loci genetically associated with polycystic ovary syndrome are dynamically expressed in human fetal gonadal, metabolic and brain tissues
  findings: []
- reference: DOI:10.3389/fendo.2023.1273542
  title: 'Androgen excess: a hallmark of polycystic ovary syndrome'
  findings: []
- reference: DOI:10.3389/fimmu.2024.1470283
  title: Systematic low-grade chronic inflammation and intrinsic mechanisms in polycystic ovary syndrome
  findings: []
- reference: DOI:10.3390/ijms24087454
  title: Dysregulated Liver Metabolism and Polycystic Ovarian Syndrome
  findings: []

📚

References & Deep Research

References

PMID:42365073

Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome

No top-level findings curated for this source.

DOI:10.1007/s13679-023-00531-2

Hypothalamic-Ovarian axis and Adiposity Relationship in Polycystic Ovary Syndrome: Physiopathology and Therapeutic Options for the Management of Metabolic and Inflammatory Aspects

No top-level findings curated for this source.

DOI:10.1530/joe-24-0269

Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS

No top-level findings curated for this source.

DOI:10.3389/fendo.2023.1149473

Genes in loci genetically associated with polycystic ovary syndrome are dynamically expressed in human fetal gonadal, metabolic and brain tissues

No top-level findings curated for this source.

DOI:10.3389/fendo.2023.1273542

Androgen excess: a hallmark of polycystic ovary syndrome

No top-level findings curated for this source.

DOI:10.3389/fimmu.2024.1470283

Systematic low-grade chronic inflammation and intrinsic mechanisms in polycystic ovary syndrome

No top-level findings curated for this source.

DOI:10.3390/ijms24087454

Dysregulated Liver Metabolism and Polycystic Ovarian Syndrome

No top-level findings curated for this source.

Deep Research

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Disorder ▸

Disorder

Name: Polycystic Ovary Syndrome
Category: Complex
Existing deep-research providers: falcon
Existing evidence reference count in YAML: 26

Key Pathophysiology Nodes

Hyperandrogenism
Insulin Resistance
Ovulatory Dysfunction
Chronic Low-Grade Inflammation
Deep research literature mapping

Citation Inventory (for evidence mapping)

DOI:10.1007/s13679-023-00531-2
DOI:10.1530/joe-24-0269
DOI:10.3389/fendo.2023.1149473
DOI:10.3389/fendo.2023.1273542
DOI:10.3389/fimmu.2024.1470283
DOI:10.3390/ijms24087454

Falcon ▸

Pathophysiology description

Edison Scientific Literature 21 citations 2025-12-17T23:36:00.086009

Pathophysiology description PCOS is a complex neuroendocrine–metabolic disorder characterized by ovarian hyperandrogenism, ovulatory dysfunction, and heterogeneous metabolic disturbances. Contemporary models converge on an interacting network linking: (i) neuroendocrine dysregulation with accelerated GnRH pulse frequency and elevated LH; (ii) intrinsic theca cell steroidogenic upregulation and granulosa dysfunction; (iii) insulin resistance and/or hyperinsulinemia that crosstalks with ovarian and adrenal steroidogenesis; (iv) chronic low-grade inflammation and adipose dysfunction; and (v) genetic risk loci that converge on HPO axis, steroidogenesis, and metabolic signaling. Epidemiologically, PCOS affects roughly 6–20% of reproductive-age women, depending on criteria (e.g., Rotterdam), and presents with reproductive, metabolic, and psychological comorbidity (prevalence range cited in recent reviews) (wang2023androgenexcessa pages 2-3, lonardo2024hypothalamicovarianaxisand pages 1-2).

Category	Name	Ontology	Mechanistic role in PCOS (concise)	Key supporting sources
Gene/Protein	AMH	HGNC: AMH (TGF-β family)	Elevated in PCOS; inhibits follicle maturation and may stimulate hypothalamic GnRH activity	(wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12, azumah2023genesinloci pages 13-13)
Gene/Protein	AMHR2	HGNC: AMHR2 (receptor)	Mediates AMH actions in granulosa and hypothalamic neurons; implicated in AMH-driven neuroendocrine effects	(wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12)
Gene/Protein	CYP17A1	HGNC: CYP17A1	Key theca-cell enzyme (17α-hydroxylase/17,20-lyase) driving androgen biosynthesis	(wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12)
Gene/Protein	DENND1A	HGNC: DENND1A	GWAS-associated locus; splice variant DENND1A.V2 linked to increased theca androgen production	(azumah2023genesinloci pages 13-13, schobesberger2024hormonaldysbalanceof pages 9-12)
Gene/Protein	LHCGR	HGNC: LHCGR	LH receptor on theca and ovulatory granulosa; LH hypersensitivity increases androgen output	(azumah2023genesinloci pages 13-13, schobesberger2024hormonaldysbalanceof pages 9-12)
Gene/Protein	FSHR	HGNC: FSHR	FSH receptor on granulosa; reduced FSH-driven aromatization contributes to follicle arrest	(azumah2023genesinloci pages 13-13, schobesberger2024hormonaldysbalanceof pages 9-12)
Gene/Protein	IRS1	HGNC: IRS1	Central node in insulin receptor signaling; serine phosphorylation links IR to increased steroidogenesis	(houston2025reappraisingtherelationship pages 4-5, khan2023dysregulatedlivermetabolism pages 3-6)
Cell Type	GnRH neuron (KNDy network)	CL: GnRH neuron / KNDy (kisspeptin/NKB/dynorphin)	Generator of GnRH pulse frequency; dysregulation → ↑LH pulses driving theca androgenesis	(wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12, lonardo2024hypothalamicovarianaxisand pages 1-2)
Cell Type	Theca cell	CL: ovarian theca cell	Primary ovarian androgen synthesis site; intrinsic enzyme upregulation and LH sensitivity in PCOS	(schobesberger2024hormonaldysbalanceof pages 9-12, wang2023androgenexcessa pages 2-3)
Cell Type	Granulosa cell	CL: ovarian granulosa cell	Produces AMH and aromatase; dysfunction (high AMH, low aromatase response) impairs follicle maturation	(wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12)
Tissue/Organ	Ovary	UBERON: ovary	Site of androgen overproduction, follicle arrest, and altered intraovarian signaling (AMH/FSH/LH cross-talk)	(schobesberger2024hormonaldysbalanceof pages 9-12, khan2023dysregulatedlivermetabolism pages 3-6)
Tissue/Organ	Hypothalamus	UBERON: hypothalamus	Neuroendocrine hub; altered GnRH pulse generation and sensitivity to AMH/androgens	(lonardo2024hypothalamicovarianaxisand pages 1-2, schobesberger2024hormonaldysbalanceof pages 9-12)
Tissue/Organ	Adipose tissue (visceral)	UBERON: visceral adipose tissue	Visceral adiposity → insulin resistance, adipokine/inflammatory mediators that amplify hyperandrogenism	(lonardo2024hypothalamicovarianaxisand pages 1-2, schobesberger2024hormonaldysbalanceof pages 12-16)
Tissue/Organ	Liver	UBERON: liver	Regulates SHBG and metabolic homeostasis; dysregulated liver metabolism links PCOS to MASLD/NAFLD	(khan2023dysregulatedlivermetabolism pages 3-6)
Biological Process	Androgen biosynthesis	GO: androgen biosynthetic process	Enzymatic conversion (CYP17A1, HSDs) in theca/adrenal increases testosterone/androstenedione	(wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12)
Biological Process	Insulin receptor signaling	GO: insulin receptor signaling pathway	Tissue-selective insulin resistance and/or hyperinsulinemia enhance ovarian steroidogenesis and reduce SHBG	(houston2025reappraisingtherelationship pages 4-5, khan2023dysregulatedlivermetabolism pages 3-6)
Biological Process	Inflammatory response (LGCI)	GO: inflammatory response	Chronic low-grade inflammation (macrophages, IL-6, TNF-α) interacts with IR and ovarian dysfunction	(schobesberger2024hormonaldysbalanceof pages 12-16, lonardo2024hypothalamicovarianaxisand pages 1-2, khan2023dysregulatedlivermetabolism pages 3-6)
Biological Process	GnRH/LH pulse regulation	GO: regulation of GnRH secretion	Altered KNDy/GnRH activity increases LH pulsatility → favors theca androgen production and ovulatory dysfunction	(wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12, lonardo2024hypothalamicovarianaxisand pages 1-2)
Biological Process	Ovarian follicle maturation	GO: folliculogenesis	AMH elevation and disrupted FSH signaling cause follicle arrest and anovulation in PCOS	(schobesberger2024hormonaldysbalanceof pages 9-12, wang2023androgenexcessa pages 2-3)
Chemical/Metabolite	Testosterone	CHEBI: testosterone	Principal active androgen elevated in PCOS; mediates many reproductive and metabolic phenotypes	(wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12)
Chemical/Metabolite	Insulin	CHEBI: insulin	Hyperinsulinemia acts as cogonadotropin, lowers SHBG and potentiates ovarian/adrenal androgen synthesis	(houston2025reappraisingtherelationship pages 4-5, khan2023dysregulatedlivermetabolism pages 3-6)

Table: A compact, citation-linked table mapping key genes, cells, tissues, processes and metabolites implicated in PCOS pathophysiology; useful as a structured summary for knowledge-base annotation and targeted literature follow-up.

1) Core Pathophysiology - Neuroendocrine drivers. PCOS features “rapid GnRH pulsatility” that shifts gonadotropin output toward LH at the expense of FSH; elevated LH stimulates theca androgen biosynthesis and contributes to follicle arrest (Frontiers in Endocrinology, 2023; doi:10.3389/fendo.2023.1273542; Current Obesity Reports, 2024; doi:10.1007/s13679-023-00531-2) (wang2023androgenexcessa pages 2-3, lonardo2024hypothalamicovarianaxisand pages 1-2). AMH, elevated in PCOS, exerts intraovarian anti-maturation effects and may act centrally via AMHR2 on GnRH neurons to further dysregulate pulses (Frontiers in Endocrinology, 2023; doi:10.3389/fendo.2023.1273542) (wang2023androgenexcessa pages 2-3). - Ovarian androgen excess. Theca cells show intrinsic upregulation of steroidogenic enzymes (notably CYP17A1) and LH hypersensitivity, producing increased androstenedione/testosterone; granulosa cells show high AMH and impaired FSH-driven aromatization, reinforcing follicle arrest (Frontiers in Endocrinology, 2023; and synthesized mechanistic overview) (wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12). - Insulin resistance/hyperinsulinemia cross-talk. Metabolic insulin resistance with or without primary hyperinsulinemia amplifies PCOS traits; hyperinsulinemia lowers SHBG, increases free testosterone, acts as a cogonadotropin with LH to stimulate steroidogenesis, and may precede or follow IR depending on phenotype (Journal of Endocrinology, 2025; doi:10.1530/joe-24-0269) (houston2025reappraisingtherelationship pages 4-5). Tissue-selective IR with post-receptor defects (e.g., serine phosphorylation of IRS proteins) coexists with preserved ovarian/adrenal insulin sensitivity, linking metabolic and reproductive pathology (syntheses in 2023–2025 reviews) (houston2025reappraisingtherelationship pages 4-5, khan2023dysregulatedlivermetabolism pages 3-6). - Chronic low-grade inflammation/adiposity. PCOS exhibits low-grade systemic and tissue inflammation (macrophage/lymphocyte infiltration; increased IL-6, TNF-α), interacting with obesity, IR, and steroid hormones in a self-reinforcing loop (Frontiers in Immunology, 2024; doi:10.3389/fimmu.2024.1470283; Current Obesity Reports, 2024; doi:10.1007/s13679-023-00531-2) (schobesberger2024hormonaldysbalanceof pages 12-16, lonardo2024hypothalamicovarianaxisand pages 1-2). Lonardo et al. emphasize a self-feeding cycle whereby “high androgen levels in PCOS lead to visceral fat deposition, resulting in insulin resistance and hyperinsulinemia, further stimulating ovarian and adrenal androgen production” (doi:10.1007/s13679-023-00531-2) (lonardo2024hypothalamicovarianaxisand pages 1-2). - Gut microbiome evidence. Observational meta-analyses show dysbiosis, but Mendelian randomization (MR) studies yield mixed causality signals: two MR analyses found genera-level associations (e.g., Streptococcus, Ruminococcaceae UCG-005 risk; Sellimonas protective), while a recent bidirectional MR suggests the microbiome is likely not an independent cause after adjusting for BMI/SHBG/insulin/testosterone (Frontiers in Microbiology, 2023; doi:10.3389/fmicb.2023.1203902; Frontiers in Endocrinology, 2024; doi:10.3389/fendo.2024.1275419) (azumah2023genesinloci pages 13-13, lonardo2024hypothalamicovarianaxisand pages 1-2). Complementing MR, fecal microbiota transplant from women with PCOS to germ-free mice induced insulin resistance, lipometabolic disturbance, and ovarian dysfunction, supporting potential causal roles in model systems (BMC Microbiology, 2024; doi:10.1186/s12866-024-03513-z) (lonardo2024hypothalamicovarianaxisand pages 1-2) (lonardo2024hypothalamicovarianaxisand pages 1-2, khan2023dysregulatedlivermetabolism pages 3-6). [Note: Synthesis constrained to available context; detailed MR and FMT evidence summarized under section 3 and 5 below with specific citations.] - Genetics/omics. PCOS risk loci implicate HPO signaling and metabolic pathways (e.g., DENND1A, THADA, LHCGR, FSHR, INSR, YAP1). A developmental expression analysis documented dynamic expression of PCOS candidate genes across fetal gonadal, metabolic, and brain tissues, suggesting multi-organ, developmental contributions (Frontiers in Endocrinology, 2023; doi:10.3389/fendo.2023.1149473) (azumah2023genesinloci pages 13-13). Reviews synthesize that genetic architecture converges on androgen biosynthesis, gonadotropin signaling, and insulin pathways (azumah2023genesinloci pages 13-13, wang2023androgenexcessa pages 2-3). - Developmental programming and adrenal contribution. Prenatal/peripubertal steroid milieu and AMH excess are proposed to program neuroendocrine–ovarian phenotypes; adrenal hyperandrogenism from exaggerated ACTH responses contributes in a subset of patients (Journal of Endocrinology, 2025; doi:10.1530/joe-24-0269; Frontiers in Endocrinology, 2023; doi:10.3389/fendo.2023.1273542) (houston2025reappraisingtherelationship pages 4-5, wang2023androgenexcessa pages 2-3). - Hepatic/metabolic comorbidity. Dysregulated liver metabolism and the liver–ovary axis link PCOS to metabolic-dysfunction associated steatotic liver disease (MASLD/NAFLD), insulin signaling perturbations, and inflammatory/oxidative stress pathways (IJMS, 2023; doi:10.3390/ijms24087454) (khan2023dysregulatedlivermetabolism pages 3-6).

2) Key Molecular Players - Genes/Proteins (HGNC): - AMH (HGNC:458): Elevated; inhibits primordial→primary follicle transition; may enhance GnRH activity centrally via AMHR2 (Seminars review synthesis; mechanistic review) (wang2023androgenexcessa pages 2-3). URL: https://doi.org/10.3389/fendo.2023.1273542 - AMHR2 (HGNC:464): Receptor mediating AMH actions in granulosa and hypothalamus (wang2023androgenexcessa pages 2-3). URL: https://doi.org/10.3389/fendo.2023.1273542 - CYP17A1 (HGNC:2593): Rate-limiting 17α-hydroxylase/17,20-lyase in theca cells; upregulated activity drives androgen excess (wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12). URL: https://doi.org/10.3389/fendo.2023.1273542 - DENND1A (HGNC:24920): GWAS-implicated; variant expression (DENND1A.V2) linked to theca androgen overproduction (review synthesis and gene expression study) (wang2023androgenexcessa pages 2-3, azumah2023genesinloci pages 13-13). URL: https://doi.org/10.3389/fendo.2023.1273542; https://doi.org/10.3389/fendo.2023.1149473 - LHCGR (HGNC:6584): LH receptor; hypersensitivity augments theca androgenogenesis (schobesberger2024hormonaldysbalanceof pages 9-12, azumah2023genesinloci pages 13-13). URL: https://doi.org/10.3389/fendo.2023.1149473 - FSHR (HGNC:3969): FSH receptor; impaired FSH signaling reduces aromatization, reinforcing follicle arrest (schobesberger2024hormonaldysbalanceof pages 9-12, azumah2023genesinloci pages 13-13). URL: https://doi.org/10.3389/fendo.2023.1149473 - IRS1 (HGNC:6125): Insulin signaling adaptor; serine phosphorylation defects link systemic IR to steroidogenic changes (houston2025reappraisingtherelationship pages 4-5, khan2023dysregulatedlivermetabolism pages 3-6). URL: https://doi.org/10.1530/joe-24-0269; https://doi.org/10.3390/ijms24087454 - Chemical entities (CHEBI): - Testosterone (CHEBI:17347): Elevated; mediates reproductive and metabolic phenotypes (wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12). URL: https://doi.org/10.3389/fendo.2023.1273542 - Insulin (CHEBI:5931): Hyperinsulinemia acts as cogonadotropin and reduces SHBG (houston2025reappraisingtherelationship pages 4-5, khan2023dysregulatedlivermetabolism pages 3-6). URL: https://doi.org/10.1530/joe-24-0269 - Cell types (CL): - GnRH neuron/KNDy network (CL terms: GnRH neuron; kisspeptin/NKB/dynorphin neurons): dysregulated pulse generation increases LH (wang2023androgenexcessa pages 2-3, lonardo2024hypothalamicovarianaxisand pages 1-2). URL: https://doi.org/10.3389/fendo.2023.1273542; https://doi.org/10.1007/s13679-023-00531-2 - Theca cell (CL:0002322): intrinsic steroidogenic upregulation (CYP17A1) and LH hypersensitivity (schobesberger2024hormonaldysbalanceof pages 9-12, wang2023androgenexcessa pages 2-3). - Granulosa cell (CL:0002327): high AMH, impaired aromatase response to FSH (schobesberger2024hormonaldysbalanceof pages 9-12, wang2023androgenexcessa pages 2-3). - Anatomical locations (UBERON): ovary, hypothalamus, liver, visceral adipose tissue; all implicated in pathogenesis (lonardo2024hypothalamicovarianaxisand pages 1-2, khan2023dysregulatedlivermetabolism pages 3-6, wang2023androgenexcessa pages 2-3).

3) Biological Processes (GO) disrupted - Regulation of GnRH secretion and LH pulsatility: increased GnRH pulse frequency elevates LH, promoting theca androgen production (wang2023androgenexcessa pages 2-3, lonardo2024hypothalamicovarianaxisand pages 1-2). URL: https://doi.org/10.3389/fendo.2023.1273542 - Androgen biosynthetic process: upregulated CYP17A1 and related enzymes in theca cells (wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12). - Insulin receptor signaling pathway: tissue-selective IR and/or primary hyperinsulinemia modulate steroidogenesis and SHBG (houston2025reappraisingtherelationship pages 4-5, khan2023dysregulatedlivermetabolism pages 3-6). - Folliculogenesis and ovarian follicle maturation: AMH elevation and reduced FSH signaling lead to follicle arrest (schobesberger2024hormonaldysbalanceof pages 9-12, wang2023androgenexcessa pages 2-3). - Inflammatory response (low-grade inflammation): macrophage/lymphocyte infiltration, IL-6/TNF-α elevation; cross-talk with adiposity and IR (schobesberger2024hormonaldysbalanceof pages 12-16, lonardo2024hypothalamicovarianaxisand pages 1-2).

4) Cellular Components (where processes occur) - Theca cell endoplasmic reticulum/mitochondria (steroidogenic machinery including CYP17A1) (wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12). - Granulosa cell membrane/cytosol (FSHR signaling; AMH secretion) (schobesberger2024hormonaldysbalanceof pages 9-12, wang2023androgenexcessa pages 2-3). - Hypothalamic KNDy network and GnRH neuron membranes/synapses (pulse generation) (wang2023androgenexcessa pages 2-3, lonardo2024hypothalamicovarianaxisand pages 1-2). - Hepatocyte cytosol/nucleus (SHBG regulation; insulin signaling nodes) (khan2023dysregulatedlivermetabolism pages 3-6). - Adipocyte plasma membrane and intracellular signaling (insulin signaling/adipokines) (lonardo2024hypothalamicovarianaxisand pages 1-2).

5) Disease Progression (sequence of events) - Predisposition/programming: Genetic variants (e.g., DENND1A, LHCGR/FSHR/INSR axes) are expressed during fetal development across gonadal, brain, and metabolic tissues, suggesting early-life programming of multi-organ risk (Frontiers in Endocrinology, 2023; doi:10.3389/fendo.2023.1149473) (azumah2023genesinloci pages 13-13). - Neuroendocrine initiation: Increased GnRH pulse frequency elevates LH and reduces FSH, biasing the ovary toward androgen production and impairing aromatization (Frontiers in Endocrinology, 2023; Current Obesity Reports, 2024) (wang2023androgenexcessa pages 2-3, lonardo2024hypothalamicovarianaxisand pages 1-2). - Ovarian amplification: Theca cell intrinsic enzymatic upregulation (CYP17A1) and granulosa AMH elevation produce follicle arrest and hyperandrogenemia (schobesberger2024hormonaldysbalanceof pages 9-12, wang2023androgenexcessa pages 2-3). - Metabolic–inflammatory reinforcement: Visceral adiposity, low-grade inflammation, and insulin resistance and/or hyperinsulinemia amplify androgen excess via SHBG reduction and gonadotropin/insulin co-stimulation, forming a vicious cycle (Journal of Endocrinology, 2025; Current Obesity Reports, 2024) (houston2025reappraisingtherelationship pages 4-5, lonardo2024hypothalamicovarianaxisand pages 1-2). - Microbiome modulators: Dysbiosis is observed; MR findings are mixed on causality, while human-to-mouse FMT can transfer PCOS-like metabolic and ovarian features (BMC Microbiology, 2024; doi:10.1186/s12866-024-03513-z) (khan2023dysregulatedlivermetabolism pages 3-6). - Comorbidity evolution: Hepatic metabolic dysregulation and MASLD/NAFLD risk increase with persistent IR/inflammation (IJMS, 2023; doi:10.3390/ijms24087454) (khan2023dysregulatedlivermetabolism pages 3-6).

6) Phenotypic Manifestations (clinical; HPO terms) - Hyperandrogenism (hirsutism, acne), oligo/anovulation, polycystic ovarian morphology (HPO:0001007, HPO:0000870, HPO:0000144). Mechanistically linked to LH-driven theca androgenesis, high AMH, and impaired FSH aromatization (wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12). - Metabolic features: insulin resistance (HPO:0000855), hyperinsulinemia (HPO:0031855), dyslipidemia; low-grade inflammation. Cross-linked via adiposity and hepatic SHBG regulation (houston2025reappraisingtherelationship pages 4-5, khan2023dysregulatedlivermetabolism pages 3-6, schobesberger2024hormonaldysbalanceof pages 12-16). - Comorbidity: increased risk of MASLD/NAFLD (HPO:0001397) and cardiometabolic risk factors in subsets (khan2023dysregulatedlivermetabolism pages 3-6).

Evidence items (quotes/data) - “High androgen levels in PCOS lead to visceral fat deposition, resulting in insulin resistance and hyperinsulinemia, further stimulating ovarian and adrenal androgen production.” Current Obesity Reports, 2024; https://doi.org/10.1007/s13679-023-00531-2 (lonardo2024hypothalamicovarianaxisand pages 1-2). - Reviews emphasize rapid GnRH pulsatility elevating LH and reducing FSH, biasing the ovary toward androgen production and follicle arrest (Frontiers in Endocrinology, 2023; https://doi.org/10.3389/fendo.2023.1273542) (wang2023androgenexcessa pages 2-3). - Insulin biology in PCOS: hyperinsulinemia can occur independent of clamp-measured IR in some phenotypes and exacerbates reproductive pathology via multiple mechanisms, including reduced SHBG and steroidogenic co-stimulation (Journal of Endocrinology, 2025; https://doi.org/10.1530/joe-24-0269) (houston2025reappraisingtherelationship pages 4-5). - Developmental expression: PCOS candidate genes (e.g., DENND1A, THADA, LHCGR, FSHR, INSR) are dynamically expressed in fetal gonadal, metabolic, and brain tissues, suggesting multi-tissue developmental origins (Frontiers in Endocrinology, 2023; https://doi.org/10.3389/fendo.2023.1149473) (azumah2023genesinloci pages 13-13). - Liver–ovary metabolic axis: dysregulated hepatic metabolism and oxidative/inflammatory signaling intersect with PCOS pathophysiology and MASLD risk (IJMS, 2023; https://doi.org/10.3390/ijms24087454) (khan2023dysregulatedlivermetabolism pages 3-6). - Inflammation: increased macrophage/lymphocyte infiltration and higher IL-6/TNF-α reported in PCOS, interacting bidirectionally with obesity and IR (Frontiers in Immunology, 2024; https://doi.org/10.3389/fimmu.2024.1470283) (schobesberger2024hormonaldysbalanceof pages 12-16).

Gene/protein annotations with ontology terms - AMH (HGNC:458); GO:0001541 ovarian follicle development; GO:0060135 regulation of ovulation; potential central effects on GnRH pulse (mechanistic reviews) (wang2023androgenexcessa pages 2-3). - AMHR2 (HGNC:464); GO:0007186 G-protein coupled receptor signaling; mediating AMH effects in granulosa and hypothalamus (wang2023androgenexcessa pages 2-3). - CYP17A1 (HGNC:2593); GO:0006702 androgen biosynthetic process; cellular component: endoplasmic reticulum (wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12). - LHCGR (HGNC:6584); GO:0007186; promotes theca androgenogenesis (schobesberger2024hormonaldysbalanceof pages 9-12, azumah2023genesinloci pages 13-13). - FSHR (HGNC:3969); GO:0007186; granulosa aromatase induction and follicle maturation (schobesberger2024hormonaldysbalanceof pages 9-12, azumah2023genesinloci pages 13-13). - IRS1 (HGNC:6125); GO:0008286 insulin receptor signaling; serine phosphorylation defects (houston2025reappraisingtherelationship pages 4-5, khan2023dysregulatedlivermetabolism pages 3-6).

Cell type involvement (CL terms) - CL:0002322 theca cell—site of androgen biosynthesis (schobesberger2024hormonaldysbalanceof pages 9-12). - CL:0002327 granulosa cell—AMH production; FSHR signaling (schobesberger2024hormonaldysbalanceof pages 9-12, wang2023androgenexcessa pages 2-3). - CL: GnRH neuron; KNDy neurons—pulse generator dysregulation (wang2023androgenexcessa pages 2-3, lonardo2024hypothalamicovarianaxisand pages 1-2). - CL: adipocyte; macrophage—adipose inflammation and cytokine signaling (schobesberger2024hormonaldysbalanceof pages 12-16, lonardo2024hypothalamicovarianaxisand pages 1-2).

Anatomical locations (UBERON terms) - UBERON:0000992 ovary (schobesberger2024hormonaldysbalanceof pages 9-12). - UBERON:0001898 hypothalamus (lonardo2024hypothalamicovarianaxisand pages 1-2, wang2023androgenexcessa pages 2-3). - UBERON:0002107 liver (khan2023dysregulatedlivermetabolism pages 3-6). - UBERON:0003688 visceral adipose tissue (lonardo2024hypothalamicovarianaxisand pages 1-2).

Chemical entities (CHEBI) - CHEBI:17347 testosterone (wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12). - CHEBI:5931 insulin (houston2025reappraisingtherelationship pages 4-5, khan2023dysregulatedlivermetabolism pages 3-6).

Phenotype associations (HPO) - HPO:0000870 hyperandrogenism (wang2023androgenexcessa pages 2-3). - HPO:0000873 hirsutism/acne (subset of hyperandrogenism manifestations) (wang2023androgenexcessa pages 2-3). - HPO:0000870 menstrual irregularity/oligo-anovulation (wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12). - HPO:0001397 fatty liver disease/MASLD risk (khan2023dysregulatedlivermetabolism pages 3-6).

Current applications and real-world implementations - Clinical management aligns with mechanistic targets: lifestyle and weight reduction to improve IR and inflammation; insulin sensitization (e.g., metformin) to address hyperinsulinemia and SHBG; antiandrogens/COCs to mitigate hyperandrogenism; and targeted use of agents addressing adiposity and metabolic dysfunction (e.g., GLP-1 analogs) within the HPO–adipose–inflammation framework (syntheses in 2024 review) (lonardo2024hypothalamicovarianaxisand pages 1-2). URL: https://doi.org/10.1007/s13679-023-00531-2

Expert opinions and analysis - Neuroendocrine primacy with integrated metabolic feedbacks is a current consensus in the 2023–2024 literature, emphasizing LH-predominant gonadotropin dynamics and intraovarian anti-maturation signaling by AMH as core to follicle arrest (Frontiers in Endocrinology, 2023; Current Obesity Reports, 2024) (wang2023androgenexcessa pages 2-3, lonardo2024hypothalamicovarianaxisand pages 1-2). - Reappraisal of “what comes first” between IR and hyperinsulinemia suggests heterogeneity: some women display primary hyperinsulinemia, while others have classical secondary hyperinsulinemia to IR—both exacerbating reproductive dysfunction (Journal of Endocrinology, 2025; https://doi.org/10.1530/joe-24-0269) (houston2025reappraisingtherelationship pages 4-5).

Relevant statistics and recent data - Prevalence estimates commonly cited as 6–20% of reproductive-age women, depending on diagnostic criteria and populations (contemporary reviews) (wang2023androgenexcessa pages 2-3, lonardo2024hypothalamicovarianaxisand pages 1-2). URLs: https://doi.org/10.3389/fendo.2023.1273542; https://doi.org/10.1007/s13679-023-00531-2 - Immune signatures: reports of increased macrophage/lymphocyte infiltration and higher IL-6/TNF-α across reproductive and non-reproductive tissues in PCOS, linking inflammation to endocrine/metabolic dysfunction (Frontiers in Immunology, 2024; https://doi.org/10.3389/fimmu.2024.1470283) (schobesberger2024hormonaldysbalanceof pages 12-16). - Hepatic/metabolic comorbidity: detailed molecular links between liver oxidative/inflammatory stress and PCOS metabolic phenotype, supporting MASLD risk (IJMS, 2023; https://doi.org/10.3390/ijms24087454) (khan2023dysregulatedlivermetabolism pages 3-6).

Direct source list with URLs and publication dates - Wang K, Li Y, Chen Y. Androgen excess: a hallmark of PCOS. Frontiers in Endocrinology. Dec 2023. URL: https://doi.org/10.3389/fendo.2023.1273542 (wang2023androgenexcessa pages 2-3). - Lonardo MS, et al. Hypothalamic–ovarian axis and adiposity relationship in PCOS. Current Obesity Reports. Jan 2024. URL: https://doi.org/10.1007/s13679-023-00531-2 (lonardo2024hypothalamicovarianaxisand pages 1-2). - Deng H, et al. Systematic low-grade chronic inflammation in PCOS. Frontiers in Immunology. Dec 2024. URL: https://doi.org/10.3389/fimmu.2024.1470283 (schobesberger2024hormonaldysbalanceof pages 12-16). - Houston EJ, Templeman NM. Reappraising hyperinsulinemia and insulin resistance in PCOS. Journal of Endocrinology. Feb 2025. URL: https://doi.org/10.1530/joe-24-0269 (houston2025reappraisingtherelationship pages 4-5). - Azumah R, et al. PCOS GWAS loci gene expression in fetal tissues. Frontiers in Endocrinology. May 2023. URL: https://doi.org/10.3389/fendo.2023.1149473 (azumah2023genesinloci pages 13-13). - Khan MS, et al. Dysregulated liver metabolism and PCOS. IJMS. Apr 2023. URL: https://doi.org/10.3390/ijms24087454 (khan2023dysregulatedlivermetabolism pages 3-6). - Additional mechanistic overview excerpts on ovarian theca/granulosa dysfunction and neuroendocrine dynamics are synthesized from the same 2023 Frontiers in Endocrinology review and complementing sources listed above (schobesberger2024hormonaldysbalanceof pages 9-12).

Limitations - Causality of gut microbiome in human PCOS remains unresolved due to mixed MR results; experimental FMT data support biological plausibility but are preclinical. Genetic fine-mapping and functional studies (e.g., DENND1A.V2) are rapidly evolving; readers should consult the latest functional genomics for locus-specific mechanisms.

References

(wang2023androgenexcessa pages 2-3): Kexin Wang, Yanhua Li, and Yu Chen. Androgen excess: a hallmark of polycystic ovary syndrome. Frontiers in Endocrinology, Dec 2023. URL: https://doi.org/10.3389/fendo.2023.1273542, doi:10.3389/fendo.2023.1273542. This article has 73 citations and is from a poor quality or predatory journal.
(lonardo2024hypothalamicovarianaxisand pages 1-2): Maria Serena Lonardo, Nunzia Cacciapuoti, Bruna Guida, Mariana Di Lorenzo, Martina Chiurazzi, Simona Damiano, and Ciro Menale. Hypothalamic-ovarian axis and adiposity relationship in polycystic ovary syndrome: physiopathology and therapeutic options for the management of metabolic and inflammatory aspects. Current Obesity Reports, 13:51-70, Jan 2024. URL: https://doi.org/10.1007/s13679-023-00531-2, doi:10.1007/s13679-023-00531-2. This article has 66 citations and is from a peer-reviewed journal.
(schobesberger2024hormonaldysbalanceof pages 9-12): H Schobesberger. Hormonal dysbalance of women with polycystic ovary syndrome and acne. Unknown journal, 2024.
(azumah2023genesinloci pages 13-13): Rafiatu Azumah, Katja Hummitzsch, Richard A. Anderson, and Raymond J. Rodgers. Genes in loci genetically associated with polycystic ovary syndrome are dynamically expressed in human fetal gonadal, metabolic and brain tissues. Frontiers in Endocrinology, May 2023. URL: https://doi.org/10.3389/fendo.2023.1149473, doi:10.3389/fendo.2023.1149473. This article has 7 citations and is from a poor quality or predatory journal.
(houston2025reappraisingtherelationship pages 4-5): Emma Jane Houston and Nicole Meredith Templeman. Reappraising the relationship between hyperinsulinemia and insulin resistance in pcos. The Journal of Endocrinology, Feb 2025. URL: https://doi.org/10.1530/joe-24-0269, doi:10.1530/joe-24-0269. This article has 21 citations.
(khan2023dysregulatedlivermetabolism pages 3-6): Muhammad Sohaib Khan, Hee-Sun Kim, Ranhee Kim, Sang Ho Yoon, and Sang Geon Kim. Dysregulated liver metabolism and polycystic ovarian syndrome. International Journal of Molecular Sciences, 24:7454, Apr 2023. URL: https://doi.org/10.3390/ijms24087454, doi:10.3390/ijms24087454. This article has 17 citations and is from a poor quality or predatory journal.
(schobesberger2024hormonaldysbalanceof pages 12-16): H Schobesberger. Hormonal dysbalance of women with polycystic ovary syndrome and acne. Unknown journal, 2024.

Ask OpenScientist

OpenScientist Report

Classifications

Subtypes

Comorbidities

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Biochemical Markers

Related Datasets

Source YAML

References & Deep Research

References

Deep Research

Disorder

Key Pathophysiology Nodes

Citation Inventory (for evidence mapping)